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Human respiratory syncytial virus (hRSV) is the leading cause of viral respiratory tract 
infections in children.1 In 2013 there were over 60 000 infants hospitalised in the USA 
alone and the virus resulted in approximately 2.1 million outpatient visits by children 
under 5 years old.2 The virus leaves the lungs weakened and open to further secondary 
infections such as bronchitis and pneumonia, especially in immunocompromised and 
elderly patients.  Infections can lead to long-term effects and up to 70% of infants are left 
with respiratory problems for up to 10 years following hRSV bronchiolitis.3 For 
otherwise healthy children the treatment is usually supportive, using hydration and 
additional oxygen.1 Previous antiviral agents and decongestants have been used to little 
positive effect, leading to the need for new antiviral agents. 
In the work described in this thesis, key protein targets have been identified from the 11 
protein hRSV Genomes. It has been found that F, M2-1, M and N are integral for structural 
roles, transcription and virus maturation.4 M2-1 protein is a transcription factor and has 
long been a target for structural biologists due to its integral role in the virus. Chapter 2 
describes the characterisation of the protein using biophysical techniques to obtain data 
on its stability and overall fold. Further work to crystallise the protein is also included.5 
Chapter 3 builds on this work introducing the interaction between matrix protein and 
M2-1. The interaction is characterised through Surface Plasmon Resonance (SPR) and 
Fluorescence Anisotropy (FA), which gave equilibrium constants and thermodynamic 
pathways for the first time.  
Chapter 4 introduces the interaction between hRSV matrix protein and hRSV fusion 
protein. Previous work has characterised the fusion protein and identified that the 
cytoplasmic tail is the key subunit which binds to matrix protein.6 Through mutagenesis 
of a single residue, F572 was identified as the key binding residue.7 The terminal six 
amino acids were used to form a peptide which formed the basis for the experiments in 
this thesis. The work described here presents in vitro data which will build on the 
published literature to further understand the interaction. SPR and FA provide 
experimental evidence for a hypothetical binding model.  This binding model and the 
resulting equilibrium constants are discussed and evaluated. 
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The X-ray crystal structure of hRSV N protein is known8,9 and this information can be 
used to design ligands with the aim of disrupting the protein’s function.  The work 
outlined here aimed to evaluate the binding of a series of ligands that were identified by 
Arrow Therapeutics Ltd as having antiviral activity.10 Thermal shift assays were used to 
understand the stabilisation of the protein in the presence of the ligand. Dynamic light 
scattering showed the formation of aggregates of protein when exposed to various 
concentrations of ligand.  Cryo-electron microscopy shows association of the ligand to 
the protein and the consequent aggregates which form. This provided an indication of 
how the ligands could interact with the protein and suggests possible modes of action. 
In Chapter 6, hRSV M protein’s interaction with hRSV F was further investigated. The 
interaction is key for the maturation of the virus11 and if the binding could be diminished, 
the infectivity of the virus would suffer. A pocket at the dimer interface was identified, 
which opened up an opportunity for computational docking studies. Through the 
application of biophysical techniques and computational methods,12 novel ligands were 
identified and the initial characterisation of their effect on protein stability was probed. 
Key protein interactions which are involved in the maturation of the virus and its fusion 
to the host cell have been characterised and evaluated in this thesis. The opening 
chapters begin within basic protein characterisation and build to show protein 
interactions in vitro. In the later chapters, ligand subsets are identified with the aim of 
disrupting protein interactions or the protein folding. Characterisation of the protein 
ligand interactions showed protein changes and destabilisation, leading the way for 
further studies. 
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1. INTRODUCTION TO VIRUSES.  
The scope of this thesis covers the biophysical investigation of key structural 
proteins from human Respiratory Syncytial Virus (hRSV) with a view to 
understanding interactions and functions. This chapter will summarise the history 
and significance of viruses, primarily focusing on the Mononegavirales order, of 
which hRSV is a member, and the negative sense RNA viruses.13 An overview of the 
relevance of human Respiratory Syncytial Virus (hRSV) will bring context to the 
following work and the prevalence and impact of the virus will be discussed. The key 
structural proteins studied interact within the virus and without these interactions 
the infectivity of the virus and even its shape would be different.14,15 The replication 
of enveloped viruses has been poorly understood in comparison to capsidated 
viruses which can hinder critical research into the interaction of their structural 
proteins.14 Each protein studied will be introduced later in this chapter for further 
familiarisation. 
 
Following initial biophysical testing the complex task of solving the X-ray crystal 
structure of the protein must take place to find key residues which could be critical 
for the interaction of proteins within the virus.16,17 Further chapters will investigate 
the interaction of key structural proteins by in depth biophysical studies. From this 
stage the three-dimensional structures can be used to identify new anti-viral drug 
target pockets and novel scaffold targets. This computational technique uses 
complementary small drug like fragments to target the interface and so disrupt the 
formation of the complex and is outlined in Chapter 6. 
  






1.1 VIRUSES  
 
Viral infections can range from the common cold to deadly diseases such as Ebola or 
AIDS. Virology is a relatively young science; only 100 years ago the first virus was 
filtered and identified as being smaller than bacteria.18 Within the past 60 years the 
compositions of a number of viruses have been described and their electron 
microscope images have become known.18 With advances in modern biotechnology 
the structure, molecular biology of viral replication and the interactions that take 
place between the virus and host are being characterised and understood. Improved 
sanitation, safer water supplies and the development of antiviral drugs have 
dramatically reduced the threat from many of these viral agents especially in the 
developed world.13 In 1998 in excess of 3 million deaths occurred as a result of acute 
respiratory diseases, many of which were caused by viruses.19 Many viruses have no 
vaccine and continue to be of great medical significance.18  





1.2 NEGATIVE SENSE RNA VIRUSES  
 
The virus classification system is key to understanding how the proteins interact in the 
virus.20 The Baltimore classification classes viruses according to their type of genome 
(RNA or DNA) and replication method.13,21 Usually within a family, the proteins are 
similar in size and function and comparisons can be drawn across members. 
Class V, of the Baltimore classification system, is a broad class of viruses, which consists 
of two orders and eight families.21 There are also a number of unassigned species and 
genera. Many have different morphologies e.g. Filoviridae are filamentous and 
Paramyxoviridae are usually pleomorphic or round.18 The order Mononegavirales, which 
belongs to Class V, consists of four families as shown in Table 1.2.1.21 
 
 
Table 1.2.1 Families of the order Mononegavirales1,4 
There are also unassigned families included in Class V.Family Arenaviridae, which 
contains Lassa Virus.  The Lassa virus causes viral hemorrhagic fever (VHF) in human 
and non-human primates. The family Orthomyxoviridae22 which contains the influenza 
virus is also unclassified, but linked to the Mononegavirales order. The virus cannot make 
its own mRNA so uses cellular RNA as primers for initiating RNA synthesis in the cell.18 
 
Order - Mononegavirales 
Family Genus 
Bornaviridae Bornavirus 
Filoviridae Ebola Virus, Marburg Virus 
Paramyxoviridae Measles Virus, Mumps Virus, Nipah 
Virus, Hendra Virus. hRSV. 
Metapneumovirus (hMPV) 
Phabdoviridae Phabdovirus 





1.3  HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) 
 
Human Respiratory Syncytial Virus is the leading cause of viral respiratory tract 
infections in children.1 The World Health Organisation estimates an annual mortality 
rate of approximately 250,000 deaths worldwide in 2010.23 Updated figures show that 
hospitalisation of ~60 000 infants a year in the USA is caused by hRSV and in 2013 alone 
the virus resulted in 2.1 million outpatients visits by children under 5 years old.2 The 
virus, and subsequent secondary bacterial infections are also the second leading cause 
of death in elderly patients.24 It has been estimated that 87% of children by the age of 18 
months have been infected with hRSV and by the age of 3 nearly all have been infected.19  
hRSV was discovered in 1955, though thought at the time to be a childhood disease the 
virus is now known to be a serious threat to both young and old.25 In 2001 human 
metapneumovirus (hMPV) was discovered and began to be characterised, this was found 
to be another important cause of bronchiolitis and produces similar symptoms.26 hMPV 
infects children up to the age of 5 years old and co-infection with hRSV can produce a 
more severe disease.27 Symptoms of hRSV include rhinitis, cough and coryza, as the 
disease begins in the upper respiratory tract. In 25%-40% of cases the disease travels to 
the lower respiratory tract18 and can be characterised by feeding difficulties in the infant 
amongst the visual signs of respiratory distress.25 If bronchiolitis in the lower 
respiratory tract begins, a wheeze could be present which is characterised by a crackle 
in the chest.28 Bronchiolitis can lead to acute respiratory failure with severe 
bronchospasm, moderate hypoxia and carbon dioxide retention.25 Death from 
bronchiolitis is rare without underlying immunological conditions and most infected 
children recover fully.27 Some infections can lead to long-term effects; up to 70% of 
infants are left with respiratory problems for up to 10 years following hRSV bronchiolitis 
and in studies this has been linked to the child developing asthma.28 In healthy children 
treatment of hRSV symptoms is mainly supportive.1 In the past bronchodilators, 
antiviral agents and decongestants have been used to little effect.29 Hydration and 
oxygenation are now considered to be the first line of support. Where the child has 
bronchiolitis; dehydration, fever and poor feeding due to difficulty breathing are 
problematic. Intravenous fluids may be needed if the case is particularly severe.25 
Two approved drugs are available for treatment of hRSV.30 Palivizumab is a humanised 
monoclonal antibody31 to the viral fusion (F) protein and is used as a preventative 





treatment for high risk infants such as the immunocompromised and premature. 
Palivizumab reduces the need for hospital admissions but is costly, between £3000-
£5000 to treat each child.31 In the USA Palivizumab is recommended for premature 
babies born below 35 weeks’ gestation and for infants under two who have chronic lung 
disease.31 The health gains versus the cost are minimal and do not have a real impact on 
the complications which arise from hRSV. Ribavirin is also licensed for severe infections 
only and is potentially toxic to health care workers.32 New research has now given 
evidence to suggest it is also teratogenic.33 The drug is nebulised and inhaled but has 
limited therapeutic affect in patients. Ribavirin has a broad spectrum range of antiviral 
activity in vitro and obstructs the replication of hRSV, influenza, parainfluenza, 
adenovirus and measles.32  
The lack of available treatments highlights the problems that are faced in the quest for 
antiviral drugs. High costs and a lack of relative effectiveness are some of the challenges 
posed. Many problems arise from the lack of knowledge of the virus in question, which 
highlights the need for basic research to find potential drug target leads. It is known that 
virus structure and protein interactions are key for function. To understand the 
structure-function relationship, clues may be found in related viruses that reside in the 









1.3.1 STRUCTURE AND REPLICATION.  
 
hRSV is a member of the Paramyxoviridae family as described in section 1.2. It is an 
enveloped, non-segmented, negative-stranded RNA virus in the order Mononegavirales 
as shown below in Figure 1.3.1.1.1 
 
Figure 1.3.1.1. – Mononegavirales family tree18 
 
 










The hRSV virion has a spherical or filamentous form and contains a helical nucleocapsid 
within the envelope, which is derived from host cell phospholipids and proteins.18 The 
hRSV RNA genome encodes 11 proteins11 as shown in Figure 1.3.1.2. The N protein forms 
the nucleocapsid, this is associated with phosphoprotein P, large polymerase subunit L 
and the transcription elongation factors M2-1 and M2-2. The viral envelope is studded 
with three transmembrane envelope glycoproteins, SH, G and F. F is the fusion protein, 
which is involved in viral attachment with the target cell. 34,6 The glycoprotein G has been 
shown to be non-essential for fusion and is heavily glycosylated.35 SH, the small 
hydrophobic protein is a membrane protein, which is also studded into the side of the 
envelope.35 The matrix protein (M) is a peripheral membrane protein that binds the viral 
envelope and nucleocapsid, and so holds them together forming a layer in between as 










Figure 1.3.1.3.– Representation of hRSV3 
The ultrastructure of the virus was characterised in the helical form through freeze-
etching of virus filaments as shown in Figure 1.3.1.4 below. The core of the structures 
areexposed and shows the concave, inner surface of the viral envelope.15 
Fusion protein 






Figure 1.3.1.4 Filamentous virus filaments15 
  





1.4 ENVELOPED VIRUSES  










Figure 1.4.1.1 Structure of an enveloped virus.37 
Enveloped viruses generally consist of three main parts; the genetic material, the capsid 
and the envelope containing other associated proteins as seen in Figure 1.4.1.1.18 The 
primary function of the capsid is to protect the viral genome and ultimately the viral 
proteins.13,15,20 The capsid also has other functions; these can include binding to the 
genome to aid the assembly of virions. This ‘capsid-genome’ complex is called the 
nucleocapsid.18 In enveloped viruses the nucleocapsid may also interact directly with the 


























Figure 1.4.1.2 Replication cycle of an enveloped virus 18,38 
 
Viral entry is the first process during replication, this is achieved by binding to a cell 
surface receptor and inducing fusion between the envelope and the host cell 
membrane.38 In hRSV, viral proteins (F and G) anchored in the envelope or the 
nucleocapsid assist this process.39 This binding and fusion are followed by the injection 
of the viral genome into the cell.  Enveloped viruses use membrane fusion of the 
envelope with the host plasma membrane.38 One or more viral membrane proteins 










1. Prefusion – The fusion protein is in prefusion conformation with fusion peptides 
in close proximity. The virus docks into a cell membrane receptor. 
2. Extended intermediate – The fusion protein opens up and the fusion peptide 
interacts with the target bilayer.  
3. Collapse of the extended intermediate – The C terminal segment of the fusion 
protein folds back, away from the core and the deformed membrane.  
4. Hemifusion – The collapse of the intermediate brings the virus and host cell 
membrane bilayers into contact, and they merge by hemifusion. This is where the 
outer bilayers merge, but the inner stay intact.  
5. Fusion Pore formation – The hemifused bilayers open into a fusion pore and the 
final segmentation of the C-terminal ectodomain of the fusion protein snaps the 
refolded trimer into a fully symmetric, post-fusion conformation preventing the 
pore from resealing. The genomic material enters into the cell through this pore. 
 
Endocytosis, which is used to complete viral entry, usually transports fluids and small 
cell particles in animal cells, and there are multiple mechanisms available.40 Host cell 
receptors have been shown to facilitate different mechanisms of viral entry by 
endocytosis.  Once inside the cell the nucleocapsid is broken down through degradation 
by viral or host proteases, this leaves the virus free to replicate inside the host cell.40 RNA 
viruses replicate in the cytoplasm or endoplasmic reticulum of a cell whereas the DNA 
virus will continue to the nucleus.9 
The mechanism of formation of new virions is different in each class of virus, but there 
are common steps in all. First the DNA or RNA is replicated by polymerase enzymes, 
mRNA is then transcribed and used to produce viral proteins using the host cell’s 
ribosomes.18,39 The new viral proteins and genetic material can then be assembled to 
form progeny virions, which gather near the inside of the cell membrane.18,41 
Instead of cell lysis, which is the mode of exit for non-enveloped viruses, the enveloped 
viruses use budding to exit the host cell.14,42 This requires viral proteins to obtain part of 
the host-derived membrane to form an external envelope. The mechanism begins when 
the viral core components are incorporated into membrane vesicles, which also contain 
viral transmembrane proteins.14  The nucleocapsid formation induces curvature of the 
host cell membrane, to form the distinctive ‘bud’ that wraps up the viral proteins that is 





excised from the host membrane to release the enveloped particle.39,41,43,44 Finally, the 
new virus infects another host cell and the cycle is repeated. The replication cycle is key 
to understanding viral infectivity.  
 
  





1.5   HRSV MATRIX PROTEIN  
1.5.1 STRUCTURE 
 
The matrix protein (M) is a non-glycosylated phosphorylated protein of 256 amino 
acids.45 It is a structural protein, which plays a fundamental role in virion assembly by 
hindering viral transcription and promoting budding. The protein also binds to the viral 
ribonucleocapsid and to the envelope, the latter of which is an important stage in virion 
release.6 The binding is stabilised by viral glycoproteins and co-localisation with the F 
protein and SH proteins.46  
The matrix protein is smaller than those of other paramyxoviruses, at 256 amino acids 
in length compared to 335-375 amino acids.6 There is little sequence homology between 
the proteins in the family, but like its rhabdovirus equivalents, i.e. Rabies Virus Matrix, 
hRSV Matrix protein can bind RNA.47 The RNA binding region is located between amino 
acid residues 120-170. There is a number of residues in this region specifically: lysine 
residues 121, 130, 156 and 157 which are conserved throughout the pneumovirus M 











Figure 1.5.1.1  - Matrix protein monomer48 (PDB code 2VQP) RNA binding region highlighted in magenta, 
specifically conserved residues highlighted in green, Lysine 121, 130, 156 and 157.  





There are two domains per monomer, which are connected by a 13-residue flexible 
linker region and an unstructured loop region.48 The N-terminal domain (residues 1-
126) comprises a twisted -sandwich, which consists of two -sheets which are 
positioned nearly perpendicular to each other. The overall topology of the N-terminal 
domain is a curved horseshoe-like arrangement with 1 -sheet forming the concave 
outer face.48 The C-terminal domain (residues 140-255) consists of a flattened -barrel, 
which is made up of two three-stranded anti-parallel -sheets. The regions linking 








Figure 1.5.1.2.  Ribbon diagram of hRSV Matrix protein.48 (PDB code 2VQP) 
The crystal structure of the protein was solved in 2009 and interpreted as a monomeric 
structure. Recently the structure for the hRSV Matrix protein was determined to be a 
dimer by Förster et al.49 shown in Figure 1.5.1.3. This new structure gives definition to 
previously flexible regions and a clear dimerization interface. This dimerization 
interface is the same as other dimeric M structures from the Mononegavirales including 
Newcastle disease Virus (NDV)39 and human Metapneumonovirus (hMPV).50 
  













Figure 1.5.1.3 hRSV matrix protein dimer49 (PDB code: 4D4T) 
 
1.5.2. COMPARISONS TO OTHER MONONEGAVIRALES MATRIX PROTEINS. 
 
In the order Mononegavirales, a number of matrix protein X-ray crystal structures have 
been solved.39,45,51,52 This section will introduce structurally similar matrix proteins and 
discuss the similarities and differences between them and hRSV Matrix protein. Key 
conserved areas and differences could be the basis to targeting residues for antiviral 
agents to inhibit protein-protein interactions. The proteins discussed are from across 
the Mononegavirales order and include; VP40 from the Ebola (EBOV) virus, Borna (BDV) 
Virus M, Vesicular Stomatitis Virus (VSV) M and Human Metapneumonavirus (hMPV) M.  
 
  





1.5.2.1. VP40 EBOLA VIRUS (EBOV) 
 
VP40, the Ebola matrix protein, has much the same function as hRSV M, as it is also 
involved with virus assembly and budding. The C-terminal domain has similar 
membrane targeting properties to those of hRSV M, this is linked to its function within 
the budding of the virus.51,53 The N-terminal domain is thought to be responsible for the 
hexamerisation of the protein into a lattice in vivo, much like that of HIV matrix protein 
in low resolution electron microscopy images.54 The EBOV primary sequence 
comparisons with matrix proteins from other families in the order Mononegavirales 
show that the there is no significant homology between the proteins.48,50,51 
Paramyxoviridae is the only other family that contains a matrix protein of a similar size 
to Ebola virus VP40.  Other families in the order are generally approximately 100 amino 
acid shorter.   
VP40 has been crystallised as a monomer51 and also a dimer but it can oligermerise in 
vitro to form octamers when it binds RNA.55 The oligomerisation state of the protein in 
vivo is dependent on the sub-type of Ebola from which it originates whether that be Zaire 








Figure 1.5.2.1.1. Left, Ebola Virus VP40 Matrix protein monomer (PDB code: 3TCQ).51  
Right, Dimer Ebola Virus VP4056 (PDB: 4DLB) 
 
  















Figure 1.5.2.2.1. Structure of matrix protein from Borna Virus57 (PDB: 3F1J) 
 
The BDV-M protein is the smallest M protein at 16.2 kDa57 in the order Mononegavirales. 
It forms oligomers in vivo and in vitro where a tetramer is the preferred oligomerisation 
state as shown in Figure 1.5.2.2.1. The Borna Virus M has some structural analogy with 
hRSV M, but is most similar to the N-terminus of VP40 from Ebola as shown in Figure 
1.5.2.1.1. The overall fold has a L-shaped -sandwich formation containing six 
antiparallel strands57 that is similar to the overall fold of hRSV M, especially at the N-
terminus, which has been shown in hRSV M to directly bind M2-1.58 
 
  





1.5.2.3. VESICULAR STOMATITIS INDIANA VIRUS (VSV)  
 
Vesicular Stomatitis virus, in the family Rhabdovirus, has been used as the prototype for 
budding within the order.52 The VSV M protein is 26.6 kDa in size and the core 80 amino 
acids of the protein were first crystallised in 2002.52 The whole protein fold is similar to 
hRSV M where there are two distinct domains, connected by a 20 amino acid linker 
region. In hRSV M, a slightly smaller 13 amino acid linker region is present.52 The N-
terminal region of VSV M is positively charged and contains a five-stranded anti-parallel 
β-sheet with two α-helices.52 The C-terminal region has two small anti-parallel β-sheets 
and one α-helix. The stable core of the structure is shown below in Figure 1.5.2.3.1 










Figure 1.5.2.3.1. Structure of the core of VSV M.52 (PDB: 1LG7) Containing amino acids 40-120 
 
  





1.5.2.4. HUMAN METAPNEUMONAVIRUS (HMPV) 
 
Human Metapneumonavirus (hMPV) belongs to the same subfamily as hRSV. The 
crystallised form of the hMPV matrix protein is a dimer much like hRSV M. The Borna 
virus matrix proteins have been shown to form dimers and tetramers with a similar 
quaternary diamond shape.50 Unlike hRSV M, the hMPV matrix protein also has calcium 
ions bound in the crystal structure.50  
Each monomer of hMPV M is comprised of two similarly folded domains joined by a 14 
amino acid linker, an arrangement that has been found across the order in various sizes 
from 13 amino acids to 20 amino acids. The dimeric interface contains contacts between 
the N-Terminal domain and the C-Terminal domain. Each N-Terminal domain contains 
a twisted β sandwich, much like those in hRSV M.48,50 The C-Terminal domain has 
disorder in solution and in the crystal form residues 180-188 and residues 208-2018 are 











Figure 1.5.2.4.1. The dimer structure of hMPV M.50 
 
  





1.6 M2-1 PROTEIN 
1.6.1 STRUCTURE AND FUNCTION  
 
The M2-1 protein is a transcription anti-termination factor which is key for transcription 
of full length mRNAs.59 The M2 gene codes for a mRNA containing two open reading 
frames (ORFs). ORF1 codes for a 194 amino acid structural protein, M2-1, the second 
ORF codes for M2-2 a 90 amino acid protein.60 M2-1 enhances the synthesis of 
polycistronic mRNAs and is an essential cofactor of the viral RNA polymerase complex. 
It has also been found in a mono-phosphorylated and unphosphorylated forms in 
infected human cells.46 The protein is only present in the families Pneumovirinae and 
Filoviridae i.e. hRSV, Metapneumovirus and Ebola virus, which makes the protein a 
potential target for a specific antiviral agent.61  
hRSV M2-1 forms a tight tetramer of 89 kDa in solution and has been found to be highly 
-helical by circular dichroism.62 Through dynamic light scattering M2-1 is a 5.4S 
tetramer and approximately 7.6 nm in diameter.62 The N-terminus contains a Cys3-His1 
motif, where the 3 cysteine residues and one histidine residue coordinate to a single zinc 
ion.  This zinc-binding domain is essential for M2-1 function within the virus, this is also 
shown in the equivalent Ebola VP30 protein and is highly conserved throughout the 
genus.60,62,61 The zinc-binding domain has been found to support the secondary structure 
and aids in the protein’s ability to form a tetramer in solution.62 Mutation of the zinc 
coordinating residues of the Cys3-His1 motif removes the effectiveness of M2-1 as a 
transcription factor.61 
M2-1 protein has been shown to bind in a sequence specific manner to short RNAs which 
contain a 5’-end leader sequence.5 The protein was also shown to bind long RNAs 
without any sequence specificity at a Kd of approximately 30 M.5,63 To determine the 
specificity of M2-1 binding, short RNAs were assayed and yielded a Kd of 90 nM.5 The 
region between residues 40 and 80 in the M2-1 protein has been shown to be in direct 
contact with the RNA when bound.60 Further studies have identified short A-rich RNA as 
being a preferable binding partner.63 
As previously mentioned M2-1 has phosphorylated andun-phosphorylated forms. The 
phosphorylated form has been shown to interact with the nucleocapsid (N) protein. The 
phosphorylated residues in the protein were identified to be serines 58 and 6164 and are 





required for the efficient transcriptional function of M2-1, as their mutation, causes a 
severe decrease of antitermination activity.   
M2-1 also binds to the phosphoprotein (P) in the hRSV genome in a competitive manner 
in the core region of amino acids 59 to 178.65 hRSV P protein is known to bind with the 
nucleocapsid forming a large protein-protein complex, which has been found in 
inclusion bodies when all three proteins (N, M2-1 and P) are present in an unbound 
state.63 The co-localisation of M2-1 with N and P was found to be indicative of its function 
as a transcription factor in the ribonucleoprotein (RNP) complex.65  
A solution NMR structure of M2-1 core region (residues 58-177) was solved in 2012.63 
The core structure has been shown to be a monomer due to it lacking the oligomerisation 
domain as shown in Figure 1.6.1.1.62 The core domain is structurally homologous to the 
C-terminal domain of Ebola virus VP30 and contains a singular globular domain from 
residues G75 and I171.63 The NMR result was superseded by the determination of the 










Figure 1.6.1.1. The solution NMR structure of M2-158-177 shows a monomer with large regions of 
unstructured loop (PDB Code: 2L9J) 
M2-1 was crystallised in its native tetrameric form. The structure shows a disk-like 
assembly with a four-helix bundle in the centre. The helix responsible for tetramer 
formation is linked to the core domain that has been shown to be responsible for RNA 
binding.63 The RNA binding region includes two critical serine residues, S58 and S6164 
that are phosphorylated during infection which are shown on a flexible linker region.  







Figure 1.6.1.2. Left, Tetrameric RSV M2-1, Monomer unit shown in magenta. Right, close up of zinc finger 
domain with the zinc ion shown as a sphere bound to 3 Cysteine and 1 Histidine residues.5  (PDB code: 
4C3B.) 
 
1.6.2. COMPARISONS TO OTHER TRANSCRIPTION FACTORS 
1.6.2.1 M2-1 METAPNEUMOVIRUS. (HMPV) 
hMPV M2-1 crystallised in the same space group and oligomerisation state as hRSV M2-
1.50 The structure shows an asymmetric tetramer where three monomers are in the 
globular formation, which mimics hRSV M2-1. The fourth monomer shows an open 
confirmation where the core region (residues 58-177) is twisted away by approximately 
60 Å. This open formation is in contrast to the hRSV M2-1 tetramer which has all 


















Figure 1.6.2.1.1. The structure of the Human Metapneumonavirus M2-1 tetramer.50 (PDB code: 4CS7) 
 
1.6.2.2  EBOLA VIRUS VP30 
 
VP30 protein in the Ebola virus is essential for transcription as M2-1 is in hRSV. 
Currently a full-length structure of the VP30 protein has not been elucidated but a 
structure of the C-terminal domain has been resolved (VP30CTD).66 The C-terminal 
domain folds into a dimeric helical shape independent of the N-terminal domain.66 The 
full length protein has been found in virions to form hexamers, due to the presence of 







Figure 1.6.2.2.1 Crystal structure of dimeric VP30CTD.66(PDB Code:2I8B) 
  






1,7  FUSION PROTEIN (F)  
1.7.1  STRUCTURE AND FUNCTION  
The fusion protein is a glycoprotein essential for viral entry and has been identified as a 
key drug target for vaccine development.43 hRSV contains three surface glycoproteins in 
total but the fusion protein is the most highly conserved among the different strains in 
contrast to the attachment protein (G), which is highly variable.35 The fusion protein 
alone has been found to be essential for the attachment of the virus to the host cell, if 
disrupted or an inhibitor is used, fusion and entry of the virus are limited.6,37 
The hRSV fusion protein is a class I viral fusion protein, this means the protein conforms 
to a structure and interaction pathway indicative of this type.14 The final form of hRSV F 
is a trimer, where each monomer of F protein is synthesised as a 67 kDa precursor, 
known as F0, which is modified by N-linked glycans.43,67 The resulting F protein has a N-
terminal F2 protein linked by disulphide bonds to the F1 trans-membrane domain 
protein.68 
F protein is anchored into the membrane of the virion in a metastable, prefusion form. 
The protein is in two key parts, the fusion head and the cytoplasmic tail.67  The fusion 
head is triggered into undergoing a conformational change, which inserts its 
hydrophobic fusion peptide into the target cell membrane.68 The three F1 monomers 
then fold back on themselves to bring the viral and cell membranes together and initiate 
fusion.68 A cytoplasmic domain is attached by a linker to the fusion head at one end and 
























Figure 1.7.1.1 Postfusion hRSV F protein.43(PDB Code: 3RRT) 
 
1.7.1. COMPARISONS TO OTHER FUSION PROTEINS. 
1.7.1.1 EBOLA FUSION PROTEIN. (GP1,2)  
 
The Ebola fusion protein (GP1,2) is also a trimeric fusion protein which is anchored to the 
surface of the virion and is solely responsible for membrane attachment and fusion.69 
The protein is expressed by the virus as a single peptide, which, in this case, is cleaved 
by furin instead of the protolytic cleavage seen in hRSV.69 This cleavage yields the 
subunits GP1 and GP2 that associate to form a homotrimer structure, which is 

















Figure 1.7.1.1.1 The crystal structure of Ebola fusion protein (GP). The homotrimer (GP protein 1 in Blue 
and GP 2 in orange) has been crystallised bound to a human antibody Fab KZS2. (magenta)69 (PDB Code: 
3CSY) 
 
1.7.2.2 METAPNEUMOVIRUS FUSION PROTEIN (HMPV-F) 
 
Metapneumovirus as detailed above in Section 1.3.1 is in the same subfamily as hRSV 
and so it follows that the two fusion proteins would be very similar as they carry out the 
same functions.43,70 The fusion protein on hMPV is the same class I viral fusion protein 
and as in hRSV F the protein folds into a metastable, pre-fusion conformation. On 
activation the protein undergoes refolding concurrent with membrane fusion.70 The 
prefusion state (F0) is shown below in Figure 1.7.2.2.1. The two proteins cannot be 
structurally compared as hRSV F is in the post fusion state and hMPV-F is the pre fusion 
state. However this does help us understand how each protein might look in the pre or 
post fusion form in a related virus.  
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Figure 1.7.2.2.1 hMPV-F protein, F0 domain.70 (PDB Code: 4DAG) 
  





1.8 NUCLEOCAPSID PROTEIN.  
1.8.1 HRSV NUCLEOCAPSID PROTEIN.  
In 2009 the hRSV nucleocapsid (N) protein was crystallised and the structure 
determined to 3.3 Å resolution.8 
 
Figure 1.8.1.1 hRSV nucleocapsid protein shown in a decameric form. The monomer is highlighted in 
magenta. RNA is intergral to the structure.8 (orange) (PDB:2WJ8)  
The protein has been shown to form decameric and undecameric rings in solution, as 
illustrated above.8 The monomers in the decamer were found to form a ring system. 
Inter-ring contacts between the residues suggest a basis for helical packing.9 This 
packing helps stabilise the protein by mainly ionic interactions, thus the protein is stable 
as a ring in solution, which is key for the formation of a large nucleocapsid.9 In this 2009 
structure there was some ambiguity as to the location of the RNA in the ring as the 
electron density in the crystal structure was not well defined.8 Due to the essential role 
that hRSV N has in genome protection and as a replication template, the N protein is a 
key drug target and various compounds such as RSV604 have shown this to be a viable 
approach.71 Lead clinical candidate RSV-604 is discussed in depth in Chapter 5. 
In addition the protein structure was solved without hRSV phosphoprotein to 3.6 Å 
resolution. In this solution clear electron density was observed corresponding to RNA in 





Figure 1.8.1.2 unlike the earlier structure by Tawar et al. 2009.8 There are seven 
ribonucleotides in contact with each protein monomer, this is in contrast to the VSV 
nucleocapsid72 and Rabies nucleocapsid73 proteins where the RNA has been located 
inside the ring and nine ribonucleotides are bound per monomer. The RNA found in the 
proteins is arranged in rows of interchanging four and three stacked bases which 
alternate between exposed and buried within a protein groove as shown below in Figure 
1.8.1.2.9 
 
Figure 1.8.1.2 RNA shown in the cleft of hRSV N (left) and a close up view9 (right) (PDB Code: 2YHM) 
The monomer units of hRSV N are composed of the usual N-terminal domain (NTD) and 
C-terminal domains (CTD) which have extensions called the ‘N-arm’ and ‘C-arm’, these 
arms were found to make contact with the adjacent monomer and seem to give stability 
to the ring structure.9 The buried surface area between each of the monomers in the ring 
can vary from 2500 to 2600 Å2 and the interactions between them consist of salt bridges, 
hydrogen bonds and hydrophobic interactions.9 
 
When overlaid, as shown in Figure 1.8.1.3 all three structures overlap as expected with 
a RMSD (Root Mean Squared Deviation) of 0.448 Å. These differences show that there is 





flexibility in the decameric ring and that the individual protein monomers can undergo 











Figure 1.8.1.3  Overlay of each structural monomer of hRSV Nucleocapsid, Tawer et al. 8(orange, 
PDB:2WJ8), El Omari et al Orthorombic structure 9(blue, PDB Code:2YHM) and Triclinic form8 (Magenta, 









1.8.2 COMPARISONS TO OTHER MONONEGAVIRALES NUCLEOCAPSID PROTEINS 
1.8.2.1 VESICULAR STOMATA VIRUS (VSV) NUCLEOCAPSID 
Vesicular Stomata Virus (VSV), as described previously, belongs to the family 
Rhabdoviridae, its genome is only 11 kb in length and codes proteins that are similar to 
those of hRSV.72 The VSV nucleocapsid also forms decameric rings and its structure has 
been determined a number of times with different co-crystal substituents. In 2006 Green 
et al.72 crystallised the nucleocapsid protein to a resolution of 2.9 Å and found it to have 
near 10-fold rotational symmetry when crystallised with RNA in complex to the protein, 
in a similar way to that of hRSV N. It was found that the N-RNA complex consisted of 10 
molecules of recombinant VSV N protein and 9 nucleotides of bacterial RNA,72 this is in 
contrast to hRSV N which only contains 7 nucleotides in contact. Each N-RNA oligomer 
of VSV N was found to have a bi-lobed structure with RNA bound tightly in the cavity, 
which was found between the interface of the N and C- terminal helical lobes74 as shown 
in Figure 1.8.2.1.1. It was also found that the VSV N protein could shield bacterial RNA 
from ribonuclease action by close contacts with key amino acid residues of the N protein 
in the middle of the protein.75  
 
Figure 1.8.2.1.1  VSV nucleocapsid protein.72 (PDB Code: 2GIC) 
 
 





1.8.2.2 RABIES NUCLEOCAPSID PROTEIN. 
Rabies virus nucleocapsid protein acts in the same way as the N proteins of hRSV and 
VSV by protecting the genomic RNA and providing a template for replication.73 The 
structure of rabies N protein was solved in complex with viral RNA in 2006 by Albertini 
et al.73 to 3.5 Å resolution in an undecameric ring as shown below in Figure 1.8.2.2.1. 
This oligomerisation has been seen in hRSV N protein where one of the crystal forms 
was an undecameric ring, but VSV only crystallised as a decamer.  
 
 
Figure 1.8.2.2.1 Rabies nucleocapsid protein73 (PDB Code:2GTT) 
 
The small changes in the monomer and the composition of the ring packing, allow an 
extra subunit to fit and form an undecameric ring.73 The groove around the central belt 
where the RNA strands lie, which is pronounced in the hRSV N and still visible in the VSV 
protein, is almost lost in the Rabies protein. The RNA in the structure seems to intertwine 
with the ribbons of protein structure rather than sit inside the groove in the structure.  
Along with the VSV N protein, the rabies N has an important role in the switching 
between RNA transcription to replication by encapsulating the newly synthesised 
genome RNA.76 





1.9 SCOPE AND AIMS OF THIS RESEARCH.  
Many of the individual proteins encoded by the hRSV genome have been crystallised and 
characterised, but this only gives a small understanding of how these proteins interact 
together as an infectious agent. hRSV M2-1 is known to interact with both M and P63,77 
but until 201378 it was thought that M2-1 was only found in the host cell cytoplasm for 
the synthesis of mRNA. It is now known that it is involved in the formation of the 
ribonucleocapsid, where it is sandwiched between the nucleocapsid and the matrix 
protein.36 This discovery is key to the research in this thesis as the location of the M2-1 
in the virus directly affects the interactions that the protein can make. The interaction of 
M2-1 with the P protein has been characterised and the scale of the interaction has been 
reported60,62 unlike its interaction with hRSV M. Chapter 3 in this thesis strives to gain 
insight into the interaction between these two proteins M and M2-1, through 
determination of the thermodynamic pathway.  
hRSV M protein was first crystallised in 200948 and since then other matrix protein 
structures from the order Mononegavirales have become available.50–52,57 Many have 
been crystallised in the dimeric form, including hRSV M which has recently been 
crystallised and solved.79 The matrix proteins’ interactions with the fusion protein are  
key for viral budding and assembly.34 The cytoplasmic tail of the fusion protein is known 
to interact with the matrix protein, and the key residues have been identified in this 
interaction.7 This research will begin to probe the interaction using biophysical 
techniques i.e. thermal shift assays, Förster resonance energy transfer and surface 
plasmon resonance and begin to build an understanding of the binding.  
The nucleocapsid protein has long been considered a target for antiviral drugs as its 
functions are key to the encapsidation of RNA and as a replication template for the 
emergence of a new virus. In Chapter 5 high-throughput screening ligands by Arrow 
Therapeutics Ltd are introduced10 and a number of novel scaffolds are described and 
validated by in vivo assays. In this chapter the aim is to find the mode of action of these 
ligands against the hRSV N protein. If this is known, it would provide an excellent 
platform to further characterise the interaction and direct structure-activity relationship 
studies.  
The investigation of the interaction of matrix and fusion proteins is continued in Chapter 
6, where the key interaction with phenylalanine 5727 is the basis for a series of potential 





ligand compounds. The aim of the chapter is to identify a pocket in the protein so docking 
of a ligand can take place. 
GOLD80,81 is a program developed by the Cambridge Crystallographic Data Centre (CCDC) 
and enables the user to identify favourable interactions in the protein and dock large 
subsets of ligands into the identified pockets. The aim is to dock ligand compounds to 
the protein in silico and validate these hits by biophysical techniques.  
Overall this research aims to investigate key interactions in the virus’ replication cycles 
that include those between matrix and M2-1 and matrix and fusion peptide. These 
interactions will be studied to understand basic stoichiometry and thermodynamic 
pathways.  Further work to identify small molecule ligands that can bring a destabilising 
effect to the protein-protein interaction between N and M-F, conclude the thesis. The 
small molecules ligands are new targets and could lay the foundations for new anti-viral 
drugs in the future. 
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CHAPTER 2. CHARACTERISING M2-1 PROTEIN. 
The work described in this chapter used biophysical techniques, including dynamic light 
scattering and circular dichroism, to confirm the known structural data on M2-1. Further 
characterisation using ICP-MS and MALDI-TOF also confirmed the amino acid sequence 
and zinc content of the protein which has been previously characterised by Tran et al.62 
For full structural characterisation, an X-ray crystal structure is required and the use of 
thermal shift assays to determine optimum buffer conditions for crystallisation is 
outlined. M2-1 is a core transcription protein from hRSV which is found in the 
ribonucleocapsid complex.59 The M2 gene codes for mRNA containing two open reading 
frames where ORF1 codes for a 194 amino acid structural protein, M2-1. As discussed in 
Chapter 1.6, M2-1 enhances the synthesis of polycistronic mRNAs which are essential 
cofactors of viral RNA polymerase.4  In 2009, M2-1 was relatively structurally unknown. 
It was known that M2-1 formed a tight tetramer of 89 kDa and the structure was found 
to be primarily alpha helical by circular dichroism.62  In early 2012 a solution NMR 
structure was published63 as shown in Figure 1.6.1.1 of the core region between residues 
58-177 but no X-ray crystal structure was published until 2014.5 
The work described in the following chapter aimed to successfully over-express and 
purify M2-1 in order to facilitate future crystallisation. Expression trials were used to 
obtain the largest yield of protein from an E. coli system building on previous work by 
Tran et al 62 which favoured a Glutathione-S-Transferase (GST) tagged protein to 
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2.1. PROTEIN EXPRESSION AND PURIFICATION. 
 
M2-1 pGEX-6p-182 was successfully cloned by Dr. R.P. Yeo. Expression, purification and 
further analysis were carried out by the author. A pGEX vector was chosen as it provided 
a glutathione-S-transferase tag (GST tag), a high affinity to glutathione enabled 
purification from other cell debris and E. coli cytoplasm.83  The protein can be isolated 
by the addition of glutathione beads, where the GST tag on the protein binds to the free 
glutathione on the surface of the beads. The native untagged protein can be harvested 
after purification; by cleavage of the linker between the tag and the protein by 
Precission Protease enzyme. This cuts between a glutamine and a glycine residue in 
the recognition site (Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro).83–85 Protein molecular weight 












Figure 2.1.1. 15% SDS-PAGE showing cleaved hRSV M2-1 protein at ~22kDa. Lane 1.  Ladder of standard 
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The protein was further purified and characterised through size exclusion 
chromatography (SEC). Purification was required as extra bands, which were not the 
protein of interest, were present on the gel as shown above in Figure 2.1.1. The protein 
oligomerisation state could be determined by running known proteins, called size 
markers, through the system and monitoring their retention times. This is a standard 
calibration and quantifies the size of proteins in solution.  A variety of proteins with 
known retention time were used from thyroglobulin, 97 kDa to vitamin B12, 1.3 kDa. 
The protein, M2-1 was eluted after injection of 30 mL of buffer, this gave an indication 
that the protein was a tetramer (88 000 Da) in solution as previously reported.62 
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2.2. ANALYSIS BY MASS SPECTROMETRY.  
2.2.1. MALDI-TOF MS 
 
Confirmation of the identity of the protein shown on SDS PAGE was carried out by tryptic 
digest and MALDI Mass spectrometry. Dr A.P. Brown, (School of Biological and 
Biomedical Sciences, Durham University) conducted the experiment. The tryptic digest 
of the protein was carried out by extraction from a SDS PAGE gel band. Firstly the correct 
band was cut from the larger gel and the coomassie stained piece was destained using 
ammonium bicarbonate/acetonitrile (1:1 v/v).  The protein gel piece was purified by the 
addition of formic acid/water/2-propanol (1:3:2 v/v/v) which removed the SDS. The gel 
was then suspended in a buffer containing trypsin and incubated at 37 C overnight, 
where the protein was digested and then extracted from the gel using (1:2 v/v) 5% 
formic acid/acetonitrile. The extracted protein fragments were mixed with matrix 
solution, 0.02-0.03 M alpha-cyano-4-hydroxy-cinnamic acid in 0.1% TFA/acetonitrile 
(1:2 v/v). The mixture was highly acidic and deactivates the trypsin and a small sample 
was transferred onto a MALDI sample plate and allowed to dry. The sample was analysed 
in the spectrometer and the output was run though a BLAST (Basic Local Alignment 
Search Tool)88 search and a positive identification of the M2-1 protein was obtained. Full 
fragment data are found in Appendix A.  
 
2.2.2. ICP-MS 
ICP-MS (Inductively coupled plasma mass spectrometry)89 was used to confirm the 
binding capacity of the zinc finger in the purified M2-1 protein. The presence of a zinc 
finger in the N-terminus of the protein has been extensively characterised61 and a zinc 
ion was bound to the crystallised protein.5 The technique uses known concentrations of 
metal ions to produce calibration curves shown in Appendix A. Each curve plots the 
metal signals against their concentrations. This allows the user to test the unknown 
sample and receive the corresponding metal signal. This can be plotted onto the 
calibration curves to reveal the concentration of the metal ion in question. 
Purification of M2-1 traditionally includes the addition of zinc ion when the cells are 
induced and also in the lysis buffer when the purification process begins.5,64 To test the 
dependence of M2-1 on zinc ion, the protein was purified with no extra zinc in the lysis 
buffer nor were zinc ions added to the culture when the cells were induced. This sample 
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was found to contain 2.5% zinc by mass and the expression levels were found to be lower 
than when the zinc ions were added to the growth media on induction. The metalation 
of M2-1 was tested following the addition of ZnSO4 at induction, the protein was found 
on average to be 67% metalated. After size exclusion chromatography the protein was 
found to be on average 40% metalated.  Removing the zinc entirely from M2-1 had a 
particularly harsh effect on the protein and precipitation was seen after the addition of 
EDTA (10 mM) and incubation at 4 °C. 
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2.3. CIRCULAR DICHORISM. (CD) 
 
Circular dichorism (CD) spectroscopy is a form of UV spectroscopy, which uses circularly 
polarised light to determine the secondary structure content of a protein. The 
polypeptide backbone of a protein is optically active and will absorb circularly polarised 
light to give a characteristic signal. 90 The signal is the difference in extinction coefficients 
between the right and left handed polarised light in units of cm M-1 
=(L - R) = (AL - AR)/cl 
 
Where  is the overall change in in the extinction coefficient, L is the signal from the left handed 
polarised light. R is the signal from the right handed polarised light. 
This is often shown in terms of ellipticity, , where 
 =33(AL-AR) 
or molar ellipticity:35 
[] = 100/cl 
where c –concentration (mol-1), l – pathlength (cm) 
 
The ellipticity at different wavelengths of UV light depends on the secondary structure 
of the protein; -helices, -sheets and random coil each give distinctive CD spectra as 
shown in figure 2.3.1.  
 
 




Figure 2.3.1. A typical CD spectra showing the different types of secondary structure.87 
Several empirical algorithms have been developed to estimate the secondary structure 
of a protein from the corresponding CD spectrum. They work by analysing the 
experimental data in relation to the spectra of proteins with known structure. Largely 
these can be accessed online via the CDPro software package.91 All the algorithms rely 
on the assumption that the contribution to the signal from different components i.e. 
alpha helices, beta sheets within the protein are independent and can be added linearly 
to produce the net spectrum C. 
C = fk Bk 
Where fk is the fraction of secondary structure k, and Bk is the value of the secondary structure component.  
The CDpro package91 was used to determine an approximation of the secondary 
structure of M2-1 using known protein structures. The known structures have been 
tested by the method and their spectra are contained in data sets which are used as a 
standard reference. The software contains 10 data sets, 6 for soluble proteins, 2 of which 
represent membrane proteins and the final 2 contain a mixture of the two different 
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as detailed in Methods 2.8 and the raw data curves are shown in Figure 2.3.2. The signal 
is calculated as the different in the absorption of the left handed and right handed 
circularly polarised light. The first graph which plots circular dichroism (CD) against 
wavelength, shows the overall signal.  The second HT is the amount of voltage used 
across the wavelength range. At lower wavelengths the protein, air and buffer solution 
will absorb light. Less light will then hit the detector which causes the HT voltage to 











Figure 2.3.2. Raw data curve of M2-1 in 50 nM phosphate buffer solution. 
Data set 9, which contains 50 proteins in the reference set, of which 13 are membrane 
proteins, was found to obtain the best fit to the data. The reference set and experimental 
data were then analysed using 3 different algorithms (CONTILL/LL-SELCON/CDSSTR)91 
supplied in the CDpro software. The algorithms analyse the data in subtly different ways, 
there has been no identification of which one gives the better result.91 It has been found 
that the CDSSTR algorithm performs better with a smaller reference set and large 
wavelength range whereas CONTILL/LL prefers a larger reference set and smaller 
wavelength range.90,91 The program analyses wavelengths  from 180 to 240 nm where 
the protein has absorbed the circularly polarised light. The data set obtained from M2-
1, had a shorter wavelength range but by using reference set 9, a larger protein set was 
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CONTILL/LL and SELCON analyses overlaid on the experimental data are shown in 
Figure 2.3.3. 
 
Figure 2.3.3. CD spectrum of M2-1 in 50mM Phosphate buffer (190-240 nm) fitted using CONTIN/LL and 
Selcon 3 algorithms in data set 9 in the CDPro package.91 
From the graph it can be seen that the two data sets gave very similar results, but the 
CONTIN/LL system fits the experimental data from 190-200nm whereas the Selcon 3 
curve deviates more significantly from the line. The secondary structure fractions from 
the analysis are shown below in Table 2.3.3. 
 
 -Helix 310-Helix Strand Turn Irregular 
% of total 53 11 4 6 26 
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2.4. DYNAMIC LIGHT SCATTERING (DLS) 
 
This technique is known by many different names such as Photon Correlation 
Spectroscopy and is a popular method of defining the size of particles in solution. A laser 
shone onto a solution causes a Doppler shift when the light hits the moving particle, the 
size of the shift is dependent on the size of the particle. This method has several 
advantages such as a small volume is required and there is a short time frame per 
measurement. There are some general assumptions which underlie the experiment’s 
theory, the first is mentioned above where the particles must be in Brownian motion. 
This is where the particles are suspended in random motion in a fluid. The second is that 
the particles are spherical in solution as shown below.92,93 
D = kBT/6a 
Where a is the radius of the particles, kB is the Boltzmann constant, T is the temperature in Kelvin and  is 
the viscosity of the solution and D the diffusion constant of particles in solution. 
Size determination of the protein in solution was key to understanding the 
oligomerisation state. It has been previously stated that the tetramer of M2-1 forms a 15 
nm ± 4 nm structure.62 The sample from the size exclusion chromatography column was 












Figure  2.4.1 Dynamic Light Scattering trace showing an M2-1 size peak of approximately 16 nm in 
solution shown in Malvern Instruments Zetasizer Software.94 
 
























2.5. THERMAL SHIFT ASSAY (DIFFERENTIAL SCANNING FLUOROMETRY) 
 
Thermal Shift assays are used to investigate the overall stability of the protein.95 An in-
house salt screen containing 96 conditions was performed in triplicate and the results 
averaged. 
A dye, Sypro Orange, was added to the protein and salt screen mixture. The 96 well plate 
was heated from 24 C to 96 °C with a reading of fluorescence taken at 1 °C intervals. As 
the protein unfolds, the dye binds to the hydrophobic residues in the protein backbone 
producing a higher fluorescence signal.96 Every protein has some disorder in its 
structure where hydrophobic residues are exposed before any heat is added. This allows 
the dye to bind before he experiment starts and is known as a background fluorescence 
signal. The melting curve of the protein is seen through a large increase in fluorescence, 
where the 50% point of the curve is the melting temperature. The raw data melting curve 
of M2-1 in water is shown below in Figure 2.5.1 and the melting temperature was 
determined to be 47.9 °C in water through the NAMI software.95 
 
Figure 2.5.1 Raw data melting curve of M2-1 in water. 
 
The difference in melting temperature which was taken as significant is 1C, this is based 
on the sensitivity of the machine. In Figure 2.5.3 the output table of averaged results 
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University to calculate the 50% point of the curves and accurately determine the melting 
temperature. The program is driven by a numerical approach using an algorithm which 
identifies the melting curve to a defined window. The data in each window are then fitted 
by linear regression which results in a slope value (a) and a correlation coefficient (r).  
To calculate the precise melting temperature (Tm) the UnivariateSpline function from 
SciPy function95,97 is used to interpolate the experimentally obtained data points. If no 
clear Tm is found the program automatically labels the data N/S for no signal. Up to two 
inflection points can be calculated in the program if more than one melting curve can be 
seen.  
 
Figure 2.5.2. NAMI program representation of the melting temperature of M2-1. The melting temperature 
was found to be 47.9 C and is represented by the red line.95 The gold lines represent the melting window 
showing the beginning and the end of the curve. The purple curve represents the interpolated rate of 

















Figure 2.5.3. Table of salt screen melting temperature of M2-1 shown in NAMI.95 
 
NAMI illustrates the change in melting temperature relative to the control sample using 
a colour code. This colour code coordinates the shift in temperature, small changes 
under a degree remain unchanged and are shown as white. Anything above a 1 °C, shows 
in light purple which gets darker and turns blue with each increase. Similarly a 
destabilising condition is shown in yellow and gradually turns red. Some conditions 
were shown to have two peaks but on examination of the raw data the protein was found 
to be denatured under these conditions and the two peaks were found to be a result of 
the program’s, attempt to fit the data.95 The protein was stabilised by various buffer 
conditions and additives, primarily these were used to change buffer conditions during 
purification and extraction of the protein in order to optimise yield and stability, and are 






Decrease in melting 
temperature  
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Double melting 
temperature reading 
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M2-1 is a structural protein, as discussed in Chapter 1, and it binds with a number of 
proteins within the virus structure.5,36,61,98 The results of the thermal shift assay show 
that, as might be expected, M2-1 is stabilised primarily by amino acids as shown in 
Figure 2.5.4 below.  These results were used to guide the experiments discussed in 
Chapter 2.6, where the aim is to crystallise M2-1. Addition of stabilising compounds in 
crystallisation screens can be used to enable successful crystallisation.  
 
 
Figure 2.5.4. Raw data from hRSV M2-1 thermal shift assay showing compounds that exert a stabilising 



























Well 1 Well 7 Well 10 Well 13 Well 14 Well 30 Well 37 Well 58



























1 No compound N/A 42 
7 L-Histidine 50 mM 48 
10 L-Arginine-ethyl 
ester 
50 mM 49.3 
13 Gly-Gly 50 mM 48.2 
14 Gly-Gly-Gly 50 mM 47.3 
30 Ethlydiamine 50 mM 50.2 
37 Trichloroethylene 
hydrochloride 
50 mM 49.2 
58 Ammonium 
sulphate  
50 mM 48.2 
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Figure 2.6.1. Sitting drop vapour diffusion crystallisation16 
For full protein characterisation a crystal structure is required and at the beginning of 
the author’s period of study this was not available and the main aim was to crystallise 
full length M2-1.  High-throughput 96-well sitting drop screens were used to test a large 
number of conditions using the smallest volume of protein possible. The trays use the 
technique of sitting drop vapour diffusion as shown in Figure 2.6.1, containing a well 
consisting of reagent and two drops, which are a mixture of protein sample and 
reagent.16 If the protein drops are at a lower concentration than the well of reagent, 
water vapour leaves the drop and enters the well. As water leaves the contents of the 
drop become more concentrated and an equilibrium is reached when the reagent 
concentration is approximately the same as the reservoir.16 
If the concentration of one of the components is too low, then the drop will be clear. Once 
in the metastable zone, some amorphous precipitate may form and may lead to crystals. 
Once the protein shows thick precipitate one of the components is too high in 
concentration. The drops were scored using the Hampton Research Monograph Series 
as shown in Table 2.6.2.99 
  




0 Clear Drop 
1 Drop contains non-protein particles e.g Dust on drop, Fibres from 
clothes. 
2 Drop is mostly clear but contains precipitated protein with no 
edges 
3 Protein is fully precipitated with a dark colour 
4 Gelantinous protein precipitate – usually transparent 
5 Phase Separation 
6 Spherulites – droplets or 
Small structures with defined edges. 
7 Crystal growth in one dimension 
8 Crystal growth in two dimensions 
9 Crystal growth in three dimension 
 
Table 2.6.2. Hampton Research scoring guidelines for crystal identification.99 
 
Scores 3 to 6 describe the protein as having no defined edges, in many ways these are  
negative results but still provide information about which conditions the protein 
preferred.99 The pH range of the drops should be monitored, this can greatly affect the 
results of each drop. If the pH is particularly high or low then the condition can be 
avoided in future. A gelatinous precipitate (Score 4) can be a good starting point for 
optimisation and phase separation. Where (Score 5) is visible as droplets within the drop 
or as an ‘oil’ film on the surface of a drop. It can be difficult to mount crystals from this 
stage as the phase is of unknown composition.99 
From Score 6 to 9 the precipitate has definite edges. Score 6 are spherulites (transparent 
droplets or clusters), this stage can be a good start for crystallisation optimisation. 
Streak seeding can be used to optimise the drop conditions.100 Also additives e.g. MgCl2 
H.J LUMB 2015   CHAPTER 2:CHARACTERISING M2-1 
PROTEIN  
 52 
or inhibitors can be added if optimisation conditions do not yield crystals. Score 6 can 
also be micro-crystals where edges are visible in high magnification. Score 7 is crystal 
growth in one dimension which can be seen as needles. Seeding could be used to try and 
grow larger crystals in optimised conditions. Score 8 is crystal growth in two 
dimensions, optimisation can be achieved through the use of additives and seeding.  
Score 9 is three dimensional, these should be checked if salt crystals are forming in the 
wells. Buffer conditions can induce salt crystal formation, for this reason phosphate 
buffers are to be avoided. To ensure the crystals are not salt, the crystals are mounted to 
check diffraction quality which determines if they are  protein or salt crystals.16 
There are many commercial screens available which cover a wide range of conditions. 
In-house at Durham University, the Molecular Dimensions 96 well plates were preferred 
and in stock. Five screens of 96 well plates; Pact Premier101, Standard Screen 1+2102, 
JCSG+101,103, Standard Strategy and Standard screen 2102, containing various high 
throughput conditions were used.  
The first two trials at 30 µM and 60 µM M2-1 produced more clear screens (0) than 
precipitate. The general protocol provided through Molecular Dimensions states that 
approximately 50% of the drops must have a score of 2 (The drop is mostly clear but 
contains precipitated protein with no edges) or higher.99 If this is not the case then the 
concentration of the protein should be increased. The concentration of the sample was 
increased from 60 µM to 120 µM of protein. This gave some light and heavy precipitate 
across the 96 well screens after 1 week at 4 C, and some trays began to show small 
single crystals.  
In Standard Screen 1+2 a number of conditions showed a range of results. E3 – 2 %  v/v 
Dioxane, 0.1 M Bicine, 10 % w/v PEG 20,000 – Score 4 and 9. Drop C8 – No Salt, 0.1 M 
Tris, 8.5 pH and 2.0 M ammonium sulphate. – Score 4 and 9. Drop C8 contained 
ammonium sulphate, sulphates are known to form salt crystals as they interact with 
metal ions in the system. This was confirmed by mounting the crystal onto the 
goniometer and irradiating the sample with a beam of monochromatic X-rays. There was 
no regular repeating pattern of reflections seen. The crystals were determined to be salt. 
The single structures in drop E3 were not followed up as they had the same shape as the 
salt crystals in C8. A higher concentration of protein, 150 µM was used and the same 
conditions were re-tried. The standard 96 well sitting drop trays were constructed using 
the same commercial screen range as before.  After 5 days a drop started to show needles 
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as shown in Figure 2.6.3. The drop conditions were from Pact Premier plate and found 
in  D10 – 0.2 MgCl2, 0.1 mM Tris-HCl, pH 8.0 with 20% [w/v] PEG 6000.101 
 
Figure 2.6.3 Flat needles formed by 150 µM M2-1 in 0.2 MgCl2, 0.1m Tris-HCl, pH 8.0 with 20% [w/v] PEG 
6000. 
 
Optimisation is used to test different buffer conditions around the hit condition to try 
and improve the shape, size and stability of the initial hit. The hanging drop method 
works in much the same way as a sitting drop, with a vapour equilibrium between the 
well reservoir and drop being formed.16  This method is popular for crystallisations of 
macromolecules as the crystals formed can be easily accessed and the drops resealed 
quickly. Multiple drops, each with a different protein to buffer ratio can be tested in the 
same well. The needles were tested using the in-house diffractometer and no diffraction 
was obtained, this could be due to a non-diffracting protein crystal or an amorphous 
object. An increase in concentration may further help to form the 3rd dimension of the 
crystal that is lacking in 2D needles.    
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Further screens at 195 µM M2-1 concentration were tested. These gave dipyramidal 
crystals of approximately 50 µm in length as shown below in Figure 2.6.4. The conditions 
in the drop were found in Pact Premier, E5, 0.2M calcuim acetate, 0.1M Tris at pH 7.5 
and 25% PEG 2000 MME.101 
 
Figure 2.6.4. 195 µM M2-1 in 0.2M Calcuim Acetate, 0.1M Tris at pH 7.5 and 25% PEG 2000 MME. Crystal 
length was approximately 50 µm in length.  
Seeding was used to try and grow larger crystals as the initial screen yielded small fragile 
crystals which would be susceptible to radiation damage during data collection.  The 
crystals for seeding were crushed in situ, and then a cat whisker was coated in crushed 
crystals. The cat whisker was used in a straight line through the new optimisation drops 
to leave small amounts of crushed crystals in the well. This formed small nucleation sites 
where new crystals could form and the tray was incubated at 22 °C.  
After 2 weeks the trays had grown the same crystals and to the same size. These were 
harvested and frozen using liquid nitrogen and sent for analysis at Diamond, 
Oxfordshire, UK. Cryo-protectant of 30% glycerol was used to protect the crystal from 
cracking during freezing. P.D Townsend tested the crystals and no diffraction was found. 
Unfortunately the structure was solved by Tanner et al.5 in 2014 before more crystals 









Overall, this chapter summarises the characterisation of M2-1 through biophysical 
techniques. The aim of the chapter was to understand the structure of the protein so 
further binding studies with other structural proteins in hRSV are possible. Without a 
full length structure it is extremely difficult to understand where possible contacts and 
binding may occur.  
Firstly the protein was cloned by R. P. Yeo at Durham University in 2010. DNA 
sequencing confirmed that the protein ORF was full length and no mutations had 
occurred in the cloning process.  The Author then began protein expression trials using 
E.coli to produce a high enough yield for biophysical characterisation. Expression 
through E. coli was preferred for the relative cost of the research and the yield of protein 
produced. A GST affinity tag had been used in the cloning process, which allowed for a 
clean purification process. At the N terminus of M2-1, a zinc finger was a key structural 
finger which had been characterised previously.61  Further research showed a more 
stable protein was produced when zinc ion was added to the expression broth.   
MALDI-TOF analysis confirmed the sequence identity of the expression protein, M2-1. 
This was followed by ICP-MS to determine if the zinc finger was full occupied and to 
understand the stability of the protein in the presence of zinc ions. 
Dynamic light scattering and Circular Dichorism data were already available for M2-1, 
but this was repeated to ensure the protein was folded in the correct state. The results 
for these experiments correlated with the known values, here the diameter for the 
tetrameric M2-1 was found to be approximately 16 nm and it was observed to be 53% 
alpha helical in structure.62 
Thermal Shift assays were used to determine stabilising buffer conditions through 96 
well screening.95 The screen contained many different conditions from metal ions 
through to amino acids and varying salt conditions. The most stabilising compounds 
were used as additives in the buffers for purification and crystallisation. Stabilising 
compounds were found to be L-Histidine, L-Arginine-ethyl ester, Glycine-glycine 
dipeptide, Gly-Gly-Gly tripeptide and diethylamine.  
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In 2011 at the beginning of the Author’s period of study, no protein crystal structure for 
M2-1 was available. Many efforts were tried as detailed in the chapter, unfortunately 
Tanner et al. achieved diffracting crystals and subsequently published a full length 
structure in 20145 and at this point crystallisation efforts were abandoned.   
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2.8  METHODS 
2.8.1 EXPRESSION AND PURIFICATION OF M2-1 PROTEIN.  
A pGEX-6 vector containing the ORF of M2-1 protein, obtained from R. P. Yeo, was 
transformed into E. coli BL21-Codonplus and grown on ampicillin LB agar plates 
overnight at 37 °C. One colony was picked from the resulting plate and was incubated in 
0.2 L of LB broth (Tryptone 10 g/L, sodium chloride 10 g/L, yeast extract 5 g/L; Melford 
Laboratories Ltd., Suffolk, UK, 25 g/L) overnight at 37 °C. 0.01 L of the starter culture 
was used to inoculate 1 L of LB Broth in a 2.5 L conical flask, the bacteria were grown in 
the presence of ampicillin (100 mg/mL) and carbenicillin (100 mg/mL) at 37 °C for 5 
hours or until optical density at 600 nm reached 0.6-0.8. Expression was induced using 
isopropyl-β-D-1-thiogalactopyranoside (IPTG, 0.8 mM; Sigma Aldrich, UK) and left to 
shake overnight at 28 °C at 180 rpm. The bacterial cells were harvested by centrifugation 
at 4000 × g for 20 minutes in a Beckmann Coulter TM J-20 XP centrifuge, using rotor JLA 
8000 and the cell pellet was stored at -80 °C.  
Protein extraction was achieved through resuspending the pelleted cells in 0.02 L of  
lysis buffer (50 mM Tris,1 M NaOH, 5 mM CaCl2, 5 mM MgCl2 pH 7.6). Lysozyme (1 
mg/mL), DNase (1 µg/mL), RNase (1 µg/mL) and protease inhibitor tablet (cOmplete 
Mini™, EDTA-Free, Roche Diagnostics Ltd, West Sussex, UK)  were added once the pellet 
was resuspended. The cells were lysed by sonication for 240 seconds at 20 kHz and 3-
[(3-cholamindopropyl)dimethylammonio]-1-propanesulphonate hydrate (CHAPS, final 
concentration 8 mM in ddH2O) was added to the mixture and centrifuged at 50,000 x g 
for 30 minutes Beckmann Coulter TM J-20 XP centrifuge, using rotor JA 25.50 to remove 
cellular debris.  
The supernatant was treated with pre-equilibrated glutathione-agarose beads (50% 
suspension, 500 l/ mL)  and mixed by inversion for 2 hours at 4 °C. This was then 
centrifuged in a Beckman CoulterTM AllegraTM X-22R centrifuge for 20 minutes at 4 °C to 
sediment the beads and the supernatant discarded. The beads were resuspended in 10 
mL cleavage buffer (50 mM Tris,1 M NaOH, 1 mM DTT, pH 7.4) 
The mixture was then loaded onto a clear plastic column. The buffer was allowed to flow 
through under gravity until just above the bead line, whereupon a 3 M NaCl high salt 
wash was added. The beads were washed a further 2 times with Precission cleavage 
buffer.  The protein was eluted from the beads by the addition of Precission Protease 
(5 µL/ mL of lysate, GE Healthcare, UK). The column was stored at 4 °C for 48 hours. The 
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protein was eluted with successive washes of Precission Cleavage buffer (3 mL total 
volume), fractions were analysed by SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis) 
Fractions containing the protein were loaded onto a Superdex 16/60 200 size exclusion 
Fast Protein Liquid Chromatography column on an AKTA prime system (G.E. Healthcare, 
Buckinghamshire, UK) and were eluted in 50 mM Tris, 200 mM NaCl , pH 7 at 0.8 mPa 
pressure. Where protein was present, a UV-absorbance was shown. These fractions were 
analysed again by SDS-PAGE and the protein containing fractions were combined. 
 
2.8.2 THERMAL SHIFT ASSAYS (TSA) 
 
Fluorescence data was collected on an Applied Biosystems 7500 FAST Real-Time PCR 
System with an excitation range of 455-485 nm. 8 μL of M2-1 (1mg/mL) was pipetted 
into each well of a 96-well plate Semi-Skirted FAST trays (Starlabs, Suffolk, UK) and 10 
μL different known buffers (detailed in Appendix A.3) were added into each well. 2 μL of 
SYPRO Orange ( 5 fold concentration) was also added to give 20 μL in each well.  
The fluorescence emission signal at 567-596 nm was used for data analysis. The 
temperature was held for 1 minute per degree from 24 to 95 °C. NAMI, a Python 
programme written by M. Grøftehauge and N. Hajizadeh, was used to analyse the data 
collected.95 
 
2.8.3  SDS-PAGE (SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS) 
 
The purified protein was analysed using a 15% acrylamide resolving gel: 5 mL 
ProtoFlow 30% acrylamide gel (Flowgen Bioscience Ltd., Nottingham, UK), 2.5 mL buffer 
(1.5 M Tris, 0.4 % (w/v) SDS pH 8.8), 2.3 mL water, 0.1 mL 10 % SDS (Aldrich, Poole, 
UK), 0.1 mL 10 % (w/v) ammonium persulphate (APS) solution in water and 0.004 mL 
N,N,N’,N’-tetramethylethylenediamine (TEMED; Fluka). The stacking gel was made 
from: 1.7 mL ProtoFlow 30 % acrylamide gel (Flowgen), 2.5 mL buffer (0.5 M Tris, 0.4 % 
(w/v) SDS pH 6.8), 5.55 mL water, 0.1 mL 10 % SDS (Aldrich,), 0.1 mL 10 % (w/v) APS 
solution in water and 0.01 mL TEMED (Fluka). Protein samples were prepared by 
addition of protein loading buffer (2.5 mL 1 M Tris-HCl pH 6.8, 0.5 mL ddH20, 1.0g SDS, 
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0.8 mL 0.1% bromophenol blue, 4 mL 100% Glycerol, 2 mL 14.3 M β-mercaptoethanol 
(100% stock) and adjusted to 10 mL using ddH20, 5 µL in each 15 µL sample) and heated 
to 95 °C for 5 minutes then loaded onto the gel with a protein ladder molecular weight 
marker in the first well (10 – 250 kDa; New England Biolabs., Hertfordshire, UK). The gel 
was run at 200 V for 1 hour and stained using InstantBlueTM (Expedeon, Cambridge, UK) 
 
2.8.3. DETERMINATION PROTEIN CONCENTRATION  
2.8.3.1  NANODROP 1000 
The concentration of the protein was determined using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Kent, UK) by measuring absorbance at 280 nm 
where 1 IAU = 1 mg / ml. The protein concentration was increased using a Vivaspin 6 
(MWCO 10,000; GE Healthcare Life Sciences). Samples were centrifuged at 4000  g in a 
Beckman CoulterTM AllegraTM X-22R centrifuge for 20 minutes at 4 °C, tested using the 
NanoDrop 1000 spectrophotometer and repeated until the desired concentration was 
achieved.  
2.8.3.2 BRADFORD ASSAY  
Protein concentration was also verified by Bradford assay. Standard concentrations 
between 5 and 100 M of bovine serum albumin were prepared and allowed to 
equilibrate at room temperature for 30 minutes. Each sample was diluted using MilliQ 
water and Bradford reagent added.  Each concentration was measured at 595 nm using 
UV-visable spectrophotometer (Multskan Go, Thermo Scientific, UK) and the absorbance 
was plotted against the concentration to give a linear plot. The analyte protein was 
diluted and prepared in the same way and measured at 595 nm. The resulting 




2.8.4 DYNAMIC LIGHT SCATTERING 
 
A Malvern Zetasizer μV DLS system (Malvern Instruments Ltd., Worcestershire, UK) was 
used to conduct all DLS measurements in this work. The sample was held at 25 °C and 
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allowed to equilibrate for 60 seconds prior to analysis. Each size measurement was 
determined from 13 runs of 10 seconds in 50 µL cuvettes. (Starlabs, Suffolk, UK)  
 
2.8.5 CRYSTALLISATION SCREEN METHODS 
2.8.5.1 96-WELL  SITTING DROP TRAYS  
Crystallisation conditions were screened using the sitting drop vapour diffusion method, 
together with JCSG+™,101 Pact premier™,101 Structure screen 1™,103 Structure screen 2™ 
and Clear Strategy screen™101  96-well MRC crystallisation plate (Molecular Dimensions, 
Suffolk, UK) was filled with a mix of well solution from the above screens. Protein (30 nL 
and 60 nL) was dispensed by a crystallisation robot (Innovadyne Screenmaker 96+8, 
Solve Scientific, Australia) onto the sitting wells using a predetermined 20 psi method at 
Durham University. The well contents were then added to the drops to a total volume of 
100 nL. The drops were sealed with ClearVue sheets (Molecular Dimensions, Suffolk, UK) 
and placed at temperatures ranging from 4 °C to 22 °C until growth was observed.  
2.8.5.2. 24-WELL OPTIMISATION SCREEN 
24 well clear plastic XRL™ (Molecular Dimensions, Suffolk, UK) were used to contain the 
desired well solution. The well solution (1 mL total volume) was a variation of the 96-
well sitting drop tray hit to further optimise conditions. The protein and well solution 
were pipetted onto 24 mm siliconized round cover slips (Molecular Dimensions, Suffolk, 
UK) in various concentrations and sealed with sealing grease (Molecular Dimensions, 
Suffolk, UK). The trays were placed at temperatures ranging from 4 °C to 22 °C until 
growth was observed.  
2.8.5.3. STREAK SEEDING 
Small Crystals previously grown in other 96 or 24 well trays were crushed in-situ by a 
small crystallisation trowel (Molecular Dimensions, Suffolk, UK). A cats whisker was 
coated with the crushed crystals and moved through a new protein-buffer drop on a 24 
mm siliconized round cover slip (Molecular Dimensions, Suffolk, UK) from left to right. 
The slip was sealed using sealing grease (Molecular Dimensions, Suffolk, UK) and placed 
at temperatures ranging from 4 °C to 22 °C until growth was observed.  
2.8.5.4 CRYSTAL MOUNTING. 
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A cryoprotectant solution was produced by supplementing the mother liquor with 
glycerol (30% v/v). The crystals were harvested in round litholoops (Molecular 
Dimensions, Suffolk, UK) then the crystal and loop were covered in cryoprotectant 
solution before flash freezing in liquid N2. 
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CHAPTER 3.  PROBING THE INTERACTION BETWEEN MATRIX PROTEIN AND M2-1.  
 
Previously it was thought that M2-1 was located only in the cytosol of the virus and in 
the host cell cytoplasm, but through cryotomography, it has been seen that M2-1 is likely 
to be a major structural protein.78 This newly discovered role of M2-1 reveals an 
interaction with the matrix protein and a possible interaction with the nucleocapsid and 
ribonucleocapsid formations. The work completed by Li et al.58 using hRSV M protein in 
hRSV-infected cells shows that the matrix protein inhibits viral transcription and 
colocalises to M2-1 in the cytoplasm of cells.58 Further to this, nucleocapsid protein and 
matrix protein were shown to directly interact with M2-1 in a cell-free binding assay.58 
Li et al. have also shown that it is the N-terminal 110 amino acids of the matrix protein 
which interact with M2-1.58 This interaction of M2-1 and M, with a focus on the binding 
N-terminal region of M, could be a target for antiviral research. Disruption of this 
interaction has the potential to block the interaction of M with the nucleocapsid and 
inhibit virus assembly. There are no reported data on the binding domain of M2-1 
responsible for this interaction, in contrast to its interaction with the phosphoprotein 
which has been extensively characterised.61 
This chapter discusses the preliminary investigations into the interaction of M2-1 with  
matrix protein. Firstly, direct binding will be shown and confirmed in vitro by the use of 
pulldown assays where SDS PAGE is used to show the proteins involved in binding.  Once 
the binding was confirmed the interactions were investigated using Transmission 
Electron Microscopy to visualise the aggregates which formed.  
Further characterisation of the interaction using Surface Plasmon Resonance and 
Fluorescence Anisotropy was used to gain an insight into the  thermodynamic pathway 
and to understand the stoichiometry of the proteins involved. This work is key to further 
understanding how the viral proteins interact and may give an insight into potential 
mechanisms to hinder that interaction. 
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3.1. PULLDOWN ASSAY.  
 
A pulldown assay is an in vitro method, which can be used to indicate the binding of two 
proteins. The method works by using an immobilised bait protein, in this case M2-1 
bound to glutathione beads. The protein with the suspected interaction (a prey protein) 
was then passed over the beads.104  Systems in which the prey and bait proteins interact 
will see the former, in this case M2-1 bound to the beads and if the second protein 
interacts with M2-1 binds and is eluted with the beads. If there is no interaction then in 
the subsequent wash steps the second protein is washed from the mixture. The results 
of this experiment are shown in Figure 3.1.1 where the SDS-PAGE shows that M2-1 binds 
the matrix protein in the experiment. Lane 2 shows the GST tagged M2-1 protein and 
also the free GST tag, this appears as a smear on the SDS PAGE gel as cell lysate was used 










Figure 3.1.1. 15% SDS-PAGE gel, Lane 1 – NEB Protein Ladder (10 kDa-250 kDa) Lane 2 – GST fused M2-1, 
Lane 3 – Matrix protein. Lane 4 – NEB Protein Ladder (10 kDa-250 kDa), Lane 5 – Blank GST slurry, Lane 6 







1 2 3 4 5 6 7 
GST-M2-1 
Matrix protein 
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3.2. TRANSMISSION ELECTRON MICROSCOPY (TEM). 
A Transmission Electron microscope (TEM) uses a beam of electrons instead of light to 
view the required sample.  This is achieved through a high voltage electron beam that is 
focussed by electromagnetic lenses onto a sample that has been fixed to a graphite 
matrix film by glutaldehyde crosslinking.105 Glutaldehyde cross-linking protects the 
structures formed from radiation damage by the electron beam and vacuum. Fixed 
samples were stained using uranyl acetate and air dried before being imaged in the 
microscope.106 A negative image, as seen below, was produced where the darker colour 
is the background and the lighter image is the protein structure. This contrast is relative 
to the concentration of the dye used so this was held constant for the different sets of 
proteins that were tested.  
Initially each individual protein alone was fixed to the film as a negative control to the 
complexed proteins. These images showed white shapes on a black background. The 
individual protein molecules were too small for a high resolution image to be obtained. 
The images showed molecules of M and M2-1 approximately ~20 nm in diameter as 
shown in Figure 3.2.1, which agrees with the previously reported size of the M2-1 
tetramer in solution62 and matrix protein in solution.  
 
Figure 3.2.1 Left,  M2-1 protein ~12 nm, 120,000 × zoom.  Right, Matrix protein TEM image,  ~7 nm 100 
000 × zoom. 
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Figure 3.2.2. TEM image of a protein aggregate at ~63nm. 
The image of the mixture of the two proteins M and M2-1, is shown in Figure 3.2.2. A 
number of different aggregates could be seen as shown in Figure 3.2.3, indicating a 
number of different conformations in the solution. Each of the aggregates has a dark 
centre, indicative of a point on the film where there is no protein. This could show that 









Figure 3.2.3 Smaller aggregates seen on the TEM at 120 000 × zoom. 
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Figure 3.2.4 Aggregates at ~ 40 nm and 60 nm at 120 000 × zoom. 
The hMPV M2-1 was crystallised in a ‘open’ formation as discussed in Chapter 1, where 
one monomer from the tetrameric model was swung 60 Å away from the other 
subunits.50 This is a mechanism of interaction that cannot be ruled out for hRSV M2-1, 
but the aggregates do not seem to have an obvious protrusion showing a monomer unit. 
There is, however, a large dark centre in the ~ 60 nm aggregate, as this is a negative stain 
this points towards a hole in the centre of the larger aggregate, indicating a ring like 
structure.  
From the results shown in Figures 3.2.2 and 3.2.3, two main species have been identified, 
one at approximately 40 nm and one at 60 nm in diameter. This is in comparison to the 
crystal structures of the two proteins which show M2-1 to be ~ 80 Å (8 nm) and M 
diameter in ~ 72 Å (7 nm), from point to point. The structures are similar in shape and 
dimensions so the comparisons could extend to the binding of M2-1 and M in the hMPV, 
where it could be predicted that the proteins would bind in a similar way. The monomer 
size corresponds well to the published dynamic light scattering data of 15 nm ± 4 nm62 
and the initial TEM images correlate well to the published data so the new species sizes 
would be expected to be indicative of the complexes found.  
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The new complexes that have been imaged in this chapter show that an interaction 
between the two proteins does give new complexes. Unfortunately, high resolution data 
are not obtainable using this technique, however further investigation through cryo-
electron microscopy would allow us to reevaluate the 3D structure of the complexed 
species.  The technique is not available at Durham University and the experiment could 
not be completed in the Author’s research time.  
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3.3 SURFACE PLASMON RESONANCE  
 
 
Figure 3.3.1 Surface plasmon resonance.107 
 
This technique can be used to determine thermodynamic data for the binding between 
two species using a flow method, where one species is attached to an active surface as 
shown in Figure 3.3.1. The technique uses Maxwell’s theory where the free electrons of 
the gold surface on the chip are present as plasma.108 Plasma is an electron liquid of high 
density,107 and density fluctuations of the surface liquid are called plasmons.107 The 
signal given is based on the excitation of surface plasmons when the polarised light hits 
an electrically conducting gold layer. At a specific angle the excitation occurs and the 
resulting reflected light is of reduced intensity.107 A change in the interface, i.e. when a 
sample is bound, will change the refractive index and so the thickness of the sample film 
leads to change in signal.107 
There are multiple ways that protein can be attached to the chip, these vary between 
manufacturers. The chip is commonly a glass surface which is coated with gold, then a 
self-assembled monolayer (SAM) is constructed on the gold surface.108 The SAM are inert 
organic molecules which are used as a linker layer to which non-crosslinked 
carboxymethylated dextran can adhere.107  
The dextran is a chain of 1,6 – linked glucose molecules which has very low non-specific 
absorption and a head region which can be activated to covalently bind ligands to the 
surface of the chip by amine-, thiol- or aldehyde chemistry dependant on the type of 
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chip.108 A CM5 chip is a general chip containing only dextrans on the surface, and is 
appropriate for the interaction analysis of all types of biomolecules from small organic 
molecules to proteins. The head region of the dextran chain is activated through carboxyl 
groups and functional groups on the ligand can then be coupled to the active carboxyl 
groups.107 Initially this chip was utilised as a starting point for analysis of the interaction 
between M and M2-1 so each individual protein could be tested attached to the chip. To 
activate the dextran chain activation buffers of (1-ethyl-3-[3-
dimethyaminopropyl]carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide 
(NHS) were injected through the machine to give an active surface to which the protein 
could bind.108 
 
Figure 3.3.2 1 and 2. Activation of the carboxyl group with 1-ethyl-3-[3-dimethyaminopropyl]carbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS). 3. Covalent attachment of the ligand by a primary 
amine. 108 
It was found that M2-1 did not attach successfully to the chip, where a response of -5 RU 
was seen after deactivation of the free unattached head group of the dextran strands. 
The deactivation is a key step to ensure no background signal is recorded from the 
unspecific binding that can occur through protein groups.108 Through multiple 
optimization steps it was decided that this type of chip was unsuitable for this 
experiment. An NTA chip was the secondary choice with the same dextran chains on the 
chip but this time the active head consisted of NTA (nitrilotriacetic acid). The head 
region was activated by chelating with nickel, this has a high affinity (~108 M) towards 
a 6× histidine (His6) tag on the protein of interest. The immobilization using this chip via 
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His6 has the benefit of orientating the ligand molecules in a homogenous way.107  
3.3.1 MATRIX PROTEIN CONCENTRATION SCOUTING.  
As M2-1 did not attach successfully to the CM5 chip, the NTA chip was used. The matrix 
protein was previously cloned with a His6 tag needed for the NTA chip. There is no hard 
and fast rule on how to attach the protein of interest to the chip, this is entirely 
dependent on the size and shape of the protein in question.107 The quantity of protein 
bound to the chip should be sufficient to give a response on the sensogram and also be 
sufficiently stable to give a steady baseline. A ten-fold concentration range was advised 
for a concentration scout by the G.E Healthcare NTA Chip user manual.109 Conditions for 
optimum loading were determined over a broad concentration range and were found to 
be 2 M to 20 M of M2-1 as shown in Figure 3.3.1.1 below.  
 
Figure 3.3.1.1  His6-Matrix protein concentration scout. The dissociation curve is shown from 70 s 
onwards. 
It can be seen that above 5 M there was no higher response (RU) from injecting higher 
concentrations of protein. This suggests that the protein saturated the chip and all 
activated NTA dextran was bound. In using the NTA chip there must be a compromise 
between the stability of the protein on the chip and the response. If too much protein 
binds the decay of the signal from the chip could give an unstable wandering baseline for 
the addition of the second protein.108 3 M protein of His6-tagged matrix protein was 
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3.3.2. ADDITION OF M2-1  
Matrix protein was added at 3 M to the chip, so a 2.5-20 M range of M2-1 was tested 
initially. M2-1 protein solution was flowed across at 30 L/min. The final sensogram is 
shown in Figure 3.3.2.1 where each step is labelled A-D. The chip has to be activated first 
so the NTA group can bind nickel as shown in Step A. Step B includes the addition of a 
set concentration of matrix protein and step C is the addition of M2-1 in the chosen 
concentration range. Step D is the regeneration of the chip where the EDTA solution 
deactivates the NTA group and removes any bound material. The process is repeated 
where only step C changes to test the whole M2-1 concentration range.  After 




Figure 3.3.2.1  Sensogram of Biacore 3000 run. A) NiCl2 activation B) His Matrix protein, 3 M. C) M2-1, 
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Figure 3.3.2.2 M2-1 binding on the immobilised matrix protein NTA chip.  Concentrations used from 2.5 
M to 20 M as shown in the legend. 
 
Longer injections were used to achieve saturation of the association curve of each 
concentration. On analysis this did not change the overall fit of the curves and so smaller 
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3.3.3 DATA ANALYSIS  
Using the BIAEvaluation software, supplied by G. E Healthcare, analysis of the different 
binding curves could be completed. The software analyses data using a simple 1:1 
binding mode where each curve was analysed using two separate algorithms, local and 
global fitting. In the local fitting each curve was treated as a separate experiment with 
its own kobs rate constant. The averaged equilibrium constants and association curve 
fitting are shown below. 
 
Figure 3.3.3.1 Association data local fitting curve for M2-1 addition to the immobilised matrix 
protein, shown in BIAevaluation software.110 
 
   
Figure 3.3.3.2 Residual plots of the curve fitting of M2-1 addition to the immobilised Matrix protein as 
shown in BIAevalution software.110 
2 µM M2-1 
5 µM M2-1 
8 µM M2-1 













-40 -20 0 20 40 60 80 100 120 140 160 
RU 














2 µM M2-1 
5 µM M2-1 
8 µM M2-1 
10 µM M2-1  
60 
Time (s) 













H.J LUMB 2015  CHAPTER 3: PROBING THE 
INTERACTION BETWEEN MATRIX 





A residual (e) is the difference between observed value of the dependant variable (y) 
and the predicted value (ŷ).  Plotting the values of each curve shows the statistical 
difference and the similarity of the fit, for example a perfect fit would be a horizontal line 
at residual value 0. In Figure 3.3.3.2 above, the maxima is +4 and the minimum of the 
curves at -8 residuals, which are low values and fit with a 1:1 interaction.  These are used 
in comparison to the global analysis of the same data to understand which fit is the most 
appropriate and this is discussed later in this chapter.   
 ka  kd  2 
3.66 × 103 M-1 s-1  2.73 ×10-3 s-1 14.1 
 
Table 3.3.3.3 M and M2-1 interaction. Where kd is the dissociation rate constant of the two proteins, ka is 
the association rate constant and 2 is the fitness score. 
The interaction was found to be 1:1 binding by analysis of local fit and the 2 value, which 
is a fitness score, is low in accordance with a good fit. The 1:1 binding is in contrast to 
the initial indications from the TEM where two major species were found, which could 
indicate multiple modes of action. This could suggest that one of the two species seen in 
TEM could be undergoing a rearrangement to allow further binding in one form as 
shown below in Figure 3.3.3.4. or that this species does not bind to the chip.  
 
  A) 
 
 
  B) 
 
 
Figure 3.3.3.4 A) Simple 1:1 Binding, where L is a Ligand and P is protein B) A rearrangement step shows 
the formation of a new intermediate species. 
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Figure 3.3.3.5 Global fitting curve for the experimental curve of M2-1 addition to the immobilised matrix 




Figure 3.3.3.6 Residual plots for curve fitting using a global method  of 1:1 interaction of M2-1 to the 
immobilised matrix protein as shown in BIAevalution software.110 
 
The global analysis curves and the residual plots show a larger difference in the fitting 
of the curve to the experimental data than the local analysis plots. This is seen where the 
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fit parameters for the curves shown above in Figure 3.3.3.6. The residual plots vary from 
-200 to above 300, which is in contrast to the small variance shown in the local fit.  
In the curve fitting in Figure 3.3.3.5 there is another feature that could contribute to the 
poor fit of the data. The fitted curves have a large drop where the injection stops and the 
dissociation curve begins. This is not seen in the experimental data and could be 
attributed to the inadequacy of the model of fitting.  
 
ka  kd  2 
4.8 × 103 M-1 s-1 3.11 × 10-3 s-1 1.15 × 104  
 
Table 3.3.3.7. Kinetic data for M and M2-1 using a global fit. Where kd  is the dissociation rate constant of 
the two proteins, ka is the association rate constant and  2 is the fitness score. 
 
Using both the local and global fittings, the equilibrium constant has been shown in this 
experiment to be 0.64 µM for a 1:1 interaction. It is known that M2-1 is a tetramer in 
solution62 at these concentrations. In this case where the M protein is anchored by the 
His6 tag dimerization may not be possible which could impact on the binding of the two 
proteins. The activated dextran binds to one of the two available N-terminal His6 tags in 
the hRSV M dimer.  This method of binding would mean that only one of the two available 
sites on matrix protein dimer would be used and one monomer would be anchored only 
by the interaction on the dimer interface. A high flow rate on the chip could disrupt the 
associated proteins and distort the results of this experiment. Further experimental data 
are needed using a technique where all the proteins are in solution, this could eliminate 
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3.4. FLUORESCENCE ANISOTROPY 
 
Fluorescence anisotropy is a technique which is used for many biophysical applications. 
These range from quantifying protein denaturation, measuring the dynamics of proteins 
in solution through to quantifying protein association with other macromolecules. This 
last use is particularly useful and will be applied to initially characterise the interaction 









Figure 3.4.1. The components  of a basic fluorescence anisotropy experiment.111 
A basic fluorescence anisotropy experiment will comprise of the components shown 
above in Figure 3.4.1. The method begins when polarised light is shone on the 
fluorophore, an electron is excited into a higher energy state and extra energy is 
absorbed.75 Fluorescence Anisotropy probes this transition moment at a specific 
orientation from the absorption of energy to the emission of the photon.111,112 The 
difference between the transition moments is seen as depolarisation and can only occur 
when the light is located on a particular axis on the molecule and the emitted photon will 
have a specific polarisation.112 Light is emitted at an angle dependant on the speed at 
which the molecule tumbles, whereas the rate of tumbling is related to the particle’s 
size.111,112   
For a signal to be seen and plotted, the sample is required to have a fluorophore bound. 
In this case the matrix protein was reacted with to Rhodamine Red succinimidyl ester, a 
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protocol for this in the VAM/JMS group was known and a highly labelled protein was 
produced. Previous labelling experiments by the group with M2-1 gave less than ideal 
results where a poor yield of protein was recovered. Rhodamine red (RR) X-
succinamidyl ester is a dye shown in Figure 3.4.2, it is an amine specific fluorophore that 
attaches to the primary amine chains in lysine residues.  
 
Figure 3.4.2. Rhodamine Red (RR) X- succinimidyl ester. 
 
When the polarised light in the polarising fluorimeter is shone on to randomly oriented 
fluorophores, most of the energy will be emitted at a range of angles.  The fluorophore 
can freely change orientation in solution before the emission of a photon and the degree 
of polarisation of this light will be reduced relative to the incidence beam. The difference 
in polarisation between the incident and emitted light depends on a number of factors 
such as the length of the fluorescence lifetime as shown below. 






Where r is the observed anisotropy, r0 is the intrinsic anisotropy of the molecule,  is the fluorescence 
lifetime and  is the rotational time constant.111 
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In Fluorescence anisotropy, the fluorescent molecule involved in binding exists in the 
solution in one of two states, bound or free.  Each state will have a unique anisotropy 
value and is summerised 
A = FfAf  + FbAb 
Where Ff + Fb = 1, A= observed anisotropy value, Ff = fraction of fluorescent lignd that is free, Fb = fraction 
of fluorescent ligand that is bound, Af = Anisotropy of the free fluorescent ligand, Ab = Anisotropy of the 
bound fluorescent ligand 113 
 
For protein-protein binding, the fluorescent signal (degree of polarisation) should be 
low at the start of the experiment, where Rhodamine Red (RR) bound matrix protein is 
turning unhindered in solution and no titrant is present.112 The binding is indicated by 
an increase of the polarisation signal as the fluorophore is less able to change orientation 
due to the larger bound protein.111  It is assumed that there is no quenching of the 
fluorophore occurring, as the fluorophore is not directly involved in the binding event. 
The resulting graph of the change in relative fluorescence is shown in Figure 3.4.3 below. 
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There is a clear increase in Δr from approximately 0.7 M through to 10 M where the 
FR-matrix protein is rotating more slowly when bound to M2-1. Another binding curve 
can be seen above 10 M, but further investigations were hindered due to protein 
precipitating out of solution.  
The data were analysed by the author and J. M. Sanderson using a theoretical 
thermodynamic pathway, where the oligomerisation state of matrix protein was in 
question.  
3.4.1 M OLIGOMERISATION MODEL 
The thermodynamic model proposed, shown in Figure 3.4.1.1 includes all species 




Scheme 3.4.1.1 Thermodynamic pathway for the binding equilibria of matrix protein to M2-1. Where Mn 
is the multimer of M which is in equilibrium with M as a monomer shown as Km. M:M2-1 bind in a 
monomer:tetramer formation. This then leads to another M2-1 binding to M which is K2. 
Previously H. K. McPhee, Durham University114 demonstrated that the matrix protein can 
be identified as a dimer, tetramer and a hexamer by chemical crosslinking and mass 
spectrometry analysis. Using the model above takes into account the potential for M 
oligomerisation, whilst allowing for interaction of monometic M with M2-1.  If the model 
above in Scheme 3.4.1.1 is correct, it provides support to the binding model, where 
monomeric M binds to M2-1. Also another term where 2 M2-1 were bound to matrix 
protein allows for modelling of the formation of 2:1 stoichiometry potentially seen in the 
electron microscopy. The binding isotherm is shown below in Figure 3.4.1.2, which 
details all species in the mixture that contribute to the signal. Each [protein]/[Mtot] term 
determines the fraction of signal from each species relative to the total signal.  
 
Figure 3.4.1.2 Binding isotherm for M oligomerisation, M and M2-1 and M (M2-1)2 . Mn is the 
concentration of M in the oligomeric form and n is variable. Where rcalc  is the calculated response from all 
components from the reaction.  rfree is signal in absence of fluorophore. M2-1 is not labelled so does not 
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Figure 3.4.1.3 Binding curve of M and M2-1 showing the fit of the model to the data obtained. 
Concentration of M varies from 10 × 10-10 M to 2 × 10 -5 M. Imported from a  
 
The binding curve and fit is shown in Figure 3.4.1.3 and the concentrations of each 
component in the equilibrium binding were then calculated. It was noticed that the data 
above 10 M did not fit with the above model, it was noticed at these higher 
concentrations that a small amount of precipitate began to form. The variance of the data 
(s2) was found to be 5.32 × 10-5 and the standard deviation is 7.2 × 10-3 for calculated 
and experimental concentrations. A low value indicates that a close fit is observed using 
this thermodynamic pathway despite the variation at the higher concentrations. The 
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Table 3.4.1.4 Association and dissociation constant values from the oligomerisaton M fit. 
The data as shown above indicate a 13 fold increase in the equilibrium constant in 
comparison to the previous SPR experiments shown in Table 3.3.3.3 and 3.3.3.7. Overall 
Kspr = 0.64 µM in comparison to K1(fa) = 8.3 µM.  In K2, where a second M2-1 binds to the 




K1 K2 Km 
1.20 × 105 M-1 
 
2.88 × 104 M-1 
 
2.27 × 101 M 
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3.5. FUTURE WORK.  
 
3.5.1 ISOTHERMAL TITRATION CALORIMETRY (ITC) 
 
ITC directly measures the change in heat of the reaction between the two interactants 
and is considered one of the definitive techniques for understanding physical or 
chemical reactions. The Surface Plasmon Resonance experiments gave an Kd of the 
binding, but ITC would help characterise the interaction further. ITC is a highly sensitive 
technique and direct thermodynamic characterisation of the association of the proteins 
can be obtained.115 The relationship between the binding sites, if there are indeed 
multiple sites, could be identified to understand the cooperativity of the reaction.  
 
3.5.2 CRYO-ELECTRON TOMOGRAPHY (CRYO-ET) 
 
Cryo-Electron Tomography uses the 2D image slices of a frozen sample to form a 3D 
image.78 In this chapter the protein interactions were investigated using electron 
microscopy. This technique is limited by the resolution of the microscopy and the 
degradation of the sample. By using Cryo-Electron Tomography the limitations are 
removed as the structure of the sample is preserved from electron damage by freezing 
the sample in liquid nitrogen and placing in a vacuum chamber.36 The technique 
preserves the biological structure in the vacuum, which would be ideal for a non-
covalently linked complex such as these. Unlike Transmission Electron Microscopy there 
are no chemical fixing agents or stains used. This again preserves the structure and also 
prevents warping of the sample when exposed to the stain. This technique would be 
preferred to small angle X-ray scattering due to a lack of purification techniques for the 
complex. Cryo-EM could image the complex for shape, and thus a 3D structural shape of 
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3.5.3 BINDING REGION MUTATIONS 
 
From previous papers116,7 it is known that the N-terminal domain of the matrix protein 
interacts with the M2-1 protein. Binding region mutations could begin to pinpoint the 
exact residue/residues that are involved in the interaction. Firstly the gene would be 
recloned with small sections i.e. five amino acids each time from the N Terminal region 
removed. After optimisation and purification the truncated proteins would be tested 
using the techniques used in this chapter. The truncation that contains the interaction 
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The interaction between M and M2-1 proteins has been indicated through work by Li et 
al.58  using cytoplasmic inclusion bodies in hRSV infected cells. The proteins co-localise 
together during the experiment and on further investigation by cell free binding assays 
it was shown that M2-1 and M bind together.  Further characterisation is needed to 
determine the scope of the interaction and how important this could be for future viral 
targets.  
Initial pulldown assays were used to determine if the in vitro the interaction could be 
mapped and if indeed the two proteins do interact in the absence of the nucleocapsid 
protein.  Once the interaction was confirmed, transmission electron microscopy was 
used to try and image the aggregate of the two proteins. This was successful and two 
major species were seen on the negative stain.  The two species were unique sizes, which 
were ten-fold larger than the respective M2-1 tetramer and M dimer.   
Further binding was observed and characterised by the use of surface plasmon 
resonance and fluorescence anisotropy. The former gave a Kd of 5 mM, where the data 
were fitted to a 1:1 Langmuir interaction model. This was a true fit for concentrations of 
M2-1 below 10 M but above this, the 1:1 fitting deviated from the experimental data.  
This could be due to a second species being present above a certain concentration, which 
could be a rearrangement that mirrors that of the hMPV tetramer.50 
To begin to understand the thermodynamic pathway of the reaction, fluorescence 
anisotropy experiments were conducted. In the oligomerisation model, the fitted curve 
was found to be a close fit up to 10 M above this concentration the fit was poor. As 
matrix protein has been found to form up to a hexamer in solution so the dimerization 
form of the protein could not be relied upon. The variance between the curve and the 
observed polarisation indicated that this was the better statistical model for the data but 
further characterisation work is needed to determine if the thermodynamic pathway is 
a true representation. 
Further analysis through Cryo-Electron Tomography could yield a more conclusive 
image of the proteins binding. In this technique protein slices are imaged which can be 
pieced together to form a 3D structure of the bound proteins.78  
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In future work, Mutations of the N-Terminal of M, which has been previously detailed as 
forming the binding region117 could help to understand the binding and stoichiometry as 
well as employing Isothermal Titration Calorimetry to fully characterise the interaction.  
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3.7 METHODS  
3.7.1 EXPRESSION AND PURIFICATION OF M PROTEIN. 
 A pET-16-b vector containing the ORF of M protein, obtained from R.P. Yeo, was 
transformed into E. coli BL21-DE3 and grown on ampicillin LB agar plates overnight at 
37 °C. One colony was picked from the resulting plate and was incubated in 0.2 L of LB 
broth (Tryptone 10 g/L, sodium chloride 10 g/L, yeast extract 5 g/L; Melford 
Laboratories Ltd., Suffolk, UK, 25 g/L) overnight at 37 °C. 0.01 L of the starter culture 
was used to inoculate 1 L of LB Broth in a 2.5 L conical flask, the bacteria were grown in 
the presence of ampicillin (100 mg/mL) at 37 °C for 5 hours or until optical density at 
600 nm reached 0.6-0.8. Expression was induced using isopropyl- β-D-1-
thiogalactopyranoside (IPTG, 0.8 µM; Sigma Aldrich, UK) and left to shake overnight at 
28 °C at 180 rpm. The bacterial cells were harvested by centrifugation at 4000 × g for 20 
minutes in a Beckmann Coulter TM J-20 XP centrifuge, using rotor JLA 8000 and the cell 
pellet was stored at -80 °C.  
Protein extraction was achieved through resuspending the pelleted cells in 0.02 L of  
lysis buffer (50 mM Tris,1 M NaOH, 5 mM CaCl2, 5 mM MgCl2 pH 7.6). Lysozyme (1 
mg/mL) and protease inhibitor tablet (cOmplete Mini, EDTA-Free, Roche Diagnostics 
Ltd, West Sussex, UK) were added once the pellet was resuspended. The cells were lysed 
by sonication for 240 seconds at 20 kHz and 3-[(3-
cholamindopropyl)dimethylammonio]-1-propanesulphonate hydrate (CHAPS, final 
concentration 8 mM in ddH2O) was added to the mixture and centrifuged at 50,000 × g 
for 30 minutes Beckmann Coulter TM J-20 XP centrifuge, using rotor JA 25.50 to remove 
cellular debris.  
The supernatant was then passed through a pre equilibrated nickel affinity His-trap 
column (GE Healthcare Life Sciences, Buckinghamshire, UK). After the supernatant had 
passed through the column, Tris buffer (50 mM Tris, 300 mM NaCl pH 7.6) was run 
through, followed by an increasing concentration of imidazole (50 mM Tris, 300 mM 
NaCl, 50 mM to 1 M imidazole pH 7.6). The protein eluted at 200 – 500 mM imidazole 
and the fractions were analysed for M protein by SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis) 
The protein was buffer exchanged overnight into Tris buffer (50 mM Tris, 200 mM NaCl) 
or PBS (Gibco® PBS tablets, Life Technologies, Renfrew, Scotland) by dialysis (MWCO > 
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12,000 Da) at 4 °C. The His-tag was removed by cleavage with Factor Xa overnight, as 
per the manufacturers instructions (Novagen, Merck Chemicals Ltd., Nottingham, UK).  
The matrix protein was then stored and used at 4 °C. 
3.7.2  SDS-PAGE (SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS) 
The purified protein was analysed using a 15% acrylamide resolving gel: 5 mL 
ProtoFlow 30% acrylamide gel (Flowgen Bioscience Ltd., Nottingham, UK), 2.5 mL buffer 
(1.5 M Tris, 0.4 % (w/v) SDS pH 8.8), 2.3 mL water, 0.1 mL 10 % SDS (Aldrich, Poole, 
UK), 0.1 mL 10 % (w/v) ammonium persulphate (APS) solution in water and 0.004 mL 
N,N,N’,N’-tetramethylethylenediamine (TEMED; Fluka). The stacking gel was made 
from: 1.7 mL ProtoFlow 30 % acrylamide gel (Flowgen), 2.5 mL buffer (0.5 M Tris, 0.4 % 
(w/v) SDS pH 6.8), 5.55 mL water, 0.1 mL 10 % SDS (Aldrich,), 0.1 mL 10 % (w/v) APS 
solution in water and 0.01 mL TEMED (Fluka). Protein samples were prepared by 
addition of protein loading buffer (2.5 mL 1 M Tris-HCl pH 6.8, 0.5 mL ddH20, 1.0g SDS, 
0.8 mL 0.1% bromophenol blue, 4 mL 100% Glycerol, 2 mL 14.3 M β-mercaptoethanol 
(100% stock) and adjusted to 10 mL using ddH20, 5 µL in each 15 µL sample) and heated 
to 95 °C for 5 minutes then loaded onto the gel with a protein ladder molecular weight 
marker in the first well (10 – 250 kDa; New England Biolabs., Hertfordshire, UK). The gel 
was run at 200 V for 1 hour and stained using InstantBlueTM (Expedeon, Cambridge, UK) 
 
3.7.3  DETERMINING PROTEIN CONCENTRATION  
3.7.3.1  NANODROP 1000 
The concentration of the protein was determined using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Kent, UK) by measuring absorbance at 280 nm. 
The protein concentration was increased using a Vivaspin 6 (MWCO 10,000; GE 
Healthcare Life Sciences). Samples were centrifuged at 4000 × g in a Beckman CoulterTM 
AllegraTM X-22R centrifuge for 20 minutes at 4 °C, tested using the NanoDrop 1000 
spectrophotometer and repeated until the desired concentration was achieved.  
3.7.3.2 BRADFORD ASSAY  
Protein concentration was also verified by Bradford assay. Standard concentrations 
between 5 and 100 M of bovine serum albumin were prepared and allowed to 
equilibrate at room temperature for 30 minutes. Each sample contained the diluted 
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protein sample using MilliQ water to the appropriate concentration at 800 L and 
Bradford Reagent (Sigma Aldrich, UK) 200 L. Each concentration was measured at 595 
nm using UV-visable spectrophotometer (Multskan Go, Thermo Scientific, UK) and the 
absorbance was plotted against the concentration to give a linear plot. The protein was 
diluted and prepared in the same way and measured at 595 nm. The resulting 
absorbance was plotted on the standard graph and the concentration was found on the 
x-axis.  
3.7.4 PULL DOWN ASSAY  
M2-1 protein was prepared according to chapter 2.8.1 until crude protein was obtained. 
50 µL of protein (~30 µM) was decanted into microcentrifuge tubes and kept on ice for 
use later. 
Glutathione sepharose 4B bead slurry (G.E Healthcare, Stevenage, uk)  was decanted into 
a microcentrifuge tube (Starlabs, Milton Keynes, UK) and sendimented by centrifugation 
at 500 × gfor 5 minutes. The supernatant was decanted and 1 mL of 1 × PBS was added 
to resuspend the beads to form a 50% slurry. 
 20 µL of the 50% slurry of glutathione sepharose 4B to each centrifuge tube containing 
protein and gently mix for 1 hour at 4 °C. The slurry and protein centrifuged and the 
supernatant discarded. 100 µL of 1 × PBS was added, the tube was vortexed briefly and 
centrifuged for 10 seconds to sediment the sepharose beads. The supernatant was 
discarded and the wash was repeated 3 times.   
To elute the protein from the beads, 10 µL of  glutathione elution buffer ( 0.154 g reduced 
glutathione in 50 mL of 10 mM glutathione pH 8.0) was added to the protein slurry 
mixture. The mixture was vortexed to suspend the sepharose beads and the elution 
buffer was incubated for 5 minutes at RT. The slurry was centrifuged for 5 minutes to 
sediment the sepharose beads and the supernatants to fresh labelled tubes.  
To identify the proteins in the mixture, 10 µL aliquots of each sample run on a SDS page 
gel, as described in chapter 3.7.2. 
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3.7.5 TRANSMISSION ELECTRON MICROSCOPY  
All images obtained via transmission electron microscopy using a modified negative 
staining protocol were with assistance of A. C. Richardson. A JEOL 2100F FEG TEM with 
a GATAN GIF tridiem with 4 megapixel UltrascanTM 1000 CCD camera was used for 
imaging. 20 μL of a protein solution (either single or mixture) was pipetted to formvar-
carbon coated 400-mesh copper grid, and left to dry for 30 s at room temperature. Any 
excess was removed with standard filter paper. The grid was negatively stained with 1% 
uranyl acetate aqueous pH 4.0 for 30 s. The excess was removed from the grid, again 
with filter paper and allowed to dry briefly before imaging.   
A standard TEM protocol for focussing and using the microscopy was followed and 
carried out by A. C. Richardson.  
3.7.6 SURFACE PLASMON RESONANCE 
All experiments were conducted using G.E Healthcare Buffers and chips. A Biacore 3000 
machine was supplied by G.E Healthcare, UK.  
3.7.6.1 MATRIX PROTEIN CONCENTRATION SCOUT.  
The NTA Chip was equilibrated using 1 × HBS-EP buffer (0.01 M HEPES pH 7.4, 0.15 M 
NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20) in the machine for 20 minutes before use. 
Activation was achieved by injection of NiCl2 (0.02M, G.E Healthcare) for 60 s at 10 μL/ 
min The standard NTA Biacore protocol (G.E Healthcare, UK) was then followed which 
detailed a 10 fold concentration range injected for 60 s at 10 μL/ min. The chip was 
regenerated using EDTA (0.01M, G.E Healthcare, UK) injected for 60 s at 30 μL/ min. 
 3.7.6.2 BLANK EXPERIMENT. 
Lane 1 on the NTA chip was used for blank experiments, no other experiments were 
conducted on this lane. Activation was achieved by injection of NiCl2 (0.02M, G.E 
Healthcare) for 60 s at 10 μL/ min, the non-tagged protein was then injected at 60 s at 
30 μL/ min at desired concentrations. The chip was regenerated using EDTA (0.01M, G.E 
Healthcare, UK) injected for 60 s at 30 μL/ min. 
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3.7.6.3 SECOND PROTEIN ADDITION.  
Activation was achieved by injection of NiCl2 (0.02M, G.E Healthcare) for 60 s at 10 μL/ 
min The standard NTA Biacore protocol (G.E Healthcare, UK) was then followed which 
detailed the injection of M(His6) protein at the desired concentration for 60 s at 10 μL/ 
min. The second protein (no tag) was injected for 60 s at 30 μL/ min at the desired 
concentration.  The chip was regenerated using EDTA (0.01M, G.E Healthcare, UK) 
injected for 60 s at 30 μL/ min. 
This was repeated with 5 different non-tagged protein concentrations, which were pre 
determined using the guidelines detailed in G. E. Healthcare NTA Biacore protocol.  
 
3.7.6.4 BIAEVALUATION ANALYSIS.  
A Standard protocol from G.E Healthcare, UK was followed to analyse each data set using 
the provided software. Each concentration was normalized and blank subtracted. The 
final curves were exported in an ASCII file and plotted in Microsoft Excel. 
 
3.7.7  FLUORESCENCE ANISOTROPY  
The concentration of stocks containing RR-M peptide were predetermined by the author 
and stored at -80 °C.  RR-M peptide was added to a standard quartz cuvette and diluted 
to 500 μL with ddH20.  All measurements were taken on a Cary Eclipse Fluorescence 
Spectrophotometer (Aligent Technologies, UK) using the supplied Eclipse ADL program. 
The excitation and emission wavelength (570 nm/580 nm) was added to the program 
and the voltage was changed to reflect the sample. The voltage was changed until the 
reading voltage stood at approximately 700 m.A.U. The blank experiment, of only the 
fluorophore in buffer was taken and the G Factor noted.  
Predetermined stocks of M2-1 protein were titrated in to a quartz cuvette containing the 
fluorophore and measured. Each measurement was plotted in Microsoft Excel and the 
analysis conducted in the same program.  
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4. INTERACTIONS OF THE MATRIX PROTEIN WITH CYTOPLASMIC TAIL OF THE FUSION 
PROTEIN.  
 
As described in Chapter 1.7, hRSV F is key to the attachment of the virus to the host 
cell.11,37 The protein is a trimer, where the F2 proteins are linked together and disulphide 
bonds link these to the transmembrane domain F1.43 The transmembrane domain, or 
cytoplasmic tail of F interacts with the matrix protein and this interaction is thought to 
be key for maturation and filament formation.7 Previously, work has been conducted 
which shows that the cytoplasmic tail of the fusion protein is key to interaction between 
F and the matrix protein.7,118 This chapter expands on the published data7 and previous 
unpublished work from VAM/JMS/RPY, Durham University to try and understand the 
nature of the interaction. All work reported in this chapter was carried out alongside the 
undergraduate students: O. Neale, E. Antonio and L. Argent and in collaboration with Dr. 
J. M. Sanderson, Durham University.  
 
4.1.  SEQUENCE AND PURIFICATION.  
4.1.1 MATRIX PROTEIN. 
The matrix protein was initially cloned by Dr. R. P. Yeo at Durham University. Subsequent 
batches of the protein were purified by the author and undergraduate students E. 
Antonio, O. Neale and L. Argent.  
 
4.1.2. F PEPTIDE.  
 
This six amino acid long peptide comprises the final C-terminal amino acids of the F 
protein with the sequence NIAFSN shown Figure 4.1.2.1. This unstructured region, is 
known to bind to the matrix protein, but the details of the interaction between the two 
proteins have not been fully elucidated. Phenylalanine 572 has been demonstrated to be 
critical for mature virion formation in vivo.7 The peptides used in this work were 
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purchased on solid support from Almac Sciences and cleaved, labelled and purified by E. 
Antonio and L. Argent. 
 
Figure 4.1.2.1 F peptide amino acid structure (NIAFSN) 
 
4.1.3. MUTANT F PEPTIDE. 
 
To test the interaction and confirm that it does indeed hinge on the phenylalanine, a 
mutant peptide was designed to eliminate this interaction with matrix protein. The 
mutated peptide contains an asparagine (N) in place of the phenylalanine, this was 
chosen due to solubility and is shown in Figure 4.1.3.1.  Previous work had shown that 
replacement of the phenylalanine with alanine gives rise to solubility difficulties, which 
were incompatible with the required experimental conditions. 
 
Figure 4.1.3.1 Mutant F peptide structure (Fmut) (NIANSN) 
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4.2  THERMAL SHIFT ASSAY (DIFFERENTIAL SCANNING FLUORIMETRY, DSF) 
 
This technique was used to determine the stability of the protein and if there was an 
interaction with the peptide. The raw data is shown below and the NAMI95 program was 










Figure 4.2.1.  Raw data curve showing the melting temperature for M protein in water to be 49.6 °C 
shown in NAMI software.95 
Firstly a salt screen was analysed against matrix protein itself. The aim was to stabilise 
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to occur the proteins must be in a meta-stable state, this is greatly affected by the 
buffering system in the crystallisation screen.17,103 Many conditions that are included in 
this screen are present in commercial crystallisation screens. 96 conditions and 
concentrations were tested and the full list is detailed in the Appendix A. The full screen 
melting temperatures (Tm) results are shown in Figure 4.2.2. Many conditions stabilised 
the protein, so only those compounds which gave an increase in Tm of over 3 °C are 





















Decrease in melting 
temperature  
N/S – No signal 
Double melting 
temperature reading 
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Table 4.2.3. Matrix protein stabilising ligands over a 3 C threshold,  
4.3. SURFACE PLASMON RESONANCE  
 
As previously described in Chapter 3, Surface Plasmon Resonance can be used to 
understand binding across a number of concentration levels. M(His6) protein was again 
bound to an NTA chip. Through the previous concentration scouting in Chapter 3.3.1, 
experimental parameters were already known.  
 
4.3.1  M(HIS6) AND FUSION PEPTIDE.  
Initially, the matrix protein was attached to the chip at 3 M concentration in solution, 
as in previous experiments, this gave a satisfactory response and the fusion peptide was 
then flowed over the chip in various concentrations. The corrected results are shown 







shift (°C)  
2 mM La(NO3)3 59.0 9.40 
1.0 M Gu-HCl 58.6 9.00 
0.8 M Gu-HCl 56.5 6.90 
1.5 M NaCl 55.7 6.10 
0.6 M Gu-HCl 55.2 5.60 
1.0 M NaCl 54.8 5.20 
1.0 M NaSO4 54.0 4.40 
0.4 M Gu-HCl 53.8 4.20 
2 mM PrCl3 53.7 4.10 
2 mM HoCl3 53.3 3.70 
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Figure 4.3.1.1. Sensogram curves of F peptide (NIAFSN) response on M(His6).  
 
In comparison to the previous experiment in Chapter 3, the response in binding shows 
a very small amount of binding and the Kd could not be accurately determined from the 
curves using the BIAevaluation software107 as the dissociation curve did not fit the 
models available. However, the association curves fit with the binding model and gave a 
preliminary ka was recorded to be 103. It is known that the matrix protein in solution is 
a dimer49 and this graph raises questions as to the experimental problems of using this 
technique where one protein, of unknown oligomerisation is attached to a surface. This 
could be further investigated using a technique that uses both proteins in solution i.e. 
Fluorescence Anisotropy. 
 
4.3.2. M(HIS6), MATRIX PROTEIN AND FUSION PEPTIDE  
The 6× Histidine (His6) tag was cleaved with Factor Xa to yield matrix protein with no 
tag and this was flowed across the M(His6) protein attached on the NTA chip at 5 M 
concentration. The same concentrations of fusion peptide were flowed over the chip and 
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Figure 4.3.2.1 Binding response of F peptide to M protein. 
The difference in the two graphs is notable, clear binding is shown in Figure 4.3.2.1 and 
thermodynamic analysis could be carried out using the BIAevaluation software.110 The 
Kd obtained by a local fit was approximately 400 M. The difference between the first 
and second graphs would suggest that the binding is integral to matrix protein being a 
dimer or a higher order oligomer. Further work using fluorescence studies could confirm 
the interaction and the stoichiometry, and give a degree of understanding of the 





























mixture 1:1 7 blank sub_Y mixture mF 14 blank sub_Y
mixture 1:1 21 blank sub_Y mixture 1:! 42 blank sub_Y
7 M 14 M 
21 M 42 M 
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4.4.  FLUORESCENCE STUDIES. 
4.4.1 FÖRSTER RESONANCE ENERGY TRANSFER (FRET).  
 
Förster resonance energy transfer (FRET) is a distance-dependent interaction between 
the electronic excited states of two dye molecules in which excitation is transferred from 
a donor molecule to an acceptor molecule without emission of a photon.119,112 The 
technique has been used to investigate an assortment of biologically important binding 
interactions and will provide information on the thermodynamics and stoichiometry of 
the binding of M and F proteins. The protein and peptide can easily be fluorescently 
tagged and binding should bring the two together in close enough proximity for the 
technique to give a signal.120,121 Another consideration is that the absorption spectrum 
of the acceptor must overlap with the fluorescence emission spectrum of the donor so 
the choice of fluorophores is key. This feature allows the transfer of energy from the 
donor chromophore to the acceptor chromophore through a non-radiative dipole-dipole 









Figure 4.4.1.1. Overlap of the excitation and donor curves.122 
 
Another important consideration in the experiment is the Förster Radius (R0), this is the 
distance where the energy transfer is 50% efficient (where 50% of the excited donors 
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are deactivated by FRET).  The size of R0 is dependent on the properties of the different 
dyes in use in the experiment, but it is typically in the order of 50 Angstroms.122 The 
distance is important in this technique as the interaction has to bring together two 
fluorophores within the Förster radius for energy transfer to occur.122 
 
4.4.1.1  FUSION PEPTIDE (NIAFSN) 
Initial investigations and experiments using this peptide were conducted by E. 
Antonio.123  The protein M was tagged with a donor chromophore, in this case fluorescein 
was chosen and referred to as Fl-M. F peptide was tagged with an acceptor, Rhodamine 
Red now referred to as RR-F hereafter. Both of the fluorescent tags are known to be a 
FRET pair, with a Förster radius of 55 Å.124 Fluorescein behaves as a donor (emitting at 
525 nm) and Rhodamine Red behaves as an acceptor (emitting at 585 nm). A preliminary 
titration was carried out by E. Antonio to confirm that FRET was a suitable technique to 
investigate the interaction between Fl-M and RR-F, the resulting graph is shown below 
in Figure 4.4.1.1.1 
 
Figure 4.4.1.1.1 Emission spectra by E. Antonio for the addition of RR-F peptide to Fl-M protein123 
Matrix protein 
5 μL F protein 
10 μL F protein 
25 μL F protein 
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A decrease in the energy seen in the donor (525 nm) and the increase shown in the 
acceptor at (585 nm), shows a clear FRET interaction. There were problems with this 
initial experiment due to a contribution being seen from the Fl-M in the emission 
wavelength, where the RR-F peptide shows a small signal in the absorption spectra 
where ideally there would be no signal of RR-F in the donor wavelength or Fl-M in the 
emission. The second problem is the large change in fluorescence emitted from the 
donor at 525 nm, it would be expected to have decreased linearly, with each addition of 
RR-F and could be due to a more complex system i.e. self-quenching. 
E. Antonio completed a series of control titrations to determine which factors were 
involved in the non-linear change in Fl-M on the additions of RR-F.123 One cause of the 
non-linear relationship could be self-quenching, where the fluorophores non-radiatively 
transfer energy to other identical fluorophores. Both of the fluorophores in the 
experiment are known to self-quench and this could be problematic due to 
oligomerisation and conformational changes.  
The RR-F is a short peptide and should not have any concentration dependent 
quaternary structure and this was tested by a concentration dependant fluorescence 
graph by E. Antonio. The resulting graph should be a proportional linear relationship 
where the signal is proportional for each addition of peptide. This was confirmed and 
the RR-F peptide appears to be a monomer and not the source of the decreased signal by 
self-quenching.  
E. Antonio then tested the Fl-M in the same manner to confirm that the matrix protein 
oligomer is responsible for the decrease in signal after the addition of RR-F.123 Matrix 
protein could be multiply labelled by fluorescein on lysine residues. There are multiple 
residues on each side of the linker region where self-quenching could occur due to the 
flexibility of this region. The same concentration dependant fluorescence graph showed 
a non-linear trend and confirmed that at high concentrations in the assay ( > 5 μM) Fl-M  
shows changes in its quaternary structure. Under 4 μM it was found that the graph 
remained linear. 
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Figure 4.4.1.1.2. Binding curve attained from change in fluorescence upon addition of Fl-M and RR-F, 
Where RR-F was host and Fl-M was guest by E. Antonio.123 Errors in the data are calculated to be 
approximately 20% by E. Antonio.  
E. Antonio and J. M Sanderson fitted the data to a rectangular hyperbola fit model.123 
Rectangular hyperbola fit models are frequently used in biological systems to model 
processes,125 they are typically of the form  
V  = (Vmax S)/(Km + S) 
Where V is the biological rate, S is the concentration of the substrate in the process, the fitting constants 
Vmax and Km are the maximal rate at substrate concentration and subtsrate concentration at half the 
maximal rate.125 
The concentration of the host was known and the other concentrations were calculated 
as a fraction of the original concentration which is given by the ratio of the 
fluorescence119. The concentration of bound guest ([B]) was determined through a ratio 
of change in fluorescence at a given concentration against the change in fluorescence 
associated with fully saturated binding. The concentration of free guest ([GF]) can be 
0 0.00001 0.00002 0.00003 0.00004 0.00005 0.00006 
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determined via a ratio of fluorescence of the free guest (Fobserved-Fbackgroundhost-Fbound) 
against the fluorescence of the bound guest (Fbackgroundguest-Fbound).123 From the upper 
asymptote, shown as the green line on Figure 4.4.1.1.2 the maximum change in 
fluorescence is observed when the guest is maximally bound .123 
The binding constant (Ka) is given as the equation below, where Kdiss is the reciprocal of 
the binding constant. 122 








E. Antonio and J.M Sanderson proposed a binding model to fit the data as shown below 
in Figure 4.4.1.1.3. Note there is no MF + M intermediate state, this is due to matrix 
protein favouring the dimer in solution.  
 
 
Figure 4.4.1.1.3 Reaction scheme of Fl-M and RR-F.123 
Further experiments and analysis where the concentration of M was restricted, were 
undertaken using Klotz, Hill and Scratchard plots by E. Antonio.  
The Klotz plot shown in Figure 4.4.1.1.4, where the binding data is plotted as 
concentration of bound guest ([B]) against concentration of log free guest ([GF]). A 
generalised logistic function curve was expected where the binding constant is 
determined by the negative reciprocal of the dissociation constant.  The curves were 
found to show positive cooperativity, where binding in one site increases the affinity of 
the other binding.  
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Figure 4.4.1.1.4  Titration curve modelled by a generalised logistics function shown as the blue curve by 
E. Antonio. Errors in the data were approximated to be 16% by E. Antonio. 123 
Insufficient data were obtained to complete the curve at the higher concentrations of 
free guest ([GF]) so the binding constants obtained were only an approximation.  The 
binding constants were approximately determined from the fitted logistical function 
curve and found to be 16 M.  
Scatchard plots calculate the affinity constant of a ligand by plotting the bound/free 
ligand against the bound ligand. Rearrangement of the equation shown on page 104 










The binding constant was determined from the reciprocal of the gradient that is given 
by (-1/Kdiss) and a linear gradient is expected 125 as shown in Figure 4.4.1.1.5. 
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Figure 4.4.1.1.5. Scatchard plot for the addition of F peptide to M protein by E. Antonio.123 
 
A linear Scratchard plot was found and the lower stoichiometry binding was found to be 
non-cooperative. The data were then analysed using a Hill plot to further investigate if 
the binding in the reaction is cooperative. The model does not assume that all sites are 
independent or equivalent, but that there is fractional occupancy (f) of the sites on the 
host as shown below 
𝑓 =  
𝐺𝐹
𝑛
𝐾𝑑𝑖𝑠𝑠 −  𝐺𝐹
𝑛 
Where (f) is fractional occupance, 𝐺𝐹
𝑛  is fractional occupancy of the guest, Kdiss is the dissociation 
constant.126 
 
Where n=1 is indicative of a class of single binding sites, n= integer >1 would suggest 
multiple binding sites and non integer values n<1 and n>1 suggest negative and positive 





] =  𝑛[log(𝐺𝐹)] −  log (𝐾𝑑) 
Where  B is bound species, GF is Guest fractional occupancy.126 
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The Hill plot obtained, shown in Figure 4.4.1.1.6, demonstrates that the binding of M 
protein to the F peptide is indicative of a complex system. The result is similar to that of 
the Klotz plot where there are insufficient data points at higher concentrations to fully 




Figure 4.4.1.1.6 Hill plot for M protein binding to F peptide. The blues series shows data obtained, the red 
series where the guest was between 20% and 80% bound by E. Antonio.123 
Higher concentrations of Fl-M should be added to further investigate binding, but due to 
self-quenching of the fluorophores, this could be a challenging issue. The binding 
constant was determined from the red region of data where a consistent gradient was 
obtained and found to be approximately 1. This confirms the hypothesis and indicates 





   
K1 K2 Hyperbola Klotz Scatchard Hill 
1.8 nM 28 nM 35 nM 24 nM 28 nM 39 nM 
 
Table 4.4.1.1.7 Binding constants of the interaction of RR-F and Fl-M.  
 





















R2 = 0.9731 
log[GF] 
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4.4.1.2. MUTANT FUSION PEPTIDE (NIANSN) 
 
Further FRET experiments were conducted by Dr V.A Money to determine if binding 
would be diminished without the phenylalanine residue (F572) present in the peptide. 
The same experimental procedure was followed as detailed by E. Antonio.123 As it can be 
seen in comparison to Figure 4.4.1.1.2 there is no clear binding when the F572 is 
replaced. Self-quenching is again another consideration for the higher concentrations 
especially. The relative fluorescence does not follow a set pattern and cannot be analysed 
in the same way as the wild-type peptide, which confirms the hypothesis that the F572 




































Concentration of M protein (µM)
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4.4.2 FLUORESCENCE ANISOTROPY (FA) 
This technique was used to obtain thermodynamic values for the various interactions to 
compare to the Kd obtained through the Surface Plasmon Resonance experiments. As 
explained in Chapter 3, the degree of polarisation is low when the fluorescent peptide is 
changing orientation quickly. When binding occurs the fluorescent peptide changes 
orientation more slowly and the polarisation signal increases.  
4.4.2.1  FUSION PEPTIDE (NIAFSN) 
In this experiment the wild type peptide (NIAFSN) was tagged again with Rhodamine 
Red to form RR-F that was placed in the cuvette and non-tagged matrix protein was then 
titrated in. Various scouting experiments were conducted to understand the 
concentration range needed, previously the initial FRET experiments described above in 
4.4.1 had indicated a nanomolar Kd and this was used as a starting point. The resulting 
curve is shown below in Figure 4.4.2.1.1. 
 
Figure 4.4.2.1.1 Fluorescence anisotropy curve showing the interaction of M protein and F peptide.  
Analysis by J. M Sanderson built on the initial results from the initial FRET experiments, 














H.J LUMB 2015  CHAPTER 4: INTERACTIONS OF THE 
MATRIX PROTEIN WITH 






Figure 4.4.2.1.2 Reaction Scheme for FA analysis, where it presumed that the top pathway is preferred. 
4.4.2.1.1 FITTING WITH M* 
The M* term is used when the oligomerisation state of RSV-M protein is not defined. 
Previously, H. McPhee, Durham University showed that the matrix protein is a dimer, 
tetramer and a hexamer in solution. The 2M* term was used to fit the data using the 




The binding isotherm shows the contribution from each of the species in solution. rcalc 
is the overall signal that is seen from each species. In Figure 4.4.2.1.1.1 the term r is 
used to normalize the data.  
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Figure 4.4.2.1.1.1 Using M* term in the binding isotherm for data fitting. [F] is the concentration of guest, 
in this case fusion peptide.  
From the data analysis it can be seen that there is a concentration problem, where the 
line of best fit does not match the data.  The maximum amount for a 1:1 complex would 
be 3 nM for 100% of F being bound, therefore 99% of the F peptide would not be bound 
and the signal change for the interaction would be minimal. Is there another interaction 
which is being seen, such as a rearrangement or a change in structure of F peptide or M? 
Since F peptide is only six amino acids in length, it lacks tertiary structure and could 
change conformation in solution which could change the signal being given in the 
experiment. Non-specific binding could not be ruled out either in this instance and 
further work would be needed to understand the interaction. The thermodynamic data 
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K2 K1 Kdim Kcon 
1.34x107 M-1 6.50x1011 M-1 1.20x104 M-1 6.00x1013 M-1 
   
Table 4.4.2.1.1.2 Thermodynamic values using M* term. 
 
4.4.2.1.2 FITTING WITHOUT THE M* TERM.  
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Kdim K1 K2 
4.14x105 M 7.43x1012 M 1.83x106 M 
 
Table 4.4.2.1.2.2. Thermodynamic values for the dissociation of M protein to F protein.  
 
The reaction scheme shown below, shows the two reaction mechanisms that are 
proposed to take place. 
  
 
Figure 4.4.2.1.2.3. Proposed reaction equilibrium showing the two intermediate pathways proposed.  
ΔG is the same irrespective of route so the formation of M2F, from MF and M is 
equivalent to M2 + F as shown below 
𝐾𝑑𝑖𝑚 ×  𝐾1  =  𝐾𝑥  ×  𝐾𝑦 
 
The value for Kx as determined by Surface Plasmon Resonance was low (~400 μM) as 
shown in Chapter 4.5, in which case the value of Ky would have to be very large (~1016) 
to align with the 𝐾𝑑𝑖𝑚 −  𝐾1  pathway. The Ky value is unfeasibly large and the observed 
concentrations of MF are approximately zero indicating that the 𝐾𝑥  +  𝐾𝑦 route can be 
discounted. The value for K1 obtained through FA is unusually large and is up to 105 
magnitude difference in comparison to the figures obtained in the FRET experiments, 
this raises concerns for the feasibility of the models used for the fitting of the data in this 
instance. The complex nature of the interactions could be the reason for errors in the 
Kx 
H.J LUMB 2015  CHAPTER 4: INTERACTIONS OF THE 
MATRIX PROTEIN WITH 





models. Further fluorescence experiments would need to be conducted to understand 
the nature of the interaction. 
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4.4.2.2 MUTATED FUSION PEPTIDE (NIANSN) 
 
The same FA experiment was conducted with the Rhodamine Red mutant peptide (RR-
Fmut) to understand if the phenylalanine, as described by Shaikh et al. 7 was key amino 
acid for binding to take place. The interaction was shown to be disrupted when the RR-
Fmut was tested in the FRET experiments shown in chapter 4.4.1.2. The data in Figure 










Figure 4.4.2.2.1 Change in observed polarisation plotted against concentration. 
In comparison to the wild type peptide there is no large increase in polarisation signal 
(r). Concentrations were tested from 10-11  to 10-5 M where it was clear that there was 
no distinct pattern. The recorded changes in fluorescence shows no binding curve and 
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4.5. FURTHER WORK 
4.5.1 ISOTHERMAL TITRATION CALORIMETRY 
This technique could help corroborate the thermodynamic values obtained in chapter 
4.4 where the discrepancies may be identified and the binding model confirmed. Further 
ITC data could help to understand the stoichiometry of the binding and if indeed as 
hypothesised, the value of n>1.115 The cooperativity, as touched upon by E. Antonio can 
also be probed using this technique.  
 
4.5.2 PHOTO-CROSSLINKING 
The wild type F peptide could be engineered to include a photocrosslinker, where the 
peptide would bind the matrix protein and the binding would be analysed by mass 
spectrometry.  A photochemical crosslinking agent is a chemically inert compound, 
which require energy from light to initiate and become reactive.127 Many classes of 
compounds are available but aryl azides and diazirines are most commonly used for 
their relative low cost and ease of use.127 The crosslinked protein and peptide would be 
digested using trypsin to give small manageable peptide sequences, which would be 
identified by MALDI mass spectrometry.127 The crosslinked peptide and matrix protein 
interaction can be mapped and further mutations performed to analyse the binding to 
the matrix protein.  
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In this chapter the primary aim was to confirm that the cytoplasmic tail of fusion protein 
binds in vitro to the hRSV M protein. Through previous literature7 it has been determined 
that the residue F572 was key to the interaction between the cytoplasmic tail of hRSV 
fusion protein and matrix protein. In this chapter, the last six amino acids of the cytosolic 
tail have been modelled through the means of a small 6 amino acid peptide (NIAFSN). A 
mutated peptide was also used, where the F572 was exchanged for an asparagine 
(NIANSN).  
 
Thermal shift analysis, using a SYPRO orange fluorophore was used to establish if the 
buffering system could stabilise hRSV M. The stabilisation was key due to hRSV M 
precipitating out of solution within hours once purified.  
 
 Surface Plasmon Resonance experiments were conducted to scout the concentrations 
needed to gain a Kd for the interaction. The technique used small amounts of protein and 
peptide equally so was ideal for testing concentrations to gain an initial thermodynamic 
understanding of the interaction. The experiment was conducted in two different ways; 
where the matrix protein was attached to the chip and the peptide was flowed over and 
when the matrix protein was attached, more M protein without a tag present and then 
the peptide. The two different experiments showed dramatically different results, where 
the binding can be accounted for by two different equilibrium pathways.  
 
The binding was further analysed by two different fluorescent studies, FRET and 
Fluorescence Anisotropy. The initial FRET experiments using wild-type peptide are 
detailed from E. Antonio’s previous work. They show a clear binding curve that when fit 
to a rectangular hypobola shows a nM Kd. To confirm the intial Kd the data were fitted to 
various statistical plots including Klotz, Scatchard and Hill plots. These showed the 
magnitude of binding was indeed true and further analysis was needed to understand 
the interaction. The mutant peptide was tested in the same way and showed no specific 
binding, this confirms the original hypothesis that the F572 residue identified by Shaikh 
et. al 7  is key to the interaction.   
 
The Fluorescence Anisotropy experiments were conducted alongside the FRET 
experiments using both the wild-type and the mutant peptide. Again a binding curve was 
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seen and analysis using the same equilibrium pathway showed a binding event that was 
a 1000 times stronger than the FRET data. Further experiments need to be conducted to 
understand if the magnitude difference in binding is the technique or the interaction of 
the peptide and protein. The mutant peptide again showed no binding and confirmed 
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4.7  METHODS  
4.7.1 EXPRESSION AND PURIFICATION OF M PROTEIN. 
 A pET-16-b vector containing the ORF of M protein, obtained from R. P. Yeo, was 
transformed into E. coli BL21-DE3 (see 7.2.1) and grown on ampicillin LB agar plates 
overnight at 37 °C. One colony was picked from the resulting plate and was incubated in 
0.2 L of LB broth (Tryptone 10 g/L, sodium chloride 10 g/L, yeast extract 5 g/L; Melford 
Laboratories Ltd., Suffolk, UK, 25 g/L) overnight at 37 °C. 0.01 L of the starter culture 
was used to inoculate 1 L of LB Broth in a 2.5 L conical flask, the bacteria were grown in 
the presence of Ampicillin (100 mg/mL)  at 37 °C for 5 hours or until Optical Density at 
600 nm reached 0.6-0.8. Expression was induced using isopropyl-β-D-1-
thiogalactopyranoside (IPTG, 0.8 µM; Sigma Aldrich, UK) and left to shake overnight at 
28 °C at 180 rpm. The bacterial cells were harvested by centrifugation at 4000 x g for 20 
minutes in a Beckmann Coulter TM J-20 XP centrifuge, using rotor JLA 8000 and the cell 
pellet was stored at -80 °C.  
Protein extraction was achieved through resuspending the pelleted cells in 0.02 L of  
Lysis Buffer (50 mM Tris,1 M NaOH, 5 mM CaCl2, 5 mM MgCl2 pH 7.6). Lysozyme (1 
mg/mL) and protease inhibitor tablet (cOmplete Mini™, EDTA-Free, Roche Diagnostics 
Ltd, West Sussex, UK) were added once the pellet was resuspended. The cells were lysed 
by sonication for 240 seconds at 20 kHz and 3-[(3-
cholamindopropyl)dimethylammonio]-1-propanesulphonate hydrate (CHAPS, final 
concentration 8 mM in ddH2O) was added to the mixture and centrifuged at 50,000 × g 
for 30 minutes Beckmann Coulter TM J-20 XP centrifuge, using rotor JA 25.50 to remove 
cellular debris.  
The supernatant was then passed through a pre-equilibrated nickel affinity His-trap 
column (GE Healthcare Life Sciences, Buckinghamshire, UK). After the supernatant had 
passed through the column, Tris buffer (50 mM Tris, 300 mM NaCl pH 7.6) was run 
through, followed by an increasing concentration of imidazole (50 mM Tris, 300 mM 
NaCl, 50 mM to 1 M imidazole pH 7.6). The protein eluted at 200 – 500 mM imidazole 
and the fractions were analysed for M protein by SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis) 
The protein was buffer exchanged overnight into Tris buffer (50 nM Tris, 200 nM NaCl, 
pH 7.3) or PBS (Gibco® PBS tablets, Life Technologies, Renfrew, Scotland) by dialysis 
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(MWCO > 12,000 Da) at 4 °C. The His-tag was removed by cleavage with Factor Xa 
overnight, as per the manufacturers instructions (Novagen, Merck Chemicals Ltd., 
Nottingham, UK).  The matrix protein was then stored and used at 4 °C. 
4.7.2  SDS-PAGE (SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS) 
The purified protein was analysed using a 15% acrylamide resolving gel: 5 mL 
ProtoFlow 30% acrylamide gel (Flowgen Bioscience Ltd., Nottingham, UK), 2.5 mL buffer 
(1.5 M Tris, 0.4 % (w/v) SDS pH 8.8), 2.3 mL water, 0.1 mL 10 % SDS (Aldrich, Poole, 
UK), 0.1 mL 10 % (w/v) ammonium persulphate (APS) solution in water and 0.004 mL 
N,N,N’,N’-tetramethylethylenediamine (TEMED; Fluka). The stacking gel was made 
from: 1.7 mL ProtoFlow 30 % acrylamide gel (Flowgen), 2.5 mL buffer (0.5 M Tris, 0.4 % 
(w/v) SDS pH 6.8), 5.55 mL water, 0.1 mL 10 % SDS (Aldrich,), 0.1 mL 10 % (w/v) APS 
solution in water and 0.01 mL TEMED (Fluka). Protein samples were prepared by 
addition of protein loading buffer (2.5 mL 1 M Tris-HCl pH 6.8, 0.5 mL ddH20, 1.0 g SDS, 
0.8 mL 0.1% bromophenol blue, 4 mL 100% Glycerol, 2 mL 14.3 M β-mercaptoethanol 
(100% stock) and adjusted to 10mL using ddH20, 5 µL in each 15 µL sample) and heated 
to 95 °C for 5 minutes then loaded onto the gel with a protein ladder molecular weight 
marker in the first well (10 – 250 kDa; New England Biolabs., Hertfordshire, UK). The gel 
was run at 200 V for 1 hour and stained using InstantBlueTM (Expedeon, Cambridge, UK) 
 
4.7.3  DETERMINING PROTEIN CONCENTRATION  
4.7.3.1  NANODROP 1000 
The concentration of the protein was determined using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Kent, UK) by measuring absorbance at 280 nm. 
The protein concentration was increased using a Vivaspin 6 (MWCO 10,000; GE 
Healthcare Life Sciences). Samples were centrifuged at 4000 × g in a Beckman CoulterTM 
AllegraTM X-22R centrifuge for 20 minutes at 4 °C, tested using the NanoDrop 1000 
spectrophotometer and repeated until the desired concentration was achieved.  
4.7.3.2 BRADFORD ASSAY  
Protein concentration was also verified by Bradford assay. Standard concentrations 
between 5 and 100 M of bovine serum albumin were prepared and allowed to 
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equilibrate at room temperature for 30 minutes. Each sample contained the diluted 
protein sample using MilliQ water to the appropriate concentration at 800 L and 
Bradford Reagent (Sigma Aldrich, UK) 200 L. Each concentration was measured at 595 
nm using UV-visable spectrophotometer (Multskan Go, Thermo Scientific, UK) and the 
absorbance was plotted against the concentration to give a linear plot. The protein was 
diluted and prepared in the same way and measured at 595 nm. The resulting 
absorbance was plotted on the standard graph and the concentration was found on the 
x-axis.  
 
4.7.4 THERMAL SHIFT ASSAYS (TSA) 
 
The interaction of various protein interactions over this work was analysed by thermal 
shift assay. Fluorescence data was collected on an Applied Biosystems 7500 FAST 
Real-Time PCR System with an excitation range of 455-485 nm. 8 μL of matrix protein 
(1mg/mL) in ddH20 was pipetted into each well of a standard 96-well plate (Starlabs 
Semi-Skirted FAST) and 10 μL of known concentrations of F peptide were added to wells 
and 2 μL of SYPRO Orange (5 × final concentration) was also added to give 20 μL in each 
well.  
The fluorescence emission signal at 567-596 nm was used for data analysis. The 
temperature was held for 1 min per degree from 24 to 95 °C. NAMI, a Python programme 
written by M. Grøftehauge and N. Hajizadeh, was used to analyse the data collected.  
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4.7.5.1 SURFACE PLASMON RESONANCE 
All experiments were conducted using G. E Healthcare Buffers and chips. A Biacore 3000 
machine was supplied by G. E Healthcare, UK.  
4.7.5.1 MATRIX PROTEIN CONCENTRATION SCOUT.  
The NTA Chip was equilibrated using 1 x HBS-EP buffer (0.01 M HEPES pH 7.4, 0.15 M 
NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20) in the machine for 20 minutes before use. 
Activation was achieved by injection of NiCl2 (0.02M, G. E Healthcare) for 60 s at 10 μL/ 
min The standard NTA Biacore protocol (G. E Healthcare, UK) was then followed which 
detailed a 10 fold concentration range injected for 60 s at 10 μL/ min. The chip was 
regenerated using EDTA (0.01M, G. E Healthcare, UK) injected for 60 s at 30 μL/ min. 
 4.7.5.2 BLANK EXPERIMENT. 
Lane 1 on NTA chip was used for blank experiments, no other experiments were 
conducted on this lane. Activation was achieved by injection of NiCl2 (0.02M, G. E 
Healthcare) for 60 s at 10 μL/ min, the non-tagged protein was then injected at 60 s at 
30 μL/ min at desired concentrations. The chip was regenerated using EDTA (0.01M, G. 
E Healthcare, UK) injected for 60 s at 30 μL/ min. 
 4.7.5.3 SECOND PROTEIN ADDITION.  
Activation was achieved by injection of NiCl2 (0.02M, G. E Healthcare) for 60 s at 10 μL/ 
min The standard NTA Biacore protocol (G. E Healthcare, UK) was then followed which 
detailed the injection of M(His6) protein at the desired concentration for 60 s at 10 μL/ 
min. The second protein (no tag) was injected for 60 s at 30 μL/ min at the desired 
concentration.  The chip was regenerated using EDTA (0.01M, G.E Healthcare, UK) 
injected for 60 s at 30 μL/ min. 
This was repeated with 5 different non-tagged protein concentrations, which were pre 
determined using the guidelines detailed in G. E. Healthcare NTA Biacore protocol.  
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4.7.5.4 BIAEVALUATION ANALYSIS.  
A Standard protocol from G. E Healthcare, UK was followed to analyse each data set using 
the provided software. Each concentration was normalized and blank subtracted. The 
final curves were exported in a ASCII file and plotted in Microsoft Excel. 
4.7.6 RHODAMINE RED STOCK SOLUTION 
5 mg of 5(6)-Carboxy-rhodamine N-succinimidyl ester (Sigma Aldrich, UK) was 
dissolved in 1 mL of Dimethylsulphoxide (DMSO) to yield an 8 mM solution. 50 μL of 
Rhodamine stock solution was incubated with the protein (usually 1 mg/mL) at 22 °C 
for 4 hours. The tagged protein was separated from the untagged fluorescent molecules 
by PD10 column (G. E. Healthcare, UK), as per the manufacturer’s instructions.  
 
4.7.7  FLUORESCENCE ANISOTROPY  
The concentration of stocks containing RR-F peptide were predetermined by E. Antonio 
and stored at -80 °C.  RR-F peptide was added to a standard quartz cuvette and diluted 
to 500 μL with ddH20.  All measurements were taken on a Cary Eclipse Fluorescence 
Spectrophotometer (Aligent Technologies, UK) using the supplied Eclipse ADL program. 
The excitation and emission wavelength (570 nm/580 nm) was added to the program 
and the voltage was changed to reflect the sample. The voltage was changed until the 
reading voltage stood at approximately 700 m.A.U. The blank experiment, of only the 
fluorophore in buffer was taken and the G Factor noted.  
Predetermined stocks of M protein were titrated in to a quartz cuvette containing the 
fluorophore and measured. Each measurement was plotted in Microsoft Excel and the 
analysis conducted in the same program.  
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5. NUCLEOCAPSID PROTEIN INTERACTION WITH RSV-604 AND RELATED COMPOUNDS.  
The nucleocapsid protein (N) is a key drug target in hRSV as it acts as a replication 
template, which if disrupted could reduce the virus infectivity.8,77 Previous work carried 
out by Arrow Therapeutics Ltd, identified some potential compounds, which were 
thought to disrupt the nucleocapsid protein structure.128 This chapter begins with an 
overview of the N protein and then describes the identification of the new compounds. 
Further testing of these compounds used a variety of biophysical techniques, which has 
allowed the characterisation of the interaction in greater detail.  
Firstly thermal shift assays were used to probe if the molecules would have a stabilising 
or destabilising effect on the protein. dynamic light scattering was utilised alongside 
thermal shift assays to understand if the compounds affect the size and stacking of the 
nucleocapsid ring formation.9 As significant changes were seen, transmission electron 
microscopy was then used to visualise the difference in the protein. The results found 
begin to build a picture of the interaction and determine which molecules should be 
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The nucleocapsid protein (N) has been previously crystallised as discussed in Chapter 
1.8,9 The structures have enabled drug discovery to target the protein in a way that was 
not obtainable before. The protein forms a helical structure, as shown below in Figure 
5.1.1, which protects the viral genetic material and helps provide a scaffold for viral 
replication. These helical structures are usually comprised of decameric or undecameric 













Figure 5.1.1. The crystal structure of hRSV N8 at 3.3 Å resolution shown as a decamer in blue. A 
monomer unit is shown in magenta. (PDB code: 2WJ8)  
 
5.1.1 LEAD DRUG COMPOUNDS.  
 
Drug compounds have been previously identified through high throughput screening. 20 
000 compounds from Arrow Therapeutics LtD were screened by Chapman et al. in a 
single concentration cell-based XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-
Tetrazolium-5-Carboxanilide) assay. These assays identified active compounds which 
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inhibited any compound involved in protein replication10 through the use of tetrazolium 
salt dyes.10  
The compounds that have been previously identified have potential antiviral activity and 
were rescreened to identify their EC50 values by Arrow Therapeutics LtD. The EC50 value 
is defined as a molar concentration of an agonist, which produces 50% of the maximum 
response for that agonist. The LD50 is defined as the lethal dose of a drug for 50% of the 
population.129  These measures are used as an indicator for drug potency and 
effectiveness and a number of compounds were identified with good therapeutic ratio, 
where the LD50/EC50 is less than 50 and further tested against four different hRSV 
strains. These further identified a lead compound A-33903 as shown below.10 
 
 
Figure 5.1.1.1. Lead compound A33903. 
 
The lead compound, A-33903 showed an EC50 value in the range of 10 to 20 M over a 
number of assays.  The compound also showed favourable pharmacokinetic properties 
in a rat model with a half-life of approximately 6 hours and an oral bioavailability of 76%. 
This suggests the core of the benzodiazepine is stable in metabolism with good 
absorption properties.10,130 The lead compound was subjected to structural 
modifications to increase potency for antiviral activity. The unsubstituted 
benzodiazepine template was shown to be optimal for antiviral activity but modification 
of the amide group could increase antiviral activity. An alkyl chain, branching or cyclic 
showed a decrease in potency but when aromatic amides were tested an increase in 
potency was observed. A further increase in potency was seen when electron-donating 
groups were included. 
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Figure 5.1.1.2.  Left, lead compound A33903 with R position for electron donating group 
additions.  Right, compound 3, R= o-methoxybenzamide.10 
Compound 3 shown above contains electron donating constituents however, when 
tested in the rat model this compound showed poor bioavailabilty (4%) and a poor 
pharmacokinetic profile. This could be due to the methyoxy side chain forming 
unfavourable contacts such as electrostatic interactions, which could destabilise the 
pocket and ligand.10 Further modifications were tested at position R as shown in Figure 
5.1.1.3.  
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Figure 5.1.1.3.  A33093 lead compound shown with primary targets.10 
Compound 4 which contains a second methyl group retained the activity of compound 
3, is in contrast to compounds 5 and 6 with lengthened alkyl chains and reduced 
activities. Other compounds i.e. where R = dimethylamino (compound 7) with electron-
donating substituents gave reasonably potent molecules, but did not increase the 
potency significantly above that of the lead compound.10,128 The combination of a 
lipophilic, electronically neutral substituent i.e. the cyclohexyl group (compound 8), gave 
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Further structure activity relationship (SAR) studies showed that heteroaromatic 
compounds (compound 9) gave outstanding activity, but, like the electron-rich aromatic 
amides, have poor pharmacokinetics when tested (compounds 3-5, Figure 5.1.1.3). The 
addition of nitro groups was employed to block potential aromatic hydroxylation of 
electron-withdrawing substituents. This gave compounds 9 and 10 as shown in Figure 
5.1.1.4 above. These proved to be potent molecules, but were found to be readily 
metabolised. The lead was further modified to incorporate the 4-trifluoromethyl group, 
shown as compound 14 below in Figure 5.1.1.5. This new modification was potent in its 
antiviral activity, but was shown to be highly cell-toxic.10,128 The left pendant phenyl ring 
with a methyl substituent group gave poor activity when replaced. This was seen when 
the pendant ring was replaced with a cyclohexyl, benzyl or pyridine ring.10,128 
 
Figure 5.1.1.5  Pendant phenyl substituents128 
Further SAR studies130 were conducted on the pendant phenyl to see if any substituent 
addition could increase potency further as shown above in Figure 5.1.1.5. Any additional 
substituent was found to have a lowering of potency, only the substitition at the meta-
position with an electron-withdrawing group (compound 14) could retain any antiviral 
activity. Further SAR studies added halogen substituents on to the benzodiazepine core 
as shown in Figure 5.1.1.6. 
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Figure 5.1.1.6. Compound 18 showing the loss of activity in the chloro-substituent. In 19 the addition of a 
nitro group in the para position to the linker region and a methyl group on 7 membered ring  increases  
activity.128  
Each enantiomer was tested for activity using the high throughput XTT assays used 
previously10,71 and overwhelmingly the S-enantiomer showed a higher activity and 
potency so this was taken forward into trials. A second amine group was added at the 
last stage to further increase potency after the amide group in the linker region. This 
resulted in the final compound, RSV-604 shown in Figure 5.1.1.7, which maintained high 
potency and had good bioavailability in a rat model. 
 
Figure 5.1.1.7  RSV-604, lead drug compound from the initial screen by Arrow Therapeutics Ltd.10 
 
Further in vitro testing of the lead compounds is required from the initial screen to 
confirm and understand the anti-viral activity identified in the high throughput assays.  
The overall aim for this part of the project involving the nucleocapsid protein was to 
ascertain if the ligand molecules will interact with this specific protein. Once this had 
been determined, the compounds that did interact were taken forward to identify 
binding thermodynamics. Experiments were conducted using in vitro biophysical 
techniques i.e. Surface plasmon resonance and differential scanning fluorimetry. The 
final question which was answered is: if the compounds do bind to the N protein, how 
does this binding affect the stability of the protein in solution? The N protein rings were 
imaged by transmission electron microscopy in order to visualise this change. Future 
work comprising in vivo studies with compounds 45 and 46 shown in Table 5.1.2.1, and 
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5.1.2. COMPOUNDS AVAILABLE FOR TESTING.  
In 2013 S. Cockerill approached the VAM/RPY research team for further in vitro testing 
of the lead compound RSV-604 and a range of compounds made in the follow-up SAR 
studies. Compounds 16 and 18 were originally tested in the initial screening and 
modification stage by S. Cockerill and J. Chapman at Arrow Therapeutics Ltd.130 45 and 
46 were part of a further modification round of unpublished data and not included in the 
initial screening, these compounds are novel and little data has been collected either in 
vivo or in vitro. Compound 46 is a racemic mixture. From here on the compounds will be 
referred to as Compound 15, 16 etc.  
 
 
















Compound 45.  
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Table 5.1.2.1. Lead compounds available for testing.10 
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5.2. BIOPHYSICAL CHARACTERISATION.  
5.2.1  PURIFICATION OF NUCLEOCAPSID PROTEIN.  
The hRSV N gene was cloned into a pET16b vector by Dr. R. P. Yeo.  All work carried out 
using the vector was performed by the author and R.G. Stewart, MSci student.  
The purification of hRSV N was achieved by following the Tawar et al8 protocol where 
the N protein was purified off the His-column using multiple washes of increasing 
concentration of imidazole from 20 mM to 500 mM. The lowest concentrations of 
imidazole remove any non-specific protein which have bound to the column. The higher 
concentrations elute the protein, which was collected in 2 mL fractions and its size and 
purity were confirmed by SDS-PAGE below.  
 
 
Figure 5.2.1.1 15% SDS page gel showing fractions at 300 mM Imidazole elution. Nucleocapsid protein is 
seen at 45 kDa from the His-Trap Column.  
 
From Figure 5.2.1.1 it can be seen that pure, recombinant N protein was obtained after 
expression in E. coli. If a preparation of protein was found to be impure a size exclusion 
column was used as a final purification step.  
N protein  
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5.2.2. THERMAL SHIFT ASSAYS (DIFFERENTIAL SCANNING FLUOROMETRY) 
 
As described in Chapter 2.5, thermal shift assays can be used to determine the thermal 
stability of the protein in solution. This approach was used to begin to investigate the 
effect of the lead molecules on the nucleocapsid protein in solution. The protein was 
tested at varying concentrations (10 M to 100 M) and using different concentrations 
of drugs (30 M, 60 M and 125 M). Using different concentrations allows the probing 










Figure 5.2.2.1. Lead compound RSV604, lead compound 15. 10 Where concentration of protein ranging 
from 10 μM to 100 μM . 
 
RSV-604 is the lead compound to which the others are compared. The range of results 
shown above shows no major trend, but the ligand and the protein do interact in the 
assay. It is known that RSV-604, compound 15, is active with hRSV N in vivo but these 
results cast doubt on the effectiveness of the compound in vitro or the technique.  The 
full method is detailed in Chapter 5.4. 
 
10 20 40 60 80 100
30 μM 1.1 0.5 0.0 -2.3 -3.7 -2.8
60 μM 3.0 -0.1 -3.6 2.2 -5.1 -3.9





















µM µM µM µM µM µM 
Compound 15. 
H.J LUMB 2015  CHAPTER 5. NUCLEOCAPSID 
PROTEIN INTERACTION WITH RSV-












Figure 5.2.2.2. Compound 16. Where x axis is each concentration of protein ranging from 10 μM to 100 























10 20 40 60 80 100
30 μM 0.1 -0.4 0.0 -1.5 -2.6 -1.1
60 μM -0.4 -0.2 0.2 -1.4 -2.4 -1.8
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10 20 40 60 80 100
30 μM -0.1 -3.9 -3.4 -3.7 -6.1 -2.3
60 μM -2.7 -2.9 -2.7 -3.9 -6.2 -4.7
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Figure 5.2.2.5. Compound 46. Where x the axis is the concentration of protein ranging from 10 μM to 100 
μM. 
 
All the lead compounds showed an effect on the N protein with the most marked being 
destabilisation of the protein in solution. The thermal shift assay, although sensitive, can 
only be used to determine if the drug compound is affecting the protein in solution and 
all compounds tested did show an effect on the N protein.  
10 20 40 60 80 100
30 μM 0.6 0.8 1.1 -1.9 -1.7 -0.9
60 μM 0.2 -0.2 0.4 -2.3 -2.8 -1.6
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The drug compound could be weakly binding to the protein to be providing the 
stabilising and destabilising effects seen above. Other techniques are needed to 
understand the nature of the interaction so all drugs were taken forward at this point 
for further investigation using dynamic light scattering (DLS). DLS gives a real time size 
estimation of species in solution and hopefully how the addition of ligands can affect the 
protein in solution.92 
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5.2.3 DYNAMIC LIGHT SCATTERING.  
 
As described in Chapter 2 dynamic light scattering can be used to obtain the 
hydrodynamic radius of species in solution.92 This is particularly vital for the 
nucleocapsid protein as the protein self assembles into decameric rings and then stacks 
into a large nucleocapsid form.8,9 Previously there have only been crude assays available 
to obtain interaction data between N and the various ligands, none of these indicate the 
oligomerisation state of the protein, if it changes conformation on ligand binding or how 
the drug interacts.   
Figure 5.2.3.1. Compound 15 trace as shown on the Malvern Zetasizer software, each colour represents a 
different ligand to protein concentration shown below. 
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Compound 15 shows a shift in the protein size above a drug concentration of 100 M. 
The polydispersity of the species in solution also slightly falls indicating a uniformed 





Figure 5.2.3.2. Compound 16 trace as shown on the Malvern Zetasizer software, each colour represents a 
different ligand to protein concentration. 
Compound 16 does not seem to form a larger species by mass as the compound 15 does. 
As it is unknown how the compounds interact with the protein it is hard to hypothesise 
the role of the larger species. Again the polydispersity decreases accordingly with 
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Figure 5.2.3.3 Compound 18, as shown on the Malvern Zetasizer software, each colour represents a 










Figure 5.2.3.4 Compound 45, shown on the Malvern Zetasizer software, each colour represents a different 
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 Compound 45 shown above, shows a negligible increase in particle size until the 
addition of 200 µM where the % volume of aggregate increases significantly. In 




    
Figure 5.2.3.5 Compound 46 shown on the Malvern Zetasizer software, each colour represents a different 
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Table 5.2.3.7. Polydispersity of N in the presence of the compounds. A value of 1 indicates the sample has 
no monodisperse species in the solution.  Polydispersity in compounds 45 and 46 especially drops 
significantly. 
Polydispersity is representative of the overall protein particle size distribution width, 
where the term is calculated by the width of the DLS peak at half the height.100 Drug 
compounds 45 and 46 are from a further subset by Arrow Therapeutics LtD but have not 
been through in vivo testing. The results show a large decrease in the polydispersity, 
indicating the formation of a more monodisperse species. In the case of compound 15 
the polydispersity does decrease the most out of the tested compounds but 45 and 46 
seem more effective in initiating the aggregation. It is unknown if the protein is stacking 
in an ordered way on addition of compound, which may still allow the protein to 
function, or if there is random aggregation occurring. If the latter is occurring, this could 
be the compounds’ mode of action and could affect the nucleocapsid formation.  
The results above support the thermal shift assay results, mainly that the compounds 
have an effect on hRSV N. The formation of species with a large hydrodynamic radius in 
the solution indicates an aggregated species, but further experiments would be needed 






Polydispersity of the aggregates 
 
15 16 18 45 46 
N 0.981 0.639 0.729 0.802 0.749 
N + 50 μM drug 0.861 0.986 0.444 0.671 0.149 
N + 100 μM drug 0.952 0.718 0.494 0.795 0.141 
N + 150 μM drug 0.620 0.695 0.535 0.372 0.099 
N + 200 μM drug 0.570 0.687 0.443 0.224 0.045 
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5.2.4 TRANSMISSION ELECTRON MICROSCOPY. (TEM) 
As shown in Chapter 3.2 Transmission electron microscopy is a powerful tool to image 
biological samples.106 The aggregation seen in Chapter 5.2.3 provides many questions to 
understand which reactions are taking place and if the ligand is binding to the protein. 
The images were obtained with the help of A. C. Richardson, Durham University. The 
methods and parameters are detailed in Chapter 5.4 for clarity.  
 
5.2.4.1 NUCLEOCAPSID TEM.  
N protein was first imaged without any drug compounds present as seen in Figure 
5.2.4.1.1 below.  Individual rings can be seen which are consistent with the crystal 
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5.2.4.2. NUCLEOCAPSID PROTEIN WITH RSV604, COMPOUND 15.  
As compound 15, RSV604 is a clinical candidate and is known to be the most potent of 
the tested compounds in vivo hRSV N was tested first to understand how the compound 
















Figure 5.2.4.2.1 Nucleocapsid protein (100 µM) under TEM, shows a variation in size at 120 000 × 
magnification. 
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Figure 5.2.4.2.2 TEM image of Compound 15 (100 M) and nucleocapsid protein (100 µM)  aggregation at 
120 000 × magnification. 
 
A mixture of compound 15 (100 M) and nucleocapsid  (100 M) as also imaged as 
shown above in Figure 5.2.4.2.2. From the above image it can be seen that the aggregates 
are formed from the N rings. Dynamic light scattering experiments showed that 100 M 
concentration of drug induced a change in the hydrodynamic radius of the species in 
solution and so this would suggest that above this concentration compound 15 is active 
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5.2.4.3 NUCLEOCAPSID PROTEIN WITH COMPOUND 46. 
 
Compound 46 resulted in a decrease in polydispersity and large increase in 
hydrodynamic radius of aggregates of N above a 200 M concentration in dynamic light 











Figure 5.2.4.3.1 Initial aggregation of nucleocapsid protein (100 µM) and compound 46 (100 µM).  
The protein rings can be seen in solution, but also the formation of a larger species. The 
aggregation that occurs seems to be random and disordered.  Initially, it was thought 
that the drugs may create order and stack the protein to form filaments, but this shows 
the opposite. Further aggregation can be seen in Figure 5.2.4.3.2.  
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Figure 5.2.4.3.2 Further aggregation seen in TEM at the same protein and compound concentration. 
The largest protein aggregate is approximately 180 nm in length and 100 nm in width, 
which correlates with the dynamic light scattering data reported in Figure 5.2.3.5. 
Compound 46 showed similar results to compound 15 in the TEM images and DLS 
experiments indicate a potent compound. Further analysis is needed, for example, in the 
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Co-crystallisation is a key stage on the road to pharmaceutical research and design. The 
technique allows for a high-resolution representation of the protein and ligand bound in 
complex.16  The structure can begin to enable us to understand the mode of action of a 
drug and where the binding pocket is located in the protein.131 
There are two main methods for co-crystallisation,16 
1. Where the two species are incubated together in a known ratio usually in 
hanging drop trays. This is where the mixture of protein, ligand and buffer 
conditions are suspended above the well and a diffusion equilibrium is allowed 
to be established.16 
2. Crystals of protein alone were grown in favourable buffer conditions and the 
ligand was then added to the formed crystal. There can be problems with the 
addition of the ligand cracking the crystal if there is a structural change upon 
binding.  
In 2009 Tawar et al.8 successfully crystallised hRSV nucleocapsid protein in 10% (v/v) 
2-methyl-2, 4-pentandiol (MPD), 0.05 M ammonium acetate, 0.05 M Tris pH 7.5, 0.01 M 
MgCl2.  We replicated and expanded the conditions in a sparse matrix screen and 
nucleocapsid protein (450 M) was used. Various methods including sitting drop and 
hanging drop were tested at multiple temperatures which allowed the maximum 
number of variants to be tested at any one time. 
hRSV N was to be crystallised alone to give a target for ligand soaking if the co-
crystallisation failed to generate any crystals. This yielded mostly dark amorphous 
precipitate or phase separation when we employed the 2011 conditions; 10 % (w/v) 
PEG 400, 0.1 M KCl, 0.05M HEPES pH 7.0, 0.01 M CaCl2.9 In the 2009 conditions8 as 
discussed above, phase separation was seen and other optimisation trays were set down 
for analysis. 
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Figure 5.2.5.1 A. Phase separation, spheralites, B. Nucleation from spheralites, C. Further nucleation, D. 
amorphous precipitate 
 
Co-crystallisation trials of hRSV N and compound 15 were more fruitful, several stages 
of protein crystal growth were seen in the space of 2 weeks from day 3 as shown in 
Figure 5.2.5.1. A clear progression is seen in the crystal tray, phase separated 
spherulites, were seen in the left hand side of the tray where the MPD concentration 
ranged from 6-8 %. Within 48 hours, the spherulites formed needles from a single 
nucleation site, which progressed into the needles shown in Picture C in Figure 5.2.5.1.  
Picture D is from the higher 12-14% MPD in the optimisation tray where the protein 
precipitated. Further needle-like crystals were found in the drops after seven days as 
shown below in Figure 5.3.5.1, these were poorly shaped and required further 
optimisation and streak seeding was used to optimise the crystals.  
Seeding uses previously nucleated micro-crystals in new drops, which have been 
equilibrated at lower levels of supersaturation, this promotes crystal formation and 
usually produces better shaped crystals for diffraction. Conditions were again optimised 
to 8 % (v/v) MPD, 0.025 to 0.075 M ammonium acetate, 0.05 M Tris, pH 7.5 and 0.01 M 
MgCl2. hRSV N was mixed with solid compound 15 and the following crystals grew, which 
are shown in Figure 5.2.5.2. 
A B 
C D 
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Figure 5.2.5.2  Left, a larger crystal ~200 μM in length. Right, a seeded drop showing smaller crystals ~50  
μM in length. 
The crystal on the left in Figure 5.2.5.2 was tested on the in-house diffractometer and 
did not diffract. The smaller crystals on the streak on the right were allowed to grow 
further before freezing down with MPD and being sent to the Diamond Light Source. 
Unfortunately, the crystals failed to diffract and further work is needed to investigate 
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Previous to the work described in this chapter it was known that RSV-604, (compound 
15) was taken through to phase two clinical trials, but it was still unknown how the 
compound interacted with the nucleocapsid protein.128 The various subsets of 
compounds were obtained from S. Cockerhill (Durham University). The anti-viral 
activity of RSV-604 or compound 15 has been confirmed through in vivo and in vitro data 
previously.71 In comparison compound 16 (Lead compound – A33903) and a compound 
18 with an electron withdrawing substituent, which were precursors to compound 15 
and have not been tested.10 Compounds 45 and 46 were from a second round of design 
and had never been tested either in vivo or in vitro.  
Thermal shift assays were used to assess if the compound binds the protein, each of the 
compounds successfully gave a response and was then analysed by dynamic light 
scattering. Using the technique it could be seen that at certain compound concentrations 
the hydrodynamic radius of the aggregates increases rapidly whereas the polydispersity 
decreases. Compounds 18, 16 and 45 showed less of a change in hydrodynamic radius 
even at high concentrations. Compound 46 showed a similar response to compound 15, 
where a smaller concentration of compound added to the protein induces a large 
increase.  
These changes indicate a change in the protein structure or that a new structure forms. 
Transmission electron microscopy was used to identify the aggregates seen in the DLS 
experiments. The nucleocapsid protein alone shows small rings, similar to the crystal 
structure, but when the compounds were added, larger aggregates were seen just as the 
dynamic light scattering had shown. Large aggregates were seen with Compound 15 and 
46, where it can be seen that the nucleocapsid rings are attached to each other. The rings 
seem to be intact and form a disordered aggregates, not the long ordered tubules that 
the nucleocapsid protein would form in vivo.  
Overall this chapter shows a promising beginning for a subset of compounds, whose 
mode of action was unknown until now. Further work to understand how the protein 
binds to the ligands is key. The experiments conducted give an insight but further 
conclusive studies would direct experimental direction and targeted mutagenic studies.  
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5.4 METHODS  
5.4.1. EXPRESSION AND PURIFICATION OF N PROTEIN.  
A pET-16-b vector containing the ORF of N protein, obtained from R. P. Yeo, was 
transformed into E. coli BL21-DE3 and grown on ampicillin LB agar plates overnight at 
37 °C. One colony was picked from the resulting plate and was incubated in 0.2 L of LB 
broth (Tryptone 10 g/L, sodium chloride 10 g/L, yeast extract 5 g/L; Melford 
Laboratories Ltd., Suffolk, UK, 25 g/L) overnight at 37 °C. 0.01 L of the starter culture 
was used to inoculate 1 L of LB Broth in a 2.5 L conical flask and the bacteria were grown 
in the presence of ampicillin (100 mg/mL) at 37 °C for 5 hours or until Optical Density 
at 600 nm reached 0.6-0.8. Expression was induced using isopropyl-β-D-1-
thiogalactopyranoside (IPTG, 0.8 µM; Sigma Aldrich, UK) and left to shake overnight at 
28 °C at 180 rpm. The bacterial cells were harvested by centrifugation at 4000 × g for 20 
minutes in a Beckmann Coulter TM J-20 XP centrifuge, using rotor JLA 8000 and the cell 
pellet was stored at -80 °C.  
Protein extraction was achieved through resuspending the pelleted cells in 0.02 L of  
Lysis Buffer (50 mM Tris,1 M NaOH, 5 mM CaCl2, 5 mM MgCl2 pH 7.6). Lysozyme (1 
mg/mL) and protease inhibitor tablet (cOmplete Mini, EDTA-Free, Roche Diagnostics 
Ltd, West Sussex, UK) were added once the pellet was resuspended. The cells were lysed 
by sonication for 240 seconds at 20 kHz and 3-[(3-
cholamindopropyl)dimethylammonio]-1-propanesulphonate hydrate (CHAPS, final 
concentration 8 mM in ddH2O) was added to the mixture and centrifuged at 50,000 × g 
for 30 minutes Beckmann Coulter TM J-20 XP centrifuge, using rotor JA 25.50 to remove 
cellular debris.  
The supernatant was then passed through a pre-equilibrated nickel affinity His-trap 
column (GE Healthcare Life Sciences, Buckinghamshire, UK). After the supernatant had 
passed through the column, Tris buffer (50 mM Tris, 300 mM NaCl pH 7.6) was run 
through, followed by an increasing concentration of imidazole (50 mM Tris, 300 mM 
NaCl, 50 mM to 1 M imidazole pH 7.6). The protein eluted at 200 – 500 mM imidazole 
and the fractions were analysed for N protein by SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis). 
The protein was buffer exchanged overnight into Tris buffer (50 nM Tris, 200 nM NaCl, 
pH 7.3) or PBS (Gibco® PBS tablets, Life Technologies, Renfrew, Scotland) by dialysis 
(MWCO > 12,000 Da) at 4 °C. The His-tag was removed by cleavage with Factor Xa 
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overnight, as per the manufacturer’s instructions (Novagen, Merck Chemicals Ltd., 
Nottingham, UK).  The matrix protein was then stored and used at 4 °C. 
5.4.2. SDS-PAGE (SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS) 
 
The purified protein was analysed using a 15 % acrylamide resolving gel: 5 mL 
ProtoFlow 30% acrylamide gel (Flowgen Bioscience Ltd., Nottingham, UK), 2.5 mL buffer 
(1.5 M Tris, 0.4 % (w/v) SDS pH 8.8), 2.3 mL water, 0.1 mL 10 % SDS (Aldrich, Poole, 
UK), 0.1 mL 10 % (w/v) ammonium persulphate (APS) solution in water and 0.004 mL 
N,N,N’,N’-tetramethylethylenediamine (TEMED; Fluka). The stacking gel was made from: 
1.7 mL ProtoFlow 30 % acrylamide gel (Flowgen), 2.5 mL buffer (0.5 M Tris, 0.4 % (w/v) 
SDS pH 6.8), 5.55 mL water, 0.1 mL 10 % SDS (Aldrich,), 0.1 mL 10 % (w/v) (APS) 
solution in water and 0.01 mL TEMED (Fluka). Protein samples were prepared by 
addition of protein loading buffer (2.5 mL 1 M Tris-HCl pH 6.8, 0.5 mL ddH20, 1.0g SDS, 
0.8 mL 0.1% bromophenol blue, 4 mL 100% glycerol, 2 mL 14.3 M β-mercaptoethanol 
(100% stock) and adjusted to 10 mL using ddH20, 5 µL in each 15 µL sample) and heated 
to 95 °C for 5 minutes then loaded onto the gel with a protein ladder molecular weight 
marker in the first well (10 – 250 kDa; New England Biolabs., Hertfordshire, UK). The gel 
was run at 200 V for 1 hour and stained using InstantBlueTM (Expedeon, Cambridge, UK). 
 
5.4.3.  DETERMINING PROTEIN CONCENTRATION  
5.4.3.1  NANODROP 1000 
The concentration of the protein was determined using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Kent, UK) by measuring absorbance at 280 nm. 
The protein concentration was increased using a Vivaspin 6 (MWCO 10,000; GE 
Healthcare Life Sciences). Samples were centrifuged at 4000 × g in a Beckman CoulterTM 
AllegraTM X-22R centrifuge for 20 minutes at 4 °C, tested using the NanoDrop 1000 
spectrophotometer and repeated until the desired concentration was achieved.  
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5.4.3.2 BRADFORD ASSAY  
Protein concentration was also verified by Bradford assay. Standard concentrations 
between 5 and 100 M of bovine serum albumin were prepared and allowed to 
equilibrate at room temperature for 30 minutes. Each sample contained the diluted 
protein sample at 800 L and Bradford Reagent (Sigma Aldrich, UK) 200 L. Each 
concentration was measured at 595 nm using UV-visable spectrophotometer (Multskan 
Go, Thermo Scientific, UK) and the absorbance was plotted against the concentration to 
give a linear plot. The protein was diluted and prepared in the same way and measured 
at 595 nm. The resulting absorbance was plotted on the standard graph with 
concentration was found on the x-axis.  
 
5.4.4. THERMAL SHIFT ASSAYS (TSA) 
 
The interaction of proteins over this work was analysed by thermal shift assays. 
Fluorescence data were collected on an Applied Biosystems 7500 FAST Real-Time PCR 
System with an excitation range of 455-485 nm. The fluorescence emission signal at 567-
596 nm was used for data analysis. 8 μL of varying concentrations of RSV N protein (10 
to 100 μM), 10 μl of various ligand concentrations (50 to 250 μM) and 2 μL of SYPRO 
Orange (5 × final concentration), were pipetted into a standard 96-well PCR plate 
(Starlabs Semi-Skirted FAST) to give final volumes of 20 μL in each well.  
The temperature was held for 1 min per degree from 24 to 95 °C. NAMI, a Python 
programme written by M. Grøftehauge and N. Hajizadeh, was used to analyse the data 
that were collected. 95 
 
5.4.5. DYNAMIC LIGHT SCATTERING 
 
A Malvern Zetasizer μV DLS system (Malvern Instruments Ltd., Worcestershire, UK) was 
used to conduct all DLS measurements in this work. The sample was held at 25 °C and 
allowed to equilibrate for 60 s prior to analysis. First, the DLS measurement of 100 μL of 
hRSV N/M was taken. Then, increasing concentrations (50 to 200 μM) of drug compound 
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were added, mixed and the DLS measured on each addition.  Each size measurement was 
determined from the averaging of 13 runs of 10 s each. 
 
5.4.6. TRANSMISSION ELECTRON MICROSCOPY  
All images obtained via transmission electron microscopy using a modified negative 
staining protocol were with assistance of A.C. Richardson. A JEOL 2100F FEG TEM with 
a GATAN GIF tridiem with 4 megapixel UltrascanTM 1000 CCD camera was used for 
imaging.  
20 μL of a protein solution (either single or mixture) was pipetted on to a formvar-
carbon coated 400-mesh copper grid, and left to dry for 30 s at room temperature. Any 
excess was removed with standard filter paper. The grid was negatively stained with 4% 
(w/v) aqueous uranyl acetate pH 4.0 for 30 s. The excess was removed from the grid, 
again with filter paper and allowed to dry briefly before imaging.   
A standard TEM protocol for focussing and using the microscope was followed by A. C 
Richardson. 
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CHAPTER 6. IDENTIFICATION AND DOCKING OF DRUG LIKE MOLECULES INTO THE 
MATRIX PROTEIN OF HRSV. 
 
This chapter will introduce the concept of drug discovery and design from the earliest 
stage through to biophysical testing. The techniques in this chapter were used to firstly 
identify potential binding sites in hRSV M using the CASTp server.132 A suitable site was 
found and pocket parameters such as volume were computed. The pocket in hRSV M 
contains amino acid contacts in the dimer interface, if these were disrupted using ligands 
the structure of hRSV M would be compromised.  To obtain the ligand molecules needed 
for docking, the ZINC server was used as a library. The ZINC server identified new 
potential drug-like molecules from a subset of over 1 million compounds to the final few 
hits.  In vitro analysis was used to validate the drug-like molecules’ activities against the 
target and will potentially lead the way for a new anti-viral candidate. 
 
6.1 INTRODUCTION TO DRUG DISCOVERY AND DESIGN.  
6.1.1 EARLY DEVELOPMENT.  
 
The 20th Century dawned with a renewed interest in drugs and medical practice but it 
was not until the end of the Second World War and the introduction of antibiotics that 
drug discovery began its golden age.133 The beginnings of rational drug design began in 
the 1950s where a theoretical understanding of the drug-target interaction and 
experimental drug testing could aid advancement in the field. The 1960s were the origin 
for modern antiviral therapies134 and during this decade the first experimental antivirals 
were developed in the hope of treating the herpes virus. They used traditional trial and 
error methods where cultures of cells were infected with the target virus and the 
experimental compounds were introduced. This was very hit-or-miss and lacked the 
knowledge of how the virus worked so it was not very efficient. In the 1980s full genetic 
sequences of the target viruses began to emerge and virus structure and function could 
be examined in detail. This led to an increased understanding of the compounds needed 
to interrupt viral replication cycles, and its usefulness can be seen in the dozens of anti-
viral treatments now available.134 
H.J LUMB 2015  CHAPTER 6. IDENTIFICATION AND 
DOCKING OF DRUG LIKE MOLECULES 
INTO THE MATRIX PROTEIN OF HRSV  
 
 157 
6.1.2. MODERN PRACTICE.  
 
New antiviral drug design follows a general idea of identifying the viral proteins, or parts 
of those proteins, which can be disabled by a future drug.130,134 The proteins, and the 
smaller targets, should share as little homology to those found in the host as possible to 
lessen the potential side effects. If the target is also common across many strains of the 
virus or even within the same family of viruses this can be advantageous and would give 
the drug a wide effectiveness in its use.130 Once the target is identified, drug-like 
compounds can begin to be isolated and tested from a larger subset, this process is 
shown in figures 6.1.2.1 and 6.1.2.2. The development pipeline below shows the stages 
from a target in the virus being defined to a drug being on the open market. There are 
two main stages in the pipeline, the pre-clinical stages coloured in red, are from 
molecular target discovery up to human clinical trials. The second stage is clinical, where 
the drug should prove its purpose, efficacy and safety before the human trial stage, and 





Figure 6.1.2.1 Preclinical stages of drug discovery.136 
 
At the end of the preclinical development all data should be presented to the drug council 
of the country where the developments took place and the decision is made as to 
whether the drug will continue to the clinical stage. The financial investment required to 
trial a drug is large and only the top candidates will make it to the end. Data from testing 
in vivo using animal models and pharmacokinetic (PK) and pharmacodynamics (PD) 
data should also be presented at this stage and these will give some indication of the 
actions of the drug in the body and relevant dose. These are the precursor to clinical 
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Figure 6.1.2.2 Clinical stages of drug discovery.136 
 
If the drug passes pre-clinical trials it will enter stage 0, where the PK and PD data are 
tested in primates. Typically a small number of individuals (usually <10) are tested with 
sub Therapeutic doses and the oral bioavailability and half-life of the drug are 
determined.134 Stage I tests the drug on healthy human volunteers to determine the 
dosage of the drug. The doses are often sub-therapeutic, but can rise; the patient number 
is larger in this stage.130,135,136 Stage II moves the drug into patients so that efficacy and 
safety of the drug at a therapeutic dose can be known.136 Until this stage the drug in 
question has not needed to prove its therapeutic effect on the condition. A typical sample 
size of ~200 patients is needed at this stage to ensure reproducibility and this is where 
the majority of drugs fail.136 The reasons for failure can be as simple as the drug did not 
work as expected or showed toxic side effects.137 Stage III continues on from stage II 
where a larger sample size (~1000 patients) is used alongside a physician to determine 
the full effect of the drug on the patients.130,136 This is technically the last stage of testing 
and if the drug passes then it can be marketed to the public. Stage IV is often cited as post 
marketing surveillance where the long-term effects of the drugs can be monitored, if any 
problems arise at this stage the drug can be withdrawn.136 Overall these pipelines take 
over 15 years and at the end the drug still may not be approved for use by government 
agencies.137  
This lengthy process and the constraints involved have been a driving force for rational 
drug design. The technique combines X-ray crystallography along with the 
computational imaging and docking of a ligand. In comparison to high throughput 
screening and in vivo testing, the new technique affords many advantages which are 
detailed in the following chapter 6.1.3.  
 
  
Stage I Stage II Stage III Approval Stage 0 
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6.1.3 DOCKING AND VIRTUAL SCREENING 
 
The increasing prevalence of X-ray protein crystallography during the 20th century has 
greatly increased our knowledge of protein structure which, coupled with increasing 
computer power, has paved the way for new rational structure-based drug design.138 
From the early beginnings of rigid docking through to the modern approach and 
improvements that can more accurately predict the biophysical state of binding, 
progress has been rapid and wide reaching.  
 
6.1.3.1. EARLY DAYS – RIGID DOCKING AND EARLY TECHNIQUES. 
 
Molecular docking is usually defined as solving the problem of identification of low-
energy binding modes of a small molecule, or ligand, within the active site of a 
macromolecule, or receptor, whose structure is known.139 To create a ligand the 
programme employed must have an accurate model of the molecular energetics to 
position the ligand, an efficient algorithm to search for the potential binding modes and 
the ability to show this in a defined way, usually on a screen through a graphical 
interface.138,140 
The first definition of molecular surface was published by Lee and Richards141, where 
they described how surface atoms can be distinguished from buried atoms and how the 
total surface of the molecule is the sum of the atomic surfaces.141 Further work 
completed the theory and was published by Greer and Bush in 1978.142 This method, 
which calculated the molecular surface and displayed the data as a contour map, was 
based on the proposition by Richards et al143 in the previous year. This earlier method 
utilised water in the model and started to apply van der Waals interactions where water 
is excluded in the structure, mimicking protein dynamics in solution. The theoretical 
work paved the way for the field of Molecular Graphics to be developed.144 The first 
automatic docking program, DOCK was developed through molecular graphics and uses 
a geometric approach with rigid docking. This approach explores the geometrically 
feasible alignments of ligands139,145 in the known structure. Algorithms included in the 
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program examine binding geometries and evaluate the molecules in terms of steric 
overlap and thus give specific molecular conformations.145 
Further developments through the 1980s began to include scoring functions, solvent 
surface calculations and flexibility into the docking model. Flexibility in docking was 
introduced in early docking programs such as FLOG146 (Flexible Ligand Orientated on a 
Grid) and flexX140.  
 
6.1.3.2. DEVELOPMENT OF GOLD.  
 
The GOLD (Genetic Optimisation for Ligand Docking) program was developed in the 
1990s and uses a general algorithm147. It is an automated docking system which explores 
ligand conformational flexibility using partial flexibility of the protein and conforms to 
the requirement that the ligand must displace loosely bound water on binding. A general 
algorithm uses concatenated 8-byte strings, which represent torsions of rotatable bonds 
that undergo certain alterations to increase diversity.147 The general algorithm collects 
data from the structure of each pose of the ligand and for each of these poses encodes a 
possible solution to the binding problem, these are called chromosomes. A pose of a 
ligand is where the same ligand is docked into the pocket, but a number of bonds are 
rotated or it can bind in multiple places, all within pre-selected limits.148 
The docking uses pharmacophore points also known as fitting points which generate 
ligand poses. These points consist of donor-acceptor fitting points i.e. hydrogen bonds, 
and hydrophobic interactions.138 The program requires the user to define an 
approximate binding site and location, this is pinpointed with a user-defined sphere, the 
radius of which is chosen to incorporate the relevant residues.147 Each possible solution, 
namely, a ligand orientated within the protein binding site, is also assigned a fitness 
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6.1.3.3. A GOLD RUN 
 
Each run of GOLD has a number of operations, where GOLD uses the information of each 
number of rotatable bonds and the ligand flexibility to determine how many operations 
are required. A 100% efficiency of all possible ligands would produce a large set of poses, 
if there are multiple poses then each counts as an operation.80 Search efficiency should 
be selected, 100% is ideal but unless the GOLD program and docking run is on a 
supercomputer this is unfeasible. A set search efficiency of 10% for the initial compound 
scout and 30% for a more in depth view, was used in this Chapter. This improves the 
speed of the search and although it lessens the number of answers, given the wide range, 
it should be sufficient to obtain a set of results which are viable. The docking run can be 
terminated early or run to completion, early termination will stop the run when the 
results reach a user defined number of solutions within a set RMSD as shown in 
Appendix B.1.12,80 The general algorithm poses all possible solutions of the ligand in the 
binding site. A third option, diverse solution will end the docking run when a number of 
solutions within a certain cluster, a diverse subset, have been found.81 These should be 
within a user defined RMSD and this method gives a set of poses which cover wider range 
of potential solutions but can take longer to reach.  
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6.1.3.4. SCORING FUNCTIONS.  
 
Four fitness functions are available when docking; GoldScore, ChemScore, ASP and 
ChemPLP.149 These differ in a number of ways, from what components are calculated 
through to which statistical model is used.150 Firstly GoldScore which was one of the 
original scoring functions and designed when GOLD was first developed.80 This fitness 
function calculates the ligand binding positions and derives a score. Hydrogen bond 
energies, van der Waals energy and torsion strain are all considered.12 ChemScore, the 
second function available in this package, uses affinity to calculate fitness. This uses a 
subset of 82 complexes and compares the current docked ligand to known values. 
Hydrophobic contact areas, ligand flexibility and metal ion interactions are used in this 
fitness function.12 ASP (Astex Statiscal Potential) is based on statistics. This is where the 
frequency of interaction between the ligand and protein atoms is calculated and 
compared against existing ligand-protein structure.151 Finally, the fourth scoring 
function is ChemPLP. This is a combination of van der Waals forces and hydrogen bonds, 
which are found in ChemScore. In ChemPLP various models are also included which 
calculate repulsion terms and model distances.148  There is no way of identifying which 
scoring function would give the most accurate answer. Comparison studies149 have 
shown that scoring functions are far from being accurate but can give an overall 
approximation for ligand docking. Of the four scoring functions available, ChemScore is 
often cited as being the scoring function which gives better correlation of results.152 In 
this Chapter, ChemScore will be used throughout.  
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6.2. MATRIX PROTEIN 
 
As previously described in Chapter 1, the human Respiratory Syncytial Virus (hRSV) 
matrix protein was described as a monomer on crystallisation to a resolution of 1.6 Å.48 
As shown below in Figure 6.2.1 the protein N-terminal region is highlighted in magenta 
and the C-terminal in dark grey. The domains are joined by a 13-residue flexible linker 
region held together by hydrophobic interactions seen across related matrix proteins e.g. 







Figure 6.2.1. The crystal structure of hRSV matrix protein, colour coded N-Terminal domain in Magenta 
(1-126), C-Terminal domain in Dark grey (140-255) and a flexible linker region in blue (residues 127-
139)48  (PDB : 2VQP) 
As discussed in Chapter 1 there are significant similarities in the proteins across the 
Mononegavirales family. Both hRSV M48 and Ebola Virus VP4051 were crystallised as 
monomers and share a similar global fold with an RMSD of 3.7 Å for C-alpha atoms. Other 
matrix proteins in the order of Mononegavirales have been crystallised but many are not 
similarly related to hRSV M in either sequence or structure. In 2014, the hRSV M 
structure was used to solve a closely related matrix protein in the same sub-family 
human metapnuemovirus (hMPV).50 All work in this sub section was completed before 
the identification of the structure of the hRSV M dimer as discussed in Chapter 6.8.2. 
 
  
H.J LUMB 2015  CHAPTER 6. IDENTIFICATION AND 
DOCKING OF DRUG LIKE MOLECULES 
INTO THE MATRIX PROTEIN OF HRSV  
 
 164 
6.2.1 MODELLING THE HRSV M DIMER.  
Modelling of the hRSV M dimer and subsequent docking runs using HADDOCK153 were 
performed in collaboration with N. J. Tatum, Durham University. The hMPV matrix 
crystal structure was used to guide the docking due to its proximity in structure to hRSV 
matrix.48,50 
The hMPV matrix protein crystal structure was published in 2014;50 and the phase 
problem was solved by molecular replacement using the hRSV M protein structure. 
Primary sequence identity between the two proteins is 37% when analysed through 
ExPASY BLAST154. The authors used small angle X-ray scattering (SAXS) to determine 
that the matrix protein of hMPV is a dimer in solution as well as in the crystal structure 
as shown below in 6.2.1.50 
 
Figure 6.2.1.1. hMPV matrix protein dimer crystal structure. Calcium ions are shown in green.50 
The dimer structure is stabilised by calcium ions, of which there is one per monomer this 
in contrast to the hRSV M monomer which was crystallised without any metal ions.48 
There are biophysical similarities between the proteins in solution as discussed in 
Chapters 3 and 4. That the hRSV M protein acts as a dimer in solution was confirmed by 
size exclusion chromatography and crosslinking where the protein leaves the column as 
a dimer of approximately 58 kDa. Also, previous work by J. Freeth155 has shown by ICP-
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6.2.2. DIMER FORMATION USING SYMMETRY-RELATED MOLECULES.  
 
Using the hMPV matrix protein,50 which crystallised as a dimer (pdb - 4LP7), the hRSV 
M protein monomer was flipped 180 and the two monomers placed together to form a 
dimer interface which resembles that of hMPV. PYMOL was used but it does not take into 
account hydrogen bonds or hydrophobic residues.156 structure viewing software. The 
model was prepared by using the symexp command and a cut off for interactions at 3 Å 
and the resulting model is shown in figure 6.2.2.1. The parameters were chosen based 
on previous work by Arnold et. al.157This model was confirmed using PDBe PISA (v1.51) 
the interface of hRSV M was analysed and a similar symmetry operation [-x+2, y, -z] gives 




Figure 6.2.2.1. Left, RSV-M symmetry fitted dimer. Right, hMPV dimer (PDB – 4LP7) 
 
A second method was used to form the hRSV M dimer, utilising the docking programme 
HADDOCK. Using the paper by Leyret et al.50 where the hMPV M structure was first 
described, a number of residues were identified as forming the potential hRSV M dimer 
interface to help guide the protein-protein docking procedure in HADDOCK. To aid 
proper docking HADDOCK requires a number of residues to be pre-determined.153 The 
molecular replacement of the hMPV M crystal structure was used to mimic the new 
H.J LUMB 2015  CHAPTER 6. IDENTIFICATION AND 
DOCKING OF DRUG LIKE MOLECULES 
INTO THE MATRIX PROTEIN OF HRSV  
 
 166 
dimer. The resulting solution gave RMS distances of 3.157 Å for 1193 atoms in hMPV 
chain A, and 3.311 Å over 1287 atoms in chain C which is statistically closer so this model 
was used in further analysis.  
It is noted in the supplementary information, that there is a hydrophobic motif xWxPx in 
the N-Terminal domain of hMPV M which is conserved across the families in the 
Mononegavirales Order including hRSV and Ebola.49 In the hRSV M structure this 
corresponds to residues 34-38 (IWVPM). In addition, the hMPV dimer structure is 
stabilised by a large network of conserved hydrophobic interactions 50. This gives rise to 
a buried surface area of 1421 Å2 for each monomer and these residues were used to 
guide the docking. If all the residues on the buried surface area were used then this could 
bias the docking towards one solution, so three residues were chosen and explored 
independently: Trp35 from the xWxPx motif; Ser198; and Asp225 as highlighted in 
Figure 6.2.2.2. Passive residues, which are the solvent accessible surface neighbours to 








Figure 6.2.2.2 Active residues selected Trp25, Ser198 and Asp225 are shown as stick representation on 
the buried surface of hRSV matrix protein.48 (PDB code 2VQP). 
  
H.J LUMB 2015  CHAPTER 6. IDENTIFICATION AND 
DOCKING OF DRUG LIKE MOLECULES 
INTO THE MATRIX PROTEIN OF HRSV  
 
 167 
6.2.3. HADDOCK WEB INTERFACE  
 
The manually fitted model of hRSV matrix protein was refined and the interface aligned 
to the interface of the hMPV matrix protein dimer using the HADDOCK webserver. 
HADDOCK (High Ambiguity Driven protein-protein DOCKing)153 uses biochemical 
and/or biophysical interaction data to produce bioinformatics predictions. Firstly the 
protein structural data should be in a pdb format, then the residues of interest should be 
highlighted as shown in Figure 6.2.2.2 in Chapter 6.2.2, which will guide the docking. 
There should also be no duplicate residue or chain numbers as the server cannot 
compute the same number as different chains.153 All water molecules and ligands were 
removed as HADDOCK assumes a water-mediated environment. The information given 
is used as Ambiguous Interaction Restraints (AIRs) to drive the docking process. The AIR 
is defined as an ambiguous distance between all residues shown to be involved in the 
reaction.153 The server takes into account hydrogen-bond donors and acceptors, 
hydrophobic regions and charge properties to estimate a docking solution.  
 
6.2.3.1. HADDOCK HRSV M DIMER MODEL 
 
The overall result of a HADDOCK docking run can be shown as a maximum of 200 top 
scoring structures in clusters. The clusters were defined as a minimum of four potential 
dimer structures and each cluster at least 7.5 Å apart from each other by RMSD. This 
produces a vast range in the clusters. HADDOCK produces a graph to show the variation 
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Figure 6.2.3.1.1. HADDOCK graph of score. The arbitrary units are plotted against the interface RMSD. The 
most negative solution is the best scoring. Interface RMSD is calculated on the backbone atoms of all 
residues involved in intermolecular contact using 10 Å cut off. 
 
Clusters 2, 3 and 4 contained a total of forty six structures, all of these structures were a 
minimum of 10 Å different from the best scoring cluster, cluster 1. Clusters 2 and 4 did 
not contain any solutions, which were recognisable as similar to the hMPV structure as 
shown in Figure 6.2.3.1.2. 
 
 
Figure 6.2.3.1.2. Top scoring models from Cluster 2 (left), Cluster 3 (orange) and Cluster 4 (magenta) 
(right) overlayed. 
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The top scoring cluster, which was cluster 1 contained 148 structures with an RMSD 
variation within the cluster of 0.5  0.3 Å. This dimer is in the cluster 1 best scoring 
solution from HADDOCK and indicates strong convergence. All clusters and statistics of 
the solutions are shown in Appendix B.3 
 
To verify the HADDOCK docking, ZDOCK 159 was used to independently dock the 
molecules, based on the active residues. The top 10 structures from a total of 500 
structures, generated by ZDOCK, were analysed for comparisons to the HADDOCK 
results. The similarities between these 10 structures were clear to see and when 
structure 5 was superimposed onto the HADDOCK structure the RMSD (Root Mean 
Squared Deviation) difference was only ~1.3 Å. Overall the protein-protein docking from 
HADDOCK and ZDOCK respectively gave similar results, with cluster 1 being the highest 
scoring. The cluster 1 model, despite the restraint violation penalty for unfulfilled active 
residues, still scored above the others and when superimposed onto the best ZDOCK 
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6.2.3.2.  THE  HRSV M DIMER MODEL.  
 
The most negative scoring model from HADDOCK was taken forward and is shown in 










Figure 6.2.3.2.1. Dimer model of hRSV Matrix protein. 
The overall fold and topology of the hRSV M and hMPV M proteins are very similar, with 
the N-terminal domains forming inter-domain hydrogen bonds with the C-terminal 




Figure 6.2.3.2.2 Overlaid structures showing the similar topology of the model hRSV M (magenta) and 
crystal structure of hMPV-M (blue) (pdb code: 4LP7) 
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The structures differ in one key region, in the loop around the hMPV-M calcium site at 
the N-terminus especially. This may be a consequence of hRSV M crystallising without 
calcium and hMPV-M crystallising with calcium and the loop being positioned to bind 
the metal ion rather than in hRSV M which does not bind calcium in the crystal structure.  
That being said the hRSV M N-terminal domain is shorter in length than the equivalent 
hMPV-M domain, which can be seen in the model overlay in Figure 6.2.3.2.3 below. Later 
comparison with the recently published hRSV M structure79 supports this dimer model 








Figure 6.2.3.2.3. The low-affinity binding site in the hMPV-M structure shown in blue. (PDB code 4LP7) 
and the smaller loop in hRSV M in Magenta.  
 
This is in contrast to the high affinity C-terminal calcium binding site in hMPV-M, the site 
is formed by residues Lys25 to Ala30. The C-terminal is solvent-exposed and is also 
unique across the Paramyoxyviradae order.50 The residues involved in the calcium 
binding in the C-terminal region are conserved in both hRSV M and hMPV M but as the 
overlay shows the loop involved in hMPV M is in an open position and possibly active as 
shown in Figure 6.2.3.2.4. This is in contrast to the loop in hRSV M which is bent in the 
opposite direction. 
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Figure 6.2.3.2.4 C-terminal calcium binding site, hMPV-M (blue) shows the loop in the active position, 
whereas the hRSV M (magenta) loop is angled away from the metal ion in a closed position. 
 
Specific hydrogen bonds, which form the dimer interface can be identified using 
Chimera160 shown below in Figure 6.2.3.2.5.  
 
 
Figure 6.2.3.2.5 Interaction residues between the dimer interface of hRSV M. 
 
Interacting residues in the dimer formation are detailed in Table 6.2.3.2.6. All values 
were calculated using Chimera.160 
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Chain A Chain B  Distance(Å) 
Ala 228 (Carbonyl O) Asn 93 (ND1) 2.86 
Glu231 (OE1) Asn 93 (ND2) 2.67 
Lys66 (NZ) Glu 231 (OE1) 2.62 
Glu 231 (Carbonyl O) Lys 232 (NZ) 2.76 
Asp 97(Carbonyl O) Lys 232 (NZ) 2.94 
Leu 96 (Carbonyl O) Lys 232 (NZ) 2.93 
Thr64 (Carbonyl O) Tyr 229 (OH) 2.65 
Ser 63 (OG) Pro 161 (Carbonyl O) 2.71 
Thr 104 (OH) Ile 159 (Carbonyl O) 2.88 
Lys 252 (NZ) Asp 105 (OD2) 2.69 
Glu 255 (OE1) Lys 60 (NZ) 2.71 
Glu 255 (OXT) Arg71 (NE) 2.70  
Glu 255 (OXT) Arg 71 (NH2) 2.91 
Glu 255 (Carbonyl O) Lys 84 (NZ) 2.67 
 
Table 6.2.3.2.6 Dimer interface residues. 
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6.3. FUSION PROTEIN.  
 
The fusion protein (F) of hRSV is one of three viral surface glycoproteins.68 The protein 
is essential for viral entry and is also highly conserved within the viral family.43 F is a 
type I viral fusion protein, where a pre- and post-fusion state is seen. The protein is 
synthesised as an inactive single-chain polypeptide that assembles into active trimers 
which are able to bind to the target cell. Although the cytoplasmic tail of the protein is 
known to be necessary for filament and mature virion formation, the mechanism of this 
is unknown. A deletion of the terminal three residues or a mutation of the F572 residue 
has been found to halt filament formation, but not to affect F-protein expression or its 
trafficking to the cell surface. 7 The matrix protein (M) also has a critical role in viral 
filament formation.11 Viruses which have been engineered without this protein, but still 
contain the other critical attachment proteins, have been found to produce shorter viral 
filaments and some did not form at all.11 
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6.3.1. FUSION PEPTIDE (NIAFSN) 
 
The last 6 residues of the cytosolic tail of hRSV M are shown below. The peptide was 
previously identified through work by Shaikh et al. where the cytosolic tail was found to 
be important in the filament formation.7 It has also been suggested that the residues 
interact with the matrix protein to produce mature filaments for viral assembly, budding 
and attachment.79 The key residue identified by Shaikh et. al. was F572, a phenyalanine, 
which when mutated resulted in all activity being diminished.7 The side chain of 
phenyalanine can now be used as a template for docking and drive the investigation into 
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6.4. POCKET PICKING ON HRSV MATRIX DIMER USING CASTP.161 
 
Active sites and binding sites of structural proteins are often found in pockets or cavities. 
The CASTp (Computed Atlas of Surface Topography of proteins) server161 identifies  
multiple factors such as area and volume of the pocket and cavity. The server identifies 
surface accessible pockets as well as interior inaccessible cavities and measures the size 
of each pocket and mouth opening.132,161 Further analysis can include solvent accessible 
surface calculations, mouth openings and molecular surface.  
The CASTp server requires a pdb file for analysis, once it has been loaded and run 
through the program the user is able to manipulate the protein to identify which pocket 
is key, if that is not known. All the pockets available on the dimer were examined and 
there were three that were large enough to be ligand binding sites as shown below in 
Figure 6.4.1. 
 
Figure 6.4.1. Major pocket 74 (left) in the cleft of the protein dimer and pocket 73 (right) shown in from 
the CASTp server.161 
 
The major pocket shown above is approximately 8600 Å3 in volume, which is larger than 
required for small ligand docking. This pocket may bind ligands, but it would be too 
promiscuous for our purpose of drug like compound binding.162 The second pocket 
highlighted was approximately 1100 Å3 in volume, as shown below, which was again 
larger than recommended for drug-like compounds under 500 Dalton molecular 
weight.163 The third pocket is smaller, approximately 450 Å3 in volume and located on 
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the dimer interface as shown in Figure 6.4.3. If a ligand could bind in this pocket there is 
the potential for disrupting the dimer interface.49 Many of the interface residues 









Figure 6.4.2. Pocket 72 - Dimer interface pocket. 
 
Figure 6.4.3 Pocket 72 key residues shown in Chimera.160 
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6.5 ZINC DATABASE 
 
To determine drug-like molecules for docking studies the ZINC database164 was used to 
search a subset of chemical compounds. ZINC is a commercially available subset of 
biologically relevant chemical compounds, which are available in a 3D format. In order 
to be useful for research the subsets are as diverse as possible and in biologically 
applicable forms.164 The ZINC database is not unique and there is significant overlap with 
other well known systems i.e. ChEMBL,165 PubChem166  and DrugBank,167 but ZINC is 
superior for our purposes due to the commercially available nature of the compounds 
that are included.  
Millions of compounds are divided into smaller subsets; drug-like, fragment-like and 
lead-like are particularly important subsets, and these were tested in this work. Lead-
like compounds are usually used for assays in vivo where binding is not directly observed 
and they tend to be in the higher molecular weight range.164 The fragment-like subset 
are ideal for X-ray crystallography and surface plasmon resonance experiments, because 
they tend to be lower in molecular weight. The drug-like subset is an amalgamation of 
historically important fragments and compounds which obey the rule of 5,168 but could 
miss out important compounds by being too similar in basic structure. The aim of the 
initial screen is to test a large number of diverse compounds. The fragment-like subset 
contained a large number of aromatic compounds, which was required to mimic the 
essential phenylalanine on the F peptide chain. Due to limited computing power only 
drug-like compounds at pH 7 were taken, which totalled 1 385 525 compounds, where 
these compounds were the most diverse in structure whilst still retaining the key 
benzene group. In later rounds, to obtain comparable data and to determine if other 
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6.6 KNIME  
 
The aim of this program is to filter by structure, molecular weight, volume and many 
other parameters. It is particularly important to screen the large number of compounds 
in the drug-like subset obtained from the ZINC server. Knime169 is a data-mining 
platform, which offers users an interface to assemble filters, known as nodes, for data 
reprocessing. Fragment-like and lead-like subsets were screened by the author and H. 
Yamada, the outcome of the subsets were investigated using the same parameters. Over 
1 000 000 compounds were taken from the pH 7 fragment-like subset, to dock all of these 
in GOLD would only be possible on a super computer so Knime is used to process and 
separate the compounds into user-defined sections. From previous work7, it is known 
that the F protein phenylalanine side chain (F572) is critical for binding to the matrix 
protein. This structure was the core of the search and a structure filter was used which 
constrains the subset to contain a benzene ring. A cyclohexane was decided against due 
to the unknown nature of the pi-pi stacking which could occur with the central tyrosine 
residues 104 and 229 in the pocket. Additional filters were added which were based on 
Lipinski’s rule of 5.168 Lipinski’s rule of 5 predicts that poor absorption of the drug is 
likely if: there are more that 5 hydrogen bond donors; more than 10 hydrogen bond 
acceptors; the molecular weight is larger than 500 Da; and the calculated log P is greater 
than 5.168 These factors were all used in node constraints in Knime. Other constraints 
that were used included the overall volume of the molecules, which was set to a 
maximum of 470 Å3, which is equivalent to the size of the proposed pocket and also there 
must be an aromatic group included. This reduced the subset down to 879 173 
compounds. To further reduce the number of potential compounds an additional set of 
more stringent rules were imposed on the subset. Further nodes were used which 
complied with the fragment rule of 3.163 This took Lipinski’s rule of 5 and reduced all 
parameters to 3 if the subset was fragment-like.  The rule of three was devised by 
researchers163 who found the most drug-like ligands were found under 300 Da but does 
not compromise the diversity of the ligands found. The parameters included: fewer than 
three rotatable bonds and hydrogen-bond donors and acceptors; and <300 in molecular 
weight. The subset was reduced to 137 498.  
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This was still too large to take through to GOLD docking and so was reduced further by 
reducing the XlogP to <3 to fit with the fragment rules. A lower limit to the volume of 
compounds was also set to rule out small promiscuous molecules. This dramatically 
reduced the number of compounds to 43 820.  This was deemed a reasonable number to 
take through to GOLD. The full pipeline for fragment–like compounds is shown below in 
Appendix B.2.  
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6.7 GOLD  
6.7.1. DEFINING THE BINDING POCKET.  
 
As described previously in 6.1.3.3 a GOLD run can firstly be thought of as defining the 
binding site. In the PYMOL viewer156 the residues, which are in the middle of the pocket 
and also form part of the dimer interface can be determined as Tyr 229 and Asn 93. The 
ball seen on screen should be placed in the centre of the binding pocket and the 
approximate coordinates taken, in this case these were X = 4.048 Å, Y = 6.036 Å and Z = 
-8.303 Å as shown below in Figure 6.7.1.1. 
 
Figure 6.7.1.1 Binding pocket, highlighted with key residues and important binding residues.150 
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The GOLD run was customised so that the number of poses that each ligand was screened 
in was reduced to compensate for computing power. The RMSD (root mean square 
deviation) was also reduced to 1 Å to obtain a subset of molecules that have small 
differences in structure and binding, but of the same central binding pocket. Search 
efficiency in an ideal world would be 100% where every pose could be analysed by the 
program, docked into place and a fitness score awarded. 30% is considered to be a 
standard fragment screen and is run as a compromise to give a general screen.12 An 
additional option was used to allow ligand flexibility, where amine bonds and rings can 
rotate and rings can twist into conformations required in the binding site. The total 




Once the run was complete the results were filtered and imaged using GOLDMine,150 a 
post processing and analysis software written by the developers of GOLD. Scoring 
functions from GOLD alone cannot be relied upon and some docked ligands may have 
extreme torsion angles or form no hydrogen bonds to the protein. GOLDMine can be used 
to filter out undesirable ligands using histograms where outliers are shown in red and 
the viable data are shown in blue.81 
Firstly hydrogen bond formation was evaluated; the ligand should form hydrogen bonds 
as stated by Lipinski’s rule of 5. This stated that there should be no more than 5 hydrogen 
donors and no more than 10 hydrogen bond acceptors.168 Hydrogen bonds, from H---X-
H typically prefer to form at 180 at the lowest energy conformation. GOLDMine 
automatically sets the minimum angle at 90 so any angles within this constraint are 
shown, but this does not necessarily mean they are the best fit in the binding pocket. 
Using histograms the outliers can be easily identified and eliminated. Torsion and clash 
can also be constrained to reduce outliers. The Gold PLP Ligand Clash is another scoring 
function, which shows undesirable ligand-protein interactions and awards penalties, 
any high values were eliminated to ensure all unfavourable torsion angles and bond 
clashes are removed.148
From this set the top scoring 10% were filtered and analysed, which yielded 62 hits in 
61 structures, where one ligand was posed in the pocket twice. Using CCDC Software –  
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Mogul170, a geometry checker can be used to check the compounds based on a library of 
molecular geometry from the Cambridge Structural Database. The library contains 
millions of bond lengths, ring conformations and torsion angles, which can be used to 
validate the structure.170 
After checking manually, 22 compounds were noted as acceptable and the top 20% were 
chosen on the basis of fitness score were taken. The compounds were then cross-
referenced back into the ZINC database for purchasing information. Even though the 
ZINC database is labelled as commercially available, sometimes the compounds are 
specially made to order or maybe out of stock at that time, this further limited the 
number of compounds which were available for in vitro testing shown in Chapter 6.8. 
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6.8 COMPOUND RESULTS  
6.8.1 DOCKED COMPOUNDS USING THE MODEL.  
 
The top 20% of the 22 compounds, in numerical order of the highest fitness score are 
detailed below, showing the chemical structure, binding pose in the pocket and 
theoretical hydrogen bonding residues in the protein.   
 










Protein Residues  Ligand group Distance/ Å 
Tyr229 NH 2.13 
Ser100 C=O 2.11 
Lys232 NH  1.77 
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Protein Residues Ligand group Distance/ Å 
Tyr229 NH 2.28 
Lys232 NH 1.51 
Glu233 NH 2.03 
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Protein Residues  Ligand group Distance/ Å 
Tyr229 NH (Imidazole) 1.81 
Tyr104 N (Imidazole) 2.10 
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Protein Residues Ligand group  Distance /Å 
Tyr229 N-H (isoindol) 1.53 
Glu233 N-H 2.26 
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Protein residues  Ligand group Distance /Å 
Tyr229 N-H 1.99 
Asp93 O-H 2.23 
 
  
H.J LUMB 2015  CHAPTER 6. IDENTIFICATION AND 
DOCKING DRUG LIKE MOLECULES 
  INTO THE MATRIX PROTEIN OF HRSV 
 189 
 














Protein Residues Ligand group Distance/ Å 
Tyr229 NH 1.63 
Lys232 NH 1.62 
Glu233 NH 2.04 
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Protein Residues Ligand Group Distance Å 
Tyr229 NH 1.633 
Glu233 NH3 2.04 
Lys232 C=O 1.61 
 
 
Many of the compounds show theoretical hydrogen bonds in the docking which 
are short compared to the average length from 2.8 Å to approximately 3.1 Å.171 
All bond lengths are approximate and it is believed that the flexibility of the 
protein and ligand may lengthen these in solution. Also the protein docking was 
conducted on a dimer model, this is an estimation and the values may change.  
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6.8.2 FURTHER DOCKING 
6.8.2.1. NEW MATRIX DIMER.  
 
In February 2015 a new paper which identifies hRSV M as a dimer was published,79 
showing the matrix protein as a dimer where no calcium ion was found in the structure 
as shown below. Using Pymol, the structures as shown in Figure 6.8.2.1.1. were overlaid 
using 1598 atoms to a RMS of 0.986. It can be seen that model was very close to the actual 





Figure 6.8.2.1.1 Left: The new hRSV matrix protein dimer (PDB code:4D4T) overlaid with the model 
interaction dimer M. Right: Overlaid structures rotated 90 °. 
The differences seen in the loop region are where a region of electron density was 
undefined in the 2009 structure.48 This was fully defined in the 2015 dimer structure, 
but it is far enough away to not change the pocket residues or distances. Even so, it was 
thought beneficial to re-dock the top 20% of the results from the 10% and 30% screen 
of fragment-like compounds to ensure a complete experiment. The compounds were 
saved in a larger sub-set file in KNIME, so each had to be filtered out by hand again, this 
was completed by a structure search as shown in Figure 6.8.2.1.2. This filtering was also 
completed for the 10% fragment-like screen, which was performed previously, and as a 
result 20 compounds were taken through for redocking. The file parameters are detailed 
in Appendix B.3. 
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6.8.2.2 DOCKING COMPOUNDS USING HRSV M DIMER. 
 
The re-docked results of the top 5 compounds from the 30% and 10% screen are shown 
below, ranked in order of scoring. Hydrogens are not explicitly shown but are the same 
as Chapter 6.8.1. 









Protein Residues  Ligand group Distance/ Å 
Tyr229 Backbone NH 2.931 
Gln61  C=O 2.833 
Tyr104 OH 2.685 
 
Compound 9 was found to be the highest scoring in both protein models. It was found 
that the same Tyr229 residue was identified in this structure as it was in our model. This 
residue was also found to be key in forming the dimer interface as described by Förster 
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Protein Resiudues Ligand group Distance/ Å 
Tyr229 Backbone NH 2.994 
Ile259 Backbone OH 2.948 
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Protein Residues Ligand group  Distance/ Å 
Tyr104 Backbone NH 2.755 
Ile159 Backbone OH 2.811 
Asn93 NH 2.638 
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All the lengths shown are more indicative of the traditional hydrogen bond when the 
hRSV M dimer was used instead of the model.  
 
6.8.2.3 MOGUL  
 
Mogul,170 as described previously, was used to check the geometry of the bonds and 
angles in the compounds above. The program checks the geometry against the CSD of 
known compounds to identify clashes or out of range torsion angles. All compounds 
tested were within the recommended ranges for each bond type.  
Protein Residues Ligand group  Distance/ Å 
Tyr229 Backbone NH 2.837 
Gln61  OH 2..894 
Ile102  Backbone NH 2.63 
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6.8.3 COMPOUNDS AVAILABLE FOR PURCHASE   
 
Compounds 9, 15 and 47 were available for immediate purchase through the ZINC 
database, so these were taken forward for further testing. Only compound 9 arrived in 
time for initial testing.  
 
6.8.3.1 COMPOUNDS AVAILABLE IN HOUSE 
 
A number of compounds that contain at least 2 aromatic rings and have a similar 
backbone to the compounds from the KNIME subset were available from J.M. Sanderson, 
Durham University. The range of compounds is detailed below in Table 6.8.3.1.1  
 
Compound group Compound Number Molecular 
weight 
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6.9 PRELIMINARY RESULTS 
The author and H. Yamada carried out the work detailed in this section. 
6.9.1 THERMAL SHIFT ASSAYS (DIFFERENTIAL SCANNING FLUORIMETRY)  
 
As previously discussed in Chapter 5, thermal shift assays can be used to determine if 
the compound can induce a stabilising or destabilising change in the protein determined 
by a hydrophobic fluorescent dye.95 The matrix protein was incubated at 35 µM 
concentration with the various compounds at three different concentrations and the 
results are shown below. A shift of not less than 2 °C was taken as significant due to the 
error in the machine and the assay. Each number in the tables below shows the melting 
tempertature change in comparison to the hRSV M protein in water.  
6.9.1.1. INDAZOLE AND BENZIMIDAZOLE (133 a-h) 
 
133a and 133c did not show significant changes in the assay whereas a dose dependant 
response was seen for the d and e subsitituents, 6 and 7-aminoindol. A similar response 
was seen in the imidazole compounds, in which the nitrogen atoms are moved into the 
1 and 3 positions of the ring. 
 
 
Figure 6.9.1.1.1 Indazole and Imidazole compound destabilisation of the matrix protein. 
 
133a 133c 133d 133e 133f 133h
200 uM -0.61 -0.63 -1.88 -1.83 -2.42 -2.84
400 uM 0.48 0.33 -2.00 -2.14 -2.57 -2.33
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It was expected that the compounds, if bound to the correct pocket would destabilise the 
protein, which as shown above seems to be true as illustrated by the decreases in melting 
temperature. The protein we believe, would bind the compounds in the binding pocket 
on the dimer interface, destabilising the interacting dimer by forming hydrogen bonds 
to the compound and not the other subunit of the dimer.  
 
6.9.1.2 ISOQUINOLINE (144 a-c)  
Lesser destabilisations were seen with the isoquinoline compounds in the assay, mostly 
these were under the 2 °C threshold required. In sample 144b there is a large jump in 
the destabilisation of the protein at 400 M, this compound was tested further at the 
higher concentration to determine if this was anomaly and showed that the compound 
is insoluble above 500 M, rendering 144b unusable in this experiment.  
 
 







200uM -0.74 -0.41 -0.08
400uM -0.68 -0.75 0.67





























40  µM 
80  µM 
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6.9.1.3 INDOLE (146 c-g ) 
 
The indole compounds showed varied responses in assays, 146c was dose-responsive 
and at 800 µM showed a large destabilisation of approximately 11 °C. In contrast 146f 
and 146g did not show any change above 2 °C and were discounted. 146d showed a 
mixed result, and further investigations using the compound found that it had limited 










Figure 6.9 1.3.1 Indole compound destabilising effect on matrix protein. 
 
6.9.1.4 PURCHASED COMPOUNDS 
 
Due to time constraints only one compound arrived before the deadline for testing. This 
was Compound 15 purchased through Mcule Inc (Budapest, Hungary) and the thermal 




146c 146d 146f 146g
200uM -1.23 -8.93 1.12 0.35
400uM -1.75 1.33 -0.20 -1.52




























400 µ  
80  µM 
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Figure 6.9.1.4.1 Compound 1 thermal shift assay result.  
The compound is dose responsive and the higher concentrations go above the 2 °C 
threshold that was required, this is a positive sign and further experiments are needed 






























µM µM µM 
H.J LUMB 2015  CHAPTER 6. IDENTIFICATION AND 
DOCKING DRUG LIKE MOLECULES 
  INTO THE MATRIX PROTEIN OF HRSV 
 203 
6.9 FURTHER WORK 
 
6.9.1 IN VIVO TESTING 
 
Using in cell-assays could help characterise the interactions and understand how the 
compounds could bind and change the protein. Plaque inhibition assays to understand 
how effective the compounds are in hindering the spread of virus could be useful for 
taking the project further.172 Plaque inhibition assays have an advantage over other in 
vivo assays due the reliable and rapid nature of determining 50% inhibitory 
concentrations.172 
 
6.9.2 ISOTHERMAL TITRATION CALORIMETRY 
 
This in vitro technique could further characterise interactions in solution and yield 
significant thermodynamic data to determine a binding model, dissociation constant and 
furthermore the changes in enthalpy, stoichiometry and entropy.115,173 Binding of the 
ligands can be compared against the binding of the wild-type peptide and competitive 
binding studies could confirm the new ligands’ effectiveness.  
 
6.9.3 MUTATIONS OF HRSV M 
 
Mutations within this binding pocket and across the dimer interface could be used to 
determine where the main contacts are forming hydrogen bonds. Residue Tyr 229 has 
been identified in this work but also by Förster et al.49 where it was identified as a 
hydrogen bond contact in the dimer interface.   
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6.11  CONCLUSIONS. 
 
A new understanding of viruses and their structures has helped the development of new 
anti-viral drug candidates. With the advent of computational docking studies, a new 
approach can be utilised where a potential binding target can be identified in hRSV M 
and small molecules can be identified and docked into place in silico. hRSV M has been 
long identified as a drug target by its function as an intergral part of the virus.48,50 The 
protein’s interaction with the fusion protein enables viral budding and maturation, that 
if disrupted results in a loss of virus maturation and a decrease in infectivity.98 Shaikh et. 
al.7 identified that the last 6 amino acids in the cytoplasmic tail were key to the 
maturation of the virus by forming a complex with hRSV M protein. Disruption of this 
interaction is key and it is hoped that the small molecules identified, may be able to 
mimic the disruption shown to be caused by mutations in the F cytoplasmic tail. 
 
The pocket identified on the surface of hRSV M is small enough, in theory, to allow small 
molecules to bind without being promiscuous and an ideal candidate for docking studies. 
The ZINC database164 provided a large molecule subset to identify drug-like molecules 
that can be taken through to the GOLD programs and subsequently to be tested in vitro. 
A fragment-like subset was taken from the database to be tested as the molecular weight 
and space fitting of the compounds fitted the chosen pocket. Over 1 million compounds 
were in the subset and these were filtered using KNIME, a data-mining platform.139 A key 
residue, a phenylalanine in the fusion protein tail has been found to show binding to 
hRSV M7 so an aromatic ring was used as the first constraint to filter. Further filters 
constrained the compounds to Lipinski’s rule of 5 and subsquently the Fragment rule of 
3.  
The compounds that fit all constraints were taken through to GOLD to be docked into the 
pocket, the results have shown a key scaffold of at least 2 aromatic rings which form 
hydrogen bonds from an amine or alcohol group. Key residues in the pocket are Tyr229 
and Asp98, which form hydrogen bonds in most of the docking results.  
The recent publication of hRSV M dimer49 only assisted in the confirmation in the dimer 
model, where the symmetry and pockets were identified in the same region. The new 
crystal structure was used to re-dock the compound, which had been identified through 
the initial search and the re-dockings gave positive solutions and similar hydrogen bond 
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contacts were found. Further validation of the compounds is needed and this could be in 
the form of in vitro testing by thermal shift assays and isothermal titration calorimetry 
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6.12 METHODS  
6.12.1 PISA SYMMETRY DIMER 
PDBe Pisa158 was used to analyse the hRSV M structure, where the second chain was 
produced by the symmetry operation [-x+2, y, -z]. This result gave the largest buried 
surface area at 943.6 Å per monomer. The new model was saved as a pdb file for further 
modifications. 
 
6.12.2 HADDOCK WEB INTERFACE 
The new Pisa pdb file was manipulated to exclude water and all residues were labelled 
differently so that HADDOCK interface153 can distinguish each individually in the docking 
process.  Three residues were identified from the dimer interface, Ser63, Asp105 and 
Lys232, these were selected as active residues that the docking should be driven towards 
and the pdb file was run through the system.  
The resulting graphs of scoring functions and energy calculations were analysed to 
obtain the best model going forward and the HADDOCK model was saved as a pdb file 
for further analysis. 
 
 
6.12.3 CASTP  
The HADDOCK model was uploaded to the CASTp server161 
(http://sts.bioe.uic.edu/castp/), the pockets were analysed and a total of 74 pockets 
were identified. Ideally the pocket would be on the dimer interface and a candidate was 
identified in pocket 72 at 450 Å3 in volume. 
6.12.4 ZINC 
The Zinc database164 was accessed via the website (http://zinc.docking.org/). Fragment-
like and drug-like subsets were chosen from the subsets menu. The compounds 
downloaded for knime screen were from the in stock row. The files were downloaded as 
SDF files and saved to the computer for easy access.  
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The Knime program was downloaded from (https://www.knime.org/).169 The program 
was used to open the sdf file previously downloaded. Each node, which is the filtering 
station was dragged from the left menu onto the main screen. The full scheme is detailed 
in Appendix B. where first node used was to convert the SDF file into a KNIME readable 
format.  
The structures were then filtered through to ensure the critical benzene from the 
Phenylalanine residue (F572) was maintained by the Substructure search. Lipinski’s 
rule of 5168 and the Fragment rule of 3163 were used to filter down using the molecular 
properties and row splitter. To connect each node the arrows were connected from the 
output arrow to the left hand arrow on the next node. Each time the node was right 
clicked and ‘start’ was selected to start the filtering process. This took anywhere from 5 
minutes to 20 hours dependent on the task and number of molecules involved.  
Once the compounds were reduced, the files were converted using ‘CDK to molecule’ and 
‘Interactive table’ so the remaining compounds could be viewed. Further conversion to 
different file types were used including ‘MolConverter’ especially for GOLD files.  
 
6.12.6 GOLD  
Molecular docking was carried out using GOLD (version 5.1)80,81. The interaction dimer 
and hRSV M dimer (PDB entry 4D4T) were taken from the PDB (www.rscb.org/pdb), 
and both models were edited in GOLD interface to include Hydrogen atoms. GOLD 
default settings were used throughout unless otherwise specified and shown in 
Appendix B.1.  
A radius of 8 Å was used about a point in between Tyr229 and Asn 93 in the binding 
pocket (X = 4.048, Y = 6.036 and Z = -8.303) and the default scoring function CHEMPLP 
and ChemScore were used to score docking poses.12 Ligands were allowed maximum 
available flexibility for all rotatable bonds in this run.  
The output mol2 files from the filtering in KNIME were used as ligands and GOLD was 
run for 3 days, until all ligands were posed. 
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CHAPTER 7. CONCLUSIONS AND FUTURE PERSPECTIVES.  
 
The prevalence of the Human Respiratory Syncytial Virus highlights the need for new 
antiviral agents. The virus and the secondary infections that follow are the second 
leading cause of death in elderly patients24 and result in millions of outpatient hospital 
visits by children under 5.174  
Although the virus was discovered in 1955, relatively little is known about the viral 
proteins which form the basis of viral infectivity. In 2001 the closely related 
metapneumovirus (hMPV),26,37 was discovered and has since been found to co-infect 
with hRSV and lead to bronchiolitis with further complications.26 Some infections can 
lead to long-term effects; where up to 70% of infants are left with respiratory problems 
for up to 10 years following hRSV bronchiolitis.28,174 
In order to understand which viral proteins are key, their functions and viral replication 
cycle have to be determined. hRSV is a negative sense RNA virus which is contained in 
class V of the Baltimore classification system.21 This class contains a number of families, 
of which many are important human diseases i.e. Mumps, measles and hRSV.  
In the family Paramyxoviridae lies a subfamily Pneumonvirinae, of which hRSV and hMPV 
are members. The genome of the virus comprises of 11 genes which codes for 10 
proteins.77 Key proteins include the nucleocapsid protein (N)46 which associates with 
genomic RNA to form a nucleocapsid. The fusion protein (F) is a glycoprotein on the 
surface and mediates cell fusion allowing the virus to enter the cell cytoplasm.7,67 M2 is 
another structural protein which has two open reading frames and M2-1 is the 
elongation factor.64 M2-1 is of specific importance to this work as it was one of the 
proteins in the virus with no published X-Ray Protein Crystallography structure in 2011. 
Finally the matrix protein (M) was solved by Money et al48 in 2009 and Förster et al49 in 
2015 found to form interactions within the virus to M2-1 and F proteins. These 
interactions could be key for understanding and targeting a process for anti-viral agents 
to disrupt.  
In Chapter 2, M2-1 was targeted for characterisation. The protein had no published X-
Ray crystal structure, only a core solution NMR structure.63 The protein was relatively 
uncharacterised with only basic information available. This ranged from the secondary 
structure of the protein backbone through circular dichroism62 and the diameter from 
dynamic light scattering.62 In this chapter, these parameters were confirmed and the 
protein was further analysed.  
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M2-1 proteins contain a zinc finger where a zinc ion is held by a Cys3-His1 motif, and this 
domain is key for the correct folding of the virus.61 ICP-MS was used to quantify the zinc 
bound in the protein compared to the standard concentrations. The protein was found 
to be more stable at higher zinc concentrations indicating that the zinc finger was highly 
influential. From these data the expression protocol was changed to include ZnSO4 at the 
point of expression.  
Crystallisation of the full length protein was attempted through multiple trials using 96 
well screening techniques. Conditions were optimised from lead conditions to yield 
bipyramid shaped crystals. Unfortunately the crystals did not diffract and Tanner et al.  
published a complete structure in 2014.5 
In Chapter 3 the focus changed to protein-protein interactions. Matrix protein was first 
crystallised in 2009 by Money et al.48 It is known to interact with M2-1 through cell 
inclusion assays58,77 and this chapter confirmed that binding does take place through the 
use of pull down assays. Dynamic light scattering was used to understand the size of the 
complex formed and transmission electron microscopy was used as a tool to image the 
complex. The TEM found 2 distinct protein aggregates in the mixture of M2-1 and M, the 
sizes ranged from ~ 30-60 µM. This low resolution technique was limited for our 
purpose so further investigations were directed to understanding the thermodynamic 
nature of the binding. Further analysis through Cryo-Electron Tomography could yield a 
more conclusive image of the protein aggregates. 
Surface Plasmon Resonance (SPR) and Fluorescence anisotropy (FA) were used to 
further understand the binding. The former technique gave a Kd of 3 mM where the data 
fitted to a 1:1 Langmuir interaction model. In FA the experiments were conducted with 
a fluorescent tag to monitor the binding in solution, in contrast to SPR where one is 
tethered to a solid surface. The results proved difficult to analyse, in the oligomerisation 
model, the fitted curve was found to be a close fit up to 10 M however above this 
concentration the fit was poor. As matrix protein has been found to form up to a hexamer 
in solution45 so the dimerized form of the protein could not be relied upon. In future 
work, mutagenesis of hRSV M binding region would yield potential to specifically target 
this interaction.  
Chapter 4 introduced hRSV F and the interaction with hRSV M. This interaction is key to 
the viral budding and maturation. Through previous work7 a key residue F572 found in 
the cytoplasmic tail of hRSV fusion protein which binds to hRSV matrix protein. A six 
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amino acid peptide consisting of the terminal amino acids of the cytoplasmic tail was 
purified and used for the following experiments.  
Initially the binding was confirmed through the use of surface plasmon resonance 
experiments. The first method involved the matrix protein binding to the chip through a 
histidine tag and the fusion peptide was then added in solution. This unfortunately 
showed little binding so an alternative experimental procedure was employed. The 
tagged matrix protein was attached to the chip, as before, but another layer of matrix 
protein was added. This allowed the formation of  possible oligomers, and when the 
fusion peptide was introduced, binding occurred.  
Fluorescence anisotropy and FRET experiments were also conducted in Chapter 4. The 
initial FRET experiment was conducted by E. Antonio, which showed clear binding when 
analysed and a nM Kd. To confirm the value statistical plots were used to further analyse 
the data. A mutant peptide was also tested to confirm that the residue identified by 
Shaikh et al. 7 was the key binding residue. Fluorescence Anisotropy experiments were 
conducted alongside FRET to confirm the possible binding. Again, a binding curve was 
seen and was analysed using the same equilibrium pathway. Some discrepancies were 
seen in the figures and in further work these would need to be investigated to 
understand if the problem is an experimental or analysis issue.  
In Chapter 5, the focus changes to understanding the interaction of small molecules with 
hRSV N protein. A small subset of compounds was made available by S Cockerhill, 
Durham University and were tested using various biophysical techniques. Thermal shift 
assays were again employed to understand the stabilising and destabilising effects of the 
compounds on hRSV N. This showed a varied destabilisation which prompted further 
investigation using Dynamic Light Scattering (DLS) and Transmission Electron 
Microscopy (TEM). DLS was used to understand how hRSV N changes during the 
interaction with the ligand compounds. It was seen that each ligand molecule formed 
aggregates at various concentrations as a large shift was seen in hydrodynamic radius. 
Transmission Electron Microscopy, which was used in Chapter 3, enables the shape of a 
sample to be imaged. From this a clear mode of action could be seen where the protein 
formed large aggregates in the presence of the ligands. Further work using mutagenesis 
to pin point the binding site would build a larger picture of how the ligands are 
interacting with the protein. Once this is known further optimisation of the structure can 
be obtained, to reduce potential problems with potential side effects and solubility 
issues.  
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In Chapter 6, the aim was to identify small fragment-like ligands which would bind to 
hRSV M. The ligands would hopefully bind in a pocket and disrupt the dimer interface, 
so disrupting the binding of fusion protein. A pocket was first identified on the surface 
of the protein using a web based server, CASTp.161 A commercially available subset of 
compounds from ZINC database164 was used to filter down from over 1 000 000 
compounds through KNIME.138 A filter was used as a template where Lipinski’s rule of 
5168 and fragment rule of 3163 and a core benzene must be in the final structure. The core 
benzene represented the phenylalanine side chain F572 which is key for binding.  
Once a smaller number of compounds was achieved, the remaining compounds were 
docked in GOLD12,80,147. These were posed in the pocket determined in CASTp and a 
fitness score was attached to each. The top 20% were evaluated and ordered from the 
manufacturers. Unfortunately, due to time constraints only one ligand, compound 15 
from the docking subset arrived for testing before the period of study ended. When 
tested by thermal shift assays the results showed a concentration-dependant 
destabilisation. This is what was expected and further studies are needed to understand 
how the ligands are destabilising the protein.  
In 2015, a new hRSV M dimer structure was published49 that confirmed the theory that 
the protein was a dimer in solution. In comparison to the model dimer structure, the 
published dimer was a close fit, where the shape and main Tyr229 contact were alike. 
The top 20% of compounds in the screen were redocked into the protein pockets using 
GOLD to validate the compounds. The docking reproduced the results from the model 
and confirmed the same hydrogen bond contacts. Further work would expand the 
testing of the compounds identified in the screening process. Structure-function activity 
relationship studies could further optimise the ligand’s structure.  
Overall this work begins to understand the complex interactions between viral proteins. 
The interactions between hRSV M2-1 and hRSV M and also hRSV F and hRSV M are key 
to the viruses’ infectivity and maturation. Targeting these interactions with small ligand 
compounds begins to specifically target the binding and will hopefully lead to new trials 
of anti-viral agents. 
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APPENDIX A.  
1. MALDI-TOF FRAGMENT ANALYSIS 
 
The output file from the pdf report received from Dr A. P Brown showing the major 
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Figure 2.2.2.Appendix A.1.2. Zinc standard curve. 
Figure A.2.2  Standard curves of known concentrations of 9 metal ions used in ICP-MS analysis. Zinc is 
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3. NAMI SALT SCREEN CONDITIONS.  
 
  1 2 3 4 5 6 
A Water  Water  Water  4 M Urea 0.5 M Urea 3.0 M Gu-HCl 
B 
1.5 M Na2 
malonate 
1.0 M Na2 
malonate 
0.8 M Na2 
malonate 
0.6 M Na2 
malonate 
0.4 M Na2 
malonate 
0.2 M Na2 
malonate 
C 1.5 M NaCl 1.0 M NaCl 0.8 M NaCl 0.6 M NaCl 0.4 M NaCl 0.2 M NaCl 
D 1.0 M MgSO4 0.8 M MgSO4 0.6 M MgSO4 0.4 M MgSO4 0.2 M MgSO4 1.0 M NaSO4 
E 0.5 M LiCl 0.2 M LiCl 0.5 M RbCl 0.2 M RbCl 0.5 M CsCl 0.2 M CsCl 
F 0.4 M MgCl2 5 mM MgCl2 5 mM CaCl2 5 mM SrCl2 1 mM ZnCl2 1 mM NiCl2 




La(NO3)3 2 mM PrCl3 2 mM NdCl3 2 mM SmCl3 
H 
5 mM 




Na2MoO4 20% glycerol 10% glycerol 
 7 8 9 10 11 12 














C  1.5 M NH4Cl  1.0 M NH4Cl  0.8 M NH4Cl  0.6 M NH4Cl  0.4 M NH4Cl  0.2 M NH4Cl 
D 0.8 M NaSO4 0.6 M NaSO4 0.4 M NaSO4 0.2 M NaSO4 0.5 M KCl 0.2 M KCl 
E 0.4 M NaF 0.1 M NaF 0.4 M NaBr 0.1 M NaBr 0.4 M NaI 0.1 M NaI 
F 5 mM MnCl2 1 mM CoCl2 1 mM CuSO4 1 mM CdSO4 
5 mM EDTA 
pH8 
5 mM EGTA pH 
8.9 
G 2 mM EuCl3 2 mM GdCl3 2 mM DyCl3 2 mM HoCl3 2 mM YbCl3 2 mM LuCl3 
H 5 mM DTT 
0.5 M Na3 
citrate 
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APPENDIX B. CHAPTER 6. COMPUTATIONAL AND INITIAL BIOPHYSICS RESULTS.   
1. SDF FRAGMENT LIKE SUBSET.  
AN EXAMPLE WAS USED, THE SDF FILE CONTAINS OVER 1 000 000 COMPOUNDS AND COULD 
NOT BE SHOWN HERE. EACH COMPOUND HAS A DESCRIPTOR AS SHOWN BELOW. 
EXAMPLE – BENZENE 
  Header, Compound of choice 
Total # atoms, total # bonds, atom lists, chiral flag setting 
(standard) and file type version. 
Atom Block 
X,Y,Z co-ordnates, Element, 
Properties i.e valence, # of 
hydrogens, charge, etc.  
Bond Block 
.Atom #, Aton #, properties 
i.e bond type, stereo and 
topology 
End of structure block 
Properties Block 
<name of property> and value 
End of File 




KNIME creates a clustered pipeline to filter from the initial SDF file obtained through 
ZINC.  Orange nodes are SDF reader input, Red are SDF output and yellow nodes are 
different types of filters. Finally Brown nodes are usually structural filters and blue 
nodes are conversion filters. The first arrow on the left on each node accepts the 
information from the subset and previous nodes. The top arrow on the right of each node 
connects to the next node and carries the compounds that have fit the criteria in that 
node. The lower right arrows on the nodes are the rejected compounds, which can be 
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3. HADDOCK CLUSTER TABLE  
Parameter 
 
Cluster 1 Cluster 2 Cluster 3 Cluster 4 
HADDOCK 
Score 
-195  5.9  147.7  6.5 98.3  5.8 -79.7  11.5 





structure / Å 
0.5  0.3 22.7  0.1 11.4  0.2 11.4  0.0 
Van der 
Waal Energy 
/ kcal mol-1 
-48.3  2.6 -81.3  8.7 -46.6  7.1 -33.9  6.0 
Electrostatic 
Energy / 



















81.7  26.99 110.1  
23.65  






81.7  26.99 110.1  
23.65 
96.1  31.69 
Z-score -1.4 -0.4 0.8 1.0 
 
The Z-score shows the standard deviation from the average, so a more negative value is 
deemed the ‘best’. 
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Cluster 1 also contained structures with most negative Z-scores, the lowest desolvation 
energy, (which indicates the best solvated models), and the lowest electrostatic energy 






H.J LUMB 2015  APPENDIX B 
 
 229 
4. GOLD CONF FILE.  
 
Search efficiency: 30% 
General Algorithm Settings 
Centre point coordinates x,y,z 
radius and the option to 
produce a cavity structure file 
Source of data files 
1= yes, 0 = no.  
Ligand flexibility flags 
